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CHAPTER 1 
INTRODUCTION 

INTRODUCTION 
In Western societies infant mortality has decreased substantially this century. Improved 
hygiene and water supply, improved nutrition, vaccination and availability of treatment for 
many infectious diseases have contributed highly to this evolution. With improved hygiene 
and vaccination schemes the spread of infectious agents is prevented. Generally improved 
health, nutritional status, again vaccination and availability of antibiotics avert a serious 
course of illness once the child is infected. In particular, the success of primary 
prevention has been tremendous as demonstrated by the sizable decrease in infant 
mortality during this century (figure 1) (1). 
Figure 1 
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In contrast, no obvious trends in occurrence of congenital malfonnations have appeared. 
The birth of a malformed infant has a great impact. Parents, society and science feel a 
strong need to provide an explanation for such an event. However t causes of congenital 
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malformations remain as yet unknown in the majority of cases, precluding large scale 
primary prevention. Consequently, despite increased options and improved possibilities for 
treatment of these cases, the relative contribution of congenital malformations to iofant 
mortality has increased (2). As illustrated in figure 2, congenital heart disease constitutes a 
major part of congenital malformations and, accordingly, has a sizeable impact on 
children's health (3). 
Figure 2 Proportional distribution of congenital anomalies 
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A concise review of current knowledge and research on the aetiology of congenital heart 
disease discloses that, at present, information on causal factors for the occurrence of 
congenital heart disease is limited. In fact, an accurate estimate of the number of cases of 
congenital heart disease that occur in the general population seems lacking at present also. 
Estimates of the prevalence of congenital heart disease appear to vary widely across 
studies. Seemingly, an accurate estimate of the size of the problem can not be easily 
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obtained. Moreover, the (birth) prevalence of congenital heart disease does not provide 
any infonnation on the impact and implications cardiovascular anomalies may have 
prenatally. Accordingly, the various congenital malformations of the cardiovascular system 
need further assessment with regard to possible consequences for the neonate as well as 
for the fetus. In this respect, possibilities for prenatal detection and subsequent 
implications are of importance also. 
Nevertheless, the potential for prenatal detection of congenital heart disease during routine 
screening and its supposed potential to improve the status for neonates and parents has 
been enthusiastically described, and indeed been introduced in several countries. Adoption 
of such a policy has also been suggested in the Netherlands. It appeared, however, that 
the efficacy of the proposed screening test had not been firmly established. Still, in view 
of currently impossible primary prevention, the possibility of secondary prevention 
following a prenatal screening test for congenital heart disease merits additional study. 
Also, a decision to set up a routine prenatal ultrasound screening program should only be 
based on reliable research data. Consequently, a prospective cohort study on 6,922 fetuses 
scanned was designed and conducted to assess the perfonnance of prenatal ultrasound 
screening as a method of early detection of congenital abnormalities. 
Irrespective of the efficacy of routine screening, once a fetal anomaly is suspected referral 
for additional examination is needed for verification. These cases then are part of a so-
called high risk population. In contrast to a policy of routine screening offered to an entire 
population, a high risk approach implies that only pregnancies or women deemed at risk 
for fetal anomalies are offered (extensive) structural ultrasound examination. Clearly, 
suspicious findings during previous examination justify extensive evaluation. However, as 
knowledge on causes and risk factors for the (re)occurrence of congenital heart disease is 
constantly expanding, indications for extensive examination, particularly anamnestic risk 
factors, may require updating. 
Subsequently, combining the iofonnation on routine screening and subsequent extensive 
examination once an anomaly is suspected, may provide a quantitative estimate of the 
impact of current clinical practice of prenatal ultrasound screening in an unselected or 
low-risk population. A decision analysis model designed to reflect the options and chances 
future parents and clinicians face, allows such a comprehensive evaluation. Finally, all 
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data and conclusions warrant overall inference and possibly even have implications for a 
public health policy. 
The magnitude of the problem and a common interest in occurrence and prevention of 
diseases of the cardiovascular system engendered a successful collaboration of the Division 
of Paediatric Cardiology, Department of Paediatrics, the Department of Epidemiology & 
Biostatistics and the Division of Prenatal Diagnosis, Department of Obstetrics and 
Gynaecology of Erasmus University Medical School Rotterdam. With the specific input of 
these disciplines the efficacy of routine fetal ultrasound screening and additional aspects of 
congenital heart disease have been evaluated and are reviewed in the research described in 
this thesis. 
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ASPECTS OF THE AETIOLOGY OF CONGENITAL HEART DISEASE 

2.1 CAUSES AND RISKS OF CONGENITAL HEART DISEASE 
The evolution of an individual human being from a single fertilised ovum is a complicated 
process of which we are largely ignorant to date. A failure of this development in utero 
has always had great impact on the parents and on the community in general. Reactions of 
fear, mourning and guilt can be expected if a family is confronted with affected offspring. 
Explanations for the occurrence of congenital malformations have been sought in various 
domains and have engendered many theories on the causes of congenital malformations. 
However, despite a long history of attention and research relatively little is known. This is 
also true for congenital heart disease. 
Recent reports on congenital cardiac anomalies still cite that approximately 80 to 90% of 
the cases encountered at birth have a multifactorial origin (1,2). This implies that for the 
majority no single causative mechanism or agent is known. Rather, a general interaction 
model of genetic susceptibility and environmental factors is proposed based on empirical 
(re)occurrence data (3). Ergo, the risk for siblings if one case has occurred has been 
estimated to be in the range of 2 to 4 %. In the event of two affected siblings this risk 
increases to 6 to 12 %. In case one of the parents is affected there is also an increased 
risk for their offspring. Moreover, the sex of the affected parent appears to influence the 
risk. The paternal risk is comparable to that of one affected sibling, whereas the maternal 
risk has a range approximately equal to that of two affected siblings (4). This disparity in 
risk is largely unexplained. It may be that in fact what is currently called multifactorial, 
including specific maternal teratogens, actually constitutes an aetiologically heterogeneous 
group. For instance, it may be that affected males are less likely to start a relation as 
compared to affected females and subsequently may not reproduce. Alternatively, a 
monogenic disorder with imprinting, that is parental sex affects the expression of genetic 
material, can be considered. Lately, inheritance of cytoplasmatic or mitochondrial DNA, 
which is derived exclusively from maternal cells, has been added as yet another 
possibility. Thorough examination of extended pedigrees may enable distinction of specific 
patterns of inheritance. Furthermore, a striking resemblance of the type of anomalies or 
an identical embryological origin has been reported in over 50% of the recurring cases, 
which may point out a common pathogenetic process running in families (2,5). The 
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estimates of recurrence rates mentioned above are currently used in counselling of parents 
for the risk they carry for bearing affected offspring in the future. 
The efforts of researchers up until now have indicated that 10 to 20 % of cases may be 
associated with specific factors that have been identified. Approximately 6 to 10% is 
brought about directly by a chromosomal anomaly. Down's syndrome, for instance, has a 
strong association with cardiovascular anomalies; approximately 40 % of trisomy 21 cases 
are affected (6). Similar associations have been reported in other structural or numerical 
disorders of autosomal or sex chromosomes, with percentages of affected individuals 
ranging from 100 % for trisomy 18 to less than 25% for some chromosomal deletions like 
cri-du-chat syndrome, del(5p) (6,7). The type of anomalies encountered in the various 
syndromes is not as similar in the anomalies determined by chromosomal anomalies as 
they are in those determined by multifactorial origin. However, clustering of certain 
malformations in a particular syndrome has been described and may be an indication of a 
common embryologic origin or, perhaps more important, point at the chromosome(s) 
involved in the development of the organ(-structures). 
A further 5 to 10% of the cardiovascular malformations can be attributed to a genetic 
(Mendelian) disorder (1,2). A sizeable number of syndromes has been described with 
specific patterns of inheritance. Autosomal dominant inheritance has a 50% recurrence 
risk for the offspring of an affected parent. Autosomal recessive inheritance bears a 25 % 
recurrence risk for siblings of affected individuals and sex-linked inheritance a 50% 
recurrence risk for male offspring of a carrier female. 
About I % of the cardiovascular malformations can be attributed to maternal diseases (8). 
Maternal type I diabetes, which carries an estimated 2% risk of affected offspring, and 
maternal phenyl ketonuria, which presents an increased risk for the fetus if not treated 
adequately, are well known. In addition, systemic lupus erythematosus, which may carry a 
risk for structural malformations besides conduction disorders, should be considered 
(Frohn-Mulder, in print). 
Finally, approximately 1 % is caused by teratogen exposure (8,9). Excessive maternal 
alcohol consumption may carry a risk of almost 1 in 3 for congenital heart disease and 
other disorders. Maternal anticonvulsants use also increases the risk for the fetus to 2 to 3 
%. Use of lithium and retinoic acid (vitamin A) increase the risk too. The importance of 
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female sex-hormones and narcotics like cocaine, heroin etc. has not yet been established 
completely. Nevertheless, it is obvious that drug use during pregnancy should be avoided 
because of potential teratogenic effects. 
2.2 RESEARCH ON THE AETIOLOGY OF CONGENITAL HEART DISEASE 
Traditionally, in embryology observations derived from autopsy series on embryos of 
human origin and infants were accumulated either after normal or abnormal development. 
Subsequently theoretical models on the pathogenesis of cardiovascular malformations were 
deduced. However, several drawbacks of this type of research appear. Though apparently 
readily available for examination, it is difficult to gather cases as only a limited number of 
parents approve of having an autopsy performed on the abortion material or on their 
deceased baby. Furthermore, a fetus may be otherwise lost during abortion. Case 
ascertainment will not be complete and, subsequently, as a number of cases will not be 
identified a genuine occurrence rate can not be established. Therefore, the impact of 
possible pathogenetic factors may be (considerably) underestimated. In addition, as the 
cases are provided by occasional abortions and not systematically gathered during follow-
up of high risk pregnancies or exposed pregnancies, actual pathogenesis can not be 
studied. 
A research model to evaluate possible teratogenic agents and pathogenetic mechanisms is 
required to enhance the yield of embryology. Despite potential differences between human 
embryology and pathogenesis, chick embryos, among other species, are frequently used 
and appear to be a satisfactory animal model (10-12). Cardiac outflow tract defects 
comparable to those seen in DiGeorge and Sphrintzen syndrome have been shown to occur 
in chick embryos after ablation of parts of the neural crest (10) and administration of all-
trans retinoic acid (12). 
A further field of research in progress on the aetiology of congenital heart disease are 
genetics and molecular biology. Recently chromosome 22 has been identified as the 
chromosome involved in DiGeorge syndrome, Sphrintzen syndrome and possibly other 
types of (familial) malformations of the cardiac outflow-tracts (13). Small deletions in 
genes located on chromosome 22 coding for the development of structures 
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embryologically derived from the pharyngeal arches may cause a wide variety of 
phenotypes ranging from minor anomalies to full blown syndromes. Future research in 
genetics and molecular biology applying cytogenetic and DNA techniques may add a great 
deal to the knowledge on the aetiology of (familial) congenital heart disease and other 
malfonnations. 
The above findings originating from two distinct areas of research, both showing a causal 
relation with a common defect, may be explained by interference of various pathogenetic 
mechanisms with a common stage of embryogenesis. Apparently, nonnal development of 
the cardiovascular system involves many interactive steps that all have to be taken to 
result in a normal heart. Conversely, a presumption that several or possibly many 
pathogenetic mechanisms may cause identical malformations should be accepted. The link 
with the timing of embryogenesis is evident. In order for an incident to act on the 
development of an organ or structure it would have to occur at the time of interest. For 
congenital heart disease a gestational age of 14 to 60 days has been proposed as the most 
vulnerable period (8). 
Genetics, molecular biology and embryology focus on the identification of a particular 
pathogenetic mechanism in individuals deemed to be at risk for having affected offspring. 
Subsequently, adequate counselling and diagnostic tests may be performed. 
Epidemiology, on the other hand, may identify populations at risk. Especially, widespread 
exposure to "low-level" risk factors, which must have a pathogenetic basis and thus may 
be considered teratogens, can be expected to have a major impact on the occurrence of 
congenital malfonnations. A small increase in risk of affected progeny may lead to a 
significant increase of cases if the exposure-rate is high. A major problem in this type of 
research will be ascertainment of the exposure and of the cases (8). First of all it may be 
difficult to assess the exposure of cases to an agent of interest. Second, finding control-
subjects not exposed and excluding flaws like bias (recall bias) and co-existing risk-factors 
(or even other teratogens) may be complex. As mentioned above, another important issue 
is the timing of exposure to the presumed teratogen. If the time frame does not coincide 
with the embryogenesis or vulnerable period of the organ or structures of interest one may 
well miss any teratogenic effect. Time specific infonnation on exposure and analysis 
according to specified and rational time periods is therefore necessary. 
20 
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Case ascertainment is yet another crucial and problematic issue. The cases that present at 
birth are but a selection of cases that occur during embryogenesis. Fetal wastage may have 
a great impact on the birth prevalence and should be accounted for. Preferably by means 
of complete ascertainment of all cases prospectively, including cases resulting in intra-
uterine death. Moreover, complete case ascertainment implies rigorous case definition and 
diagnostic criteria applied to both early aborted fetuses and newborns. Catheterisation, 
autopsy and possibly neonatal ultrasound data are to be preferred as conclusive diagnostic 
procedures for congenital heart disease. A final point that needs the attention of the 
researcher is the study-size. In order to achieve sufficient (statistical) power the number of 
participants included should be deduced from the number of cases anticipated over the 
background prevalence or incidence. In turn, of course, the number of extra cases will 
depend on the teratogenic capacity of the agent. The apparent difficulties awaiting future 
epidemiologists should not discourage, but rather challenge them as the potential yield 
could be sizeable. If widespread risk factors are identified and can subsequently be averted 
effectively at popUlation level the number of infants with congenital heart disease may 
decrease drastically. Examples of possible low level, yet widespread, teratogenic agents 
are viruses, substances commonly applied in decontamination and electromagnetic fields. 
Especially viral infections, which are very common and often occur subclinically must be 
considered in this respect. Moreover, combinations of agents may potentiate each other or 
become teratogenic when taken or occurring in combination. 
Teratogens carrying a high risk for the individual with well known examples like 
thalidomide, retinoic acid (and the rubella virus) are important to bear in mind when 
prescribing drugs to people at reproductive age, in particular pregnant women. Currently, 
the principle of non-prescription during pregnancy is well recognised and a lengthy 
process of studies assessing the safety of drugs precedes marketing. Similarly, if available, 
vaccination preceding childbearing age prevents infections with known teratogenity during 
pregnancy in most Western societies. Therefore, the number of cases originating, and 
hence potentially preventable, from prenatal exposure will be small. Furthermore, it seems 
likely that high level teratogens that women are currently exposed to have not already 
been discovered. 
In summary epidemiologic studies with complete data on large series of early abortions, 
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including karyotyping, extensive post-mortem examination, clinical data on prenatal (or 
even pre-conceptional) exposure and clinical data on relatives are a source of infonnation 
currently neglected but with a great potential. A concerted action of epidemiologists, 
clinicians, geneticists, pharmacologists and fetal or paediatric pathologists should be 
encouraged and may also add to the current 10 to 20 % of cardiovascular anomalies 
explained by a specific factor rather than by the repository of multifactorial causes. 
2.3 POSSIBILiTIES FOR PREVENTION OF CONGENITAL HEART DISEASE. 
Emanating from the fact that at present we are largely unaware of the aetiology of 
congenital malformations of the cardiovascular system it is not feasible to pursue large 
scale primary prevention. That is, it is not possible to avert the occurrence of 
malformations in the offspring at a population level. However, for individual couples with 
known risk factors for affected offspring preventive measures can be adopted. For 
instance a young woman with type I diabetes trying to conceive should have an optimal 
insulin regimen to normalise blood glucose levels even before ovulation. Similarly, once 
the genetic basis of the condition of familial heart disease has been elucidated, e.g., the 
gene(s) involved has been recognised, it may be possible to develop diagnostic tests to 
identify individuals at risk. A next step may be to offer treatment to those individuals by 
means of gene-therapy or offer prenatal diagnosis to the couples at risk. It is likely that in 
the near future a number of specific monogenic disorders giving rise to congenital 
malformations of the cardiovascular system will be identified. 
Alternatively, secondary prevention may be an option in those cases where we are aware 
of increased risk but have not identified the causative agent. If already a child is born with 
congenital heart disease the risk for future siblings is increased. This is an indication for 
extended fetal echocardiography during future pregnancies. Upon prenatal detection of a 
cardiovascular anomaly the obstetric policy may be adapted, or termination of pregnancy 
can be offered in case a fatal anomaly is detected. Thus the outcome, the birth of a 
critically ill neonate due to a congenital malformation, is prevented rather than the 
occurrence of a malformation. Genetic counselling is part of this strategy as the geneticists 
determine the recurrence risk and set the indication for extensive fetal ultrasound 
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examination or other modes of prenatal detection. However, this strategy has little impact 
numerically as it can only be offered to the small subgroup of parents known to be at risk. 
Secondary prevention at a population level by means of routine fetal ultrasound, e.g. the 
fetal four chamber view at 18 to 20 weeks gestation, has been proposed as an adequate 
and efficient procedure (14,15). Upon detection of an anomaly during a routine ultrasound 
evaluation, extended examination in a referral setting should follow in order to confirm 
the diagnosis, offer counselling and adapt the obstetric policy if required. In theory 
population screening may have a potential yield for the fetus and parents. However, we 
feel that before general introduction several issues have to be clarified. 
The efficacy of the procedure has not been proven beyond doubt. Furthermore, the natural 
history of a number of anomalies is not known. Therefore, the consequences and impact 
of prenatal diagnosis should also be addressed. Large-scale state of the art epidemiologic 
studies can address the issue of need and utility of population screening by establishing the 
yield, efficacy and safety of the procedure proposed. Although not displaying the aetiology 
of congenital heart disease secondary prevention of congenital heart disease should be 
evaluated as it may reduce neonatal distress due to congenital heart disease or even lower 
the birth prevalence of some fatal or severe anomalies as a result of termination of 
pregnancy in affected cases (16). 
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PREVALENCE OF CONGENITAL HEART DISEASE; A CRITICAL ASSESSMENT 

INTRODUCTION 
The birth prevalence of congenital malfonnations is estimated at about 2 to 3 per 100 live 
births (1,2). Anomalies of the cardiovascular system, detected in about 8 per 1000 live 
births, either isolated or in combination with other birth defects, account for a large 
proportion of this number (3). Many reports on the number of children born with 
congenital heart disease in various populations have appeared, offering a considerable 
range in frequency in the human conceptus. Variation in factors such as method of 
diagnosis, or examination of liveborn infants versus spontaneously aborted fetuses, have 
led to estimates of frequency between 2 and 680 per 1000 (4,5). Irrespective of the exact 
frequency of occurrence, congenital heart disease still causes considerable morbidity and 
mortality. While perinatal and childhood mortality related to, for instance, infectious 
diseases has decreased dramatically in the latter half of this century (6,7) the proportion of 
newborn children with congenital heart disease has remained more or less stable. Thus, 
congenital cardiovascular malfonnations have gained relative importance in contributing to 
mortality despite major advances in paediatric cardiology and cardiac surgery. For 
instance, 18.2% of 4390 infants with congenital heart disease registered in the Baltimore 
Washington Infant Study from 1981 to 1989 did not survive their first year (8). Equally, a 
significant proportion (20 to 35 %) of perinatal mortality and childhood mortality due to 
congenital anomalies is associated with cardiovascular malfonnations (6,9,10). 
As the aetiology of congenital heart disease still is largely unknown (11), prevention based 
on intervention at a causal level remains an elusive goal. As a consequence, paediatric 
cardiologists and, increasingly, geneticists and obstetricians, remain faced with a variety 
of clinical conditions which consume a large amount of the available resources for child 
health care. In this paper we will review the literature reporting data on the occurrence of 
congenital heart disease. In addition, possible explanations for the variability in the figures 
reported will be examined and, finally, recommendations for further study will be 
provided. 
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APPROACH 
Papers and books, published over the last 4 decades, on the occurrence of congenital heart 
disease in humans were studied. Primary papers on studies, describing the methods in 
sufficient detail, were selected. Subsequently, characteristics of study design, e.g., period 
of case ascertainment, length of follow-up, procedures of case ascertainment, diagnostic 
procedures applied, composition of the study population, case deflnition and study size 
were extracted, together with the flnal prevalence flgures. Finally, with these guidelines, 
comparable data on various populations, nations, and era were available. 
Our aim was to assess the influence of various characteristics of study design on the 
reported prevalence, rather than to establish an ultimate overall point estimate of the 
prevalence of congenital heart disease. Accordingly, if sufficiently detailed information 
was available the data were pooled, under the assumption of one general prevalence, 
according to categories of design features. Proportions, with a 95 % confldence interval, 
were calculated. 
FINDINGS 
The various characteristics of study design, potential sources of variability, will 
successively be assessed. In table 1 the principal methodological characteristics and the 
results of the studies reviewed are summarised. Striking differences in the reported preva-
lence of congenital heart disease appear. For instance, Fyler et al. have reported the 
lowest prevalence of congenital heart disease in a very large hospital-referral based study 
(2.08 ± 0.086 per thousand) whereas Meszaros et aI., in a much smaller population-based 
study, reported the highest prevalence (11.9 ± 2.8 per thousand)(4,22). 
period of case ascertailllllellf 
The selected reports cover a period of ascertainment of cases from 1940 to 1989. A 
chronological representation of the prevalence figures reported does not reveal a 
systematic variation over time. That is, no specific trend can be detected. 
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duration of follow-up 
The duration of follow-up. on the other hand. has a direct impact on the prevalence 
estimates. A comparison of studies with a maximum follow-up of one year (prevalence 
0.417%; 95% C.l.: 0.409 - 0.424) to studies with a follow-up of over one year 
(prevalence 0.604%; 95% C.I.: 0.592 - 0.617) shows that a longer period of follow-up is 
likely to yield a larger proportion of children with congenital malformations. This is illus-
trated in figure 1. 
Figure 1 Prevalence of congenital heart disease in relation to duration of follow-up 
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CHD = congenital heart disease; C.1. = confidence interval 
methods of ascertaillmelll 
The methods of ascertainment used may be another source of variability of the prevalence 
of congenital heart disease reported. Comparing the results of studies applying routine 
examination of all children (prevalence 0.717%; 95% C.l.: 0.691 - 0.743) to the results 
of studies using infonnation retrieved from pre-existing medical records for case finding 
(prevalence 0.448%; 95% C.I.: 0.441 - 0.455) demonstrates that routine examination 
yields a larger proportion of cases of congenital heart disease (figure 2). 
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Footnotes: 
Abbreviations: CHD = congenital heart disease; ASD = atrial septum defect; VSD = ventricular septum defect; ISC; CHDC = International Society of Cardiology; Classification 
of heart disease in Childhood; ICD = International Classification of Diseases; ODB = open ductus Botalli; A VSD = atrio-venticular septal defect 
Diagnostic procedures: 0 = history taking; 1 = physical examination; 2 = chest X-ray; 3 = ECG (electro cardiogram); 4 = phonocardiogram; 5 = e1ectromycogram; 6 = cardiac 
catheterization; 7 = angiography; 8 = echocardiography; 9 = surgery; 10 = autopsy; 11 = clinical evaluation (not specified) 
Symbols: * = estima1ed population; t = isolated CHD; :1= = calculated from the information available in the CHD register (256 births); § = series on spontaneous abortions < 24 
wks; an inverse relation between fetal size and prevalence of CHD is found, range 1 - 68 %; II = series on spontaneous abortions between 9 and 40 weeks gestational age; a direct 
relation between fetal size and prevalence of CHD is found, range 0 - 30% 
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Figure 2 Prevalence of congenital heart disease in relation to method of ascertainment 
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diagnostic procedures 
Additional factors in ascertairunent-variability are the diagnostic procedures employed. 
The results of the studies classified according to use of invasive methods only (prevalence 
0.208%; 95% C.I.: 0.199 - 0.216), as opposed to additional use of non-invasive methods 
(prevalence 0.605%; 95% C.I.: 0.596 - 0.615) clearly shows that adoption of non-
invasive procedures yield more cases (figure 3). With respect to the nature of the 
malformations detected in the different studies, the column in table 1 concerning septal 
defects indicates that the proportion of minor lesions encountered increases with the use of 
non-invasive diagnostic procedures like physical examination, chest X-ray, ECG and 
ultrasound. Figure 3 also demonstrates the effect of introduction of ultrasound diagnosis; a 
lower prevalence appears in studies applying ultrasound (prevalence 0.563%; 95% C.I.: 
0.550 - 0.595) versus studies relying on other non-invasive procedures (prevalence 
0.653%; 95% C.I.: 0.639 - 0.668). 
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Figure 3 Prevalence of congenital heart disease in relation to diagnostic precedures applied 
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composition of the study population 
Subsequently. the composition of the study population may have influenced the prevalence 
reported. Stillbirths appear to have been included more or less arbitrary in several 
studies. The effect on the prevalence of congenital heart disease reported can be confirmed 
when the data are pooled according to the inclusion of non-live born products of concep-
tion (prevalence 0.550%; 95% C.I.: 0.528 - 0.572) versus liveborn only (prevalence 
0.455%; 95% C.I.: 0.448 - 0.462). This is illustrated in figure 4. 
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Figure 4 Prevalence of congenital heart disease in relation to study population 
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definitions of congenital ileaft disease 
The definitions of congenital heart disease employed may also influence the results of the 
different studies. Regrettably, however, very little ioformation about the exact definitions 
used is available. 
size of the study 
Another issue of design is the size of the study. The size of the populations investigated 
shows a wide range, from 1,817 to over a million births. 
DISCUSSION 
The summary of the data available on the prevalence of congenital heart disease indicates 
that certain consistencies across the various studies are present. However, cautious 
interpretation of discrepancies in results reported is also warranted. It is very likely that 
differences in availability or access to diagnostic equipment or in attitudes to the use of 
autopsies exist and are further influenced by the era of study or the population studied. 
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For il15tance, in the United States the autopsy-rate increased from 5.4% to 11.9% in 
cardiac infants in approximately 10 years (4,8,30). This may have been one of the factors 
involved in the increase of prevalence of congenital heart disease (2% to ahnost 5%) 
noted over this period. Another, though less obvious illustration may be the degree of 
medical care provided for infants with chromosomal anomalies like Down syndrome. 
Culture and ever evolving ethical considerations within cultures may influence medical 
care and. as chromosomal anomalies are often associated with congenital heart disease. the 
reported prevalence may vary accordingly. Little quantitative data is available on these 
issues but qualitative assessment may help to understand the consequences of these sources 
of variability. 
Contrary to qualitative argumentation on not strictly methodological issues mentioned 
above, the results of the inventory of the available data may provide information readily 
accessible for inference. 
The era of case ascertainment may reflect the prevailing practice of medicine. Therefore, 
one may expect the prevalence reported to vary systematically over time. However, no 
specific trend, that is, either an increase or decrease in the prevalence of congenital heart 
disease over time, can be demonstrated in the reports reviewed. Other features of study 
design such as length of the period of follow up and the introduction of routine follow-up 
on all children may have surpassed the expected effects of evolving medical technology 
and societal values. 
Length of postnatal follow up is shown to importantly influence the prevalence of 
congenital heart disease found in a particular population. A shorter period of (postnatal) 
follow-up will lead to the detection of fewer cases; especially subtle malformations that 
lack evident symptoms may only be recognised at later age. 
Differences in methods of case finding or ascertainment also explain a major part of the 
variability of the prevalence. Janerich et al. have, similarly, proposed this to be a major 
reason why the prevalence of congenital defects differs widely (34). Other authors have 
also taken ascertainment into account when reviewing the prevalence of congenital heart 
disease (35,36). The completeness of ascertainment varies markedly across the various 
studies. The more comprehensive population based studies that apply routine examination 
to all infants, and additional referral if clinically indicated, report the highest prevalence, 
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whereas in hospital based studies, only using clinical and autopsy records, a lower 
prevalence is found. Likewise, a study that utilises a register designed especially to 
document congenital malformations will report a higher prevalence. In this respect, the 
results obtained by Bleuer et aI., and Calgren et aI., are illustrative (24,29). Other 
examples of the influence of case ascertainment or selection include two studies by Gerlis 
and Chinn et aI. (5,33). They reported a remarkably high prevalence of congenital heart 
disease (> 10 per hundred) in autopsy series on spontaneous abortions or stillbirths. In 
general, as the number of sources and the quality of available data increases, the 
proportion of children with malformations detected also increases. 
Awareness of (changes in) the diagnostic procedures applied may also reveal explanations 
for differences in reported results. As mentioned above, if all children are examined 
routinely within the first months of life a higher prevalence of malformations may be 
expected, especially if this involves the internal organs. Therefore, information on local 
practice of medicine appears to be essential. The effects practice and diagnostic 
procedures can have, may be illustrated by an "epidemic" of congenital heart disease that 
has been noted since 1970 by several authors (37-39). The increased numbers of cardiac 
malformations proved to be mainly mild cases, notably small ventricular septal defects. 
Probable explanations for the uincrease H in prevalence include a raised awareness and 
referral to paediatric cardiologists and improved diagnostic procedures. The authors have 
attributed a major part of the increased prevalence of congenital heart disease to the 
introduction of ultrasound as a reliable diagnostic criterium. For instance, the Baltimore 
Washington Infant Study that has added diagnoses obtained by means of ultrasound as 
(non-invasive) inclusion criterium during the period of case ascertainment have noted an 
increase of prevalence of congenital heart disease (8). As is demonstrated in figure 3, this 
is not in accordance with our findings. It may well be that, prior to introduction of 
ultrasound, cases not considered serious were not submitted to invasive teclmiques like 
catheterization and, hence, were not ascertained in studies applying invasive methods for 
inclusion. Conversely, studies not applying the strict criteria of invasive diagnostic 
procedures (or echocardiography) probably already had accomplished a high level of 
ascertainment and, subsequently, a more accurate estimate or the prevalence. It appears 
that physical examination still is one of the most important screening tools for congenital 
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heart disease (40). Nevertheless, because the heart can be examined anatomically and 
functionally, ultrasound may have the advantage that the amount of detail of the diagnosis 
and assessment of its functional implications are improved. The prevalence figure, 
however, will not differ due to use of echocardiography alone. Especially, the more 
severe cases will be noted early in life anyhow and, subsequently, the matching prevalence 
is not altered by differences in practice nor by variation in length of follow up. Autopsy 
(records), which would seem to provide a very solid end-point diagnosis, must also be 
considered carefully and in relation to local circumstances. In many countries it is not 
customary to perform an autopsy and accordingly autopsy records possibly are not as 
reliable as they may seem. Moreover, as Hoffman et at. have pointed out, the extent of 
expertise of the prosector and of detail of the post mortem examinations may vary (19). In 
particular, spontaneous abortions and stillborn fetuses may not be submitted to an 
(extended) post-mortem examination and as premature death may well be related to a 
congenital anomaly (5,33,41,42), the prevalence of congenital heart disease may be 
(grossly) underestimated. Finally, not even the use of modern diagnostic techniques and 
all available data sources will render the complete picture of congenital heart disease. 
Russel et at. have postulated that even under optimal clinical observation of an infant with 
congenital heart disease, postmortem evaluation may show important undetected cardiac 
pathology (43). 
As noted, composition or selection of the study-population also influences the prevalence 
reported. In view of the results obtained by Gerlis and Chinn, on average, one may expect 
an increased prevalence in the studies including stillbirths. Estimates of the prevalence of 
congenital heart disease in a study on spontaneous abortions almost reach 70% in the early 
fetus of < 25 mm (5,33). Furthermore, Samanek et at. found a 2.1 % prevalence of 
congenital heart disease in a large autopsy series which included stillbirths and infants that 
died from birth to the age of 15 years (44). 
In addition to the difficulties mentioned so far, problems in comparing prevalence 
numbers emerge due to varying definitions and inclusion criteria for cases of congenital 
heart disease. Authors used to refer to the embryonic origin when defining congenital 
heart disease, gradually shifting to a stepwise analysis of defects, following blood flow 
through the heart. However, definitions and classification of congenital heart disease still 
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are a matter of debate (45). The diversity of definitions causes arbitrary inclusion or 
exclusion of, for example, bicuspid aortic valve or patent ductus arteriosus, leading to 
confusing results. Studies that have distinguished between major and minor defects have 
done so on a functional basis, e.g., causing death, physical handicaps or warranting 
surgery. This resulted in a more or less stable estimate of about 4 major cardiac 
malformations per thousand live births as was noted by Hoffman (36). 
Recent hospital based Dutch data by Bruins and Temmerman corroborate with this figure 
(unpublished data). 
A problem related to case definition follows from the measure of interest; the proportion 
of infants with a congenital defect born in a particular time period. Only at the moment of 
birth a cohort can be defined and at that particular point in time, or shortly thereafter, a 
neonate with a congenital malformation can be recognised as a case. Yet, in the literature 
on congenital defects one often encounters the use of II incidence It, a measure of 
occurrence, of congenital malformations. Seemingly only a definition problem, as 
MacMahon and Pugh pointed out, the term "prevalence", or better still "prevalence at 
birth", should be used when referring to the above mentioned fraction (46). The actual 
incidence of congenital heart disease, the number of new cases that develops, can not be 
estimated. From the moment of conception onward, or even before if factors influencing 
the genu cells are taken into account, progression or induction of teratogenesis may occur, 
contributing to the actual incidence. However, because of early fetal loss many of these 
cases will never be born. Not being able to ascertain these cases precludes determination 
of the true occurrence rate. Furthennore, some malformations like small ventricular septal 
defects may heal or close spontaneously even before birth, again leading to 
underestimation of the occurrence of cardiac anomalies. It is important to realise that the 
incidence rate is a measure readily applicable in causal inference. Prevalence on the other 
hand is a measure of disease status and is a function of the occurrence of malfonnations, 
or incidence, and survival characteristics of the fetuses. Interrelating prevalence data, as if 
equivalent to incidence, directly to any conceivable risk factor may (strongly) 
underestimate the impact or teratogenic capacity of the risk factor depending on the 
ascertairunent and survival until delivery of the affected fetuses. 
The fact that many studies have reported on relatively small numbers resulting in unstable 
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estimates of proportions, i.e., wide confidence intervals, may also have influenced the 
reported figures. This statistical variability may also account for some of the differences in 
prevalence found. 
Real differences among populations may provide yet another explanation. Populations may 
differ with respect to prevailing aetiologic factors of congenital heart disease. Correa-
Villasenor et aI., reporting on a white versus black population difference in prevalence of 
congenital heart disease in the Baltimore Washington Infant Study, controlled for a 
number of socioeconomic (risk) factors like marital status, education, occupation, family 
income, number of family members, prenatal care and maternal age, possibly contributing 
to variability of prevalence estimates, and still could not explain all of the difference in 
prevalence (47). 
Similarly, the natural history of some cardiovascular malformations may influence the 
results obtained. A small muscular ventricular septal defect or patent ductus arteriosus 
might close spontaneously early in life. This implies that, apart from all methodological 
variability, the natural history of several lesions will affect prevalence over time. 
CONCLUSIONS 
Appraisal of the prevalence of congenital heart disease proves not to be unequivocal. 
Depending on a number of methodological issues, the population studied and the local 
practice of medicine, a wide range of prevalence may be obtained. However, despite the 
variability in case definition, the birth prevalence of major or severe congenital heart 
disease requiring acute medical attention has been reported with remarkable consistency. 
The prevalence of less severe cases, on the other hand, may need further research. The 
length of follow-up, case ascertainment, diagnostic procedures applied, population 
characteristics, number of participants and the case definition may all substantially 
influence the results. 
It should be stressed, however, that if only a proportion of all cases of congenital heart 
disease can be ascertained, this does not imply that a particular study is not useful. If the 
search for cases is restricted to severe congenital heart disease, for example to assess the 
resources that have to be allocated, that may well be a worthwhile enterprise. Yet, one 
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must keep in mind that such a study has limited value when the aim is a description of the 
occurrence of congenital heart disease in a population, or if the prime interest is to study a 
causal relationship. Then complete ascertainment, including anomalies inducing cases of 
premature death, is a prerequisite. 
A fmal remark can be made on the increasing numbers of congenital malformations being 
detected prenatally. Early detection of severe congenital heart disease will give parents the 
option to terminate pregnancy. Allan et al. have noted a drop in the number of newborn 
infants with hypoplastic left heart syndrome since the introduction of a prenatal screening 
program for congenital heart disease (48). Many parents chose termination of pregnancy 
after explanation of the possibilities and prognosis of this particular malformation. The use 
of ultrasound in obstetrics is widespread and the introduction of prenatal detection of 
cardiac anomalies by means of fetal echocardiography may alter the post-natal prevalence 
of congenital cardiac defects. In addition, the opportunity to detect severe malformations 
in utero has stimulated fetal care (49) and may result in reduced perinatal morbidity and 
mortality. However, the efficacy of routine fetal ultrasound screening for congenital heart 
disease in a low risk population has yet to be established. Future research focused on the 
feasibility of a fetal screening program for cardiac malformations may resolve the ongoing 
discussion on the utility of ultrasound in pregnancy. Furthermore, the impact of screening 
on the prevalence and the outcome of congenital heart disease could be evaluated. 
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CHAPTER 4 
CONGENITAL HEART DISEASE; EPIDEMIOLOGY, IMPACT 
AND FETAL IMPLICATIONS 

4.1 INTRODUCTION 
In recent decades numerous reports on congenital heart disease have appeared. Among 
these are epidemiologic studies and (national) health statistics to provide quantitative 
information regarding the impact of cardiovascular anomalies on public health. 
Furthennore, a great number of publications on various types of malfonnations is 
available. Even data on prenatally detected malformations have appeared. 
I! may, however, be difficult to link together this overwhelming body of information on 
the various aspects of cardiovascular anomalies. In the present review an effort has been 
made to comprehend some of the principal issues involved in congenital heart disease in 
order to provide a basis for further discussion and research. 
4.2 EPIDEMIOLOGY 
The prevalence of major congenital malformations has been estimated at about 3 per 
hundred live births (1,2). Of these, cardiovascular malformations constitute a significant 
proportion. The reported birth prevalence of congenital heart disease ranges from 2 to 12 
per thousand (3,4) and increases have been suggested in recent years. The variability in 
reported numbers has been addressed by several authors and appears to be related to the 
design of a study (5,6). Similarly, the recent increase in numbers may be attributed to 
improved detection of minor cases, particularly ventricular septal defects (7,8), while in 
reality the occurrence has rfmained stable. Currently, a best estimate of the prevalence of 
congenital cardiovascular malformations would be 8 per thousand live births (9), thus a 
significant proportion of the total number of congenital malformations. In 1989 the birth 
rate in the Netherlands was 12.7 per thousand inhabitants (10). The total number of births 
reached 190,079 that year, implying some 5,700 children born with congenital defects of 
which about 1,500 can be expected to have congenital heart disease. Bruins and 
Temmerman performed a prospective hospital based study in the Netherlands in order to 
estimate the prevalence of congenital heart disease in the 1980 and 1985 birth cohorts and 
closely confirmed these expected numbers of cardiovascular malformations (11). 
Cardiovascular malformations are not a single entity but can be classified according to a 
47 
Chapler 4 
large range of complicated diagnoses. Hoffman recently reviewed several series on 
congenital heart disease and although prevalence varies, the subdivision of cases according 
to diagnosis is reported with remarkable similarity (6). Ventricular septal defect constitutes 
the single largest group of about 30 % of all congenital heart disease, and is followed in 
decreasing order by patent arterial duct, atrial septal defect, pulmonary stenosis (each 
about 10 %), tetralogy of Fallot and coarctation of the aorta (each about 7%), aortic 
stenosis and transposition of the great arteries (about 5% each). These diagnoses account 
for approximately 85 % of the cardiovascular malformations encountered in children (table 
1). Note that the data from which this order has been derived are largely population based 
and may not reflect the proportions observed in a hospital setting. 
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Table 1 Prevalence (%) distribution of various types of cardiac malformations. Adapted from Hoffman (6). 
author VSD PDA ASD PS ToF CoA AS d-TGA AVSD HLH HRH TA TAPVC SV DORV Misc. Total 
CuI"", 27.1 9.5 4.3 3.8 4.1 9.8 5.4 6.0 3.0 0.8 2.4 1.4 0.8 0.0 0.0 21.7 396 
"""''''''"''' 
Rose ct aI. 31.0 7.1 11.2 10.8 8.0 3.4 8.4 2.6 0.0 1.1 0.0 0.0 0.0 0.0 16.4 464 
Toronto 
Feldtet aI. 34.6 10.6 7.3 5.01 5.0 5.6 6.1 7.8 4.5 4.5 3.4 0.0 2.8 0.0 0.0 2.8 179 
Minnesota 
Mitchcll et aI. 32.12 8.3 7.4 8.6 3.8 6.73 3.8 2.6 3.6 3.1 2.4 1.7 0.0 0.7 1.0 13.8 420 
USA multicenter 
Boundet aI. 28.1 6.5 8.3 2.7 8.6 5.6 4.1 5.6 7.4 3.3 1.5 1.2 2.1 1.5 0.0 13.6 338 
Blackpool 
Hoffman et aI. 31.3 5.5 6.1 13.5 3.7 5.5 3.7 3.7 3.7 0.6 0.6 2.5 0.6 0.6 0.6 17.8 163 
California 
Meszaros et aI. 20.9 11.9 10.4 10.4 4.5 6.0 11.0 4.5 4.5 1.5 4.5 9.0 43 H""""" 
uurscn 24.0 12.6 9.44 5.9 5.8 7.0 4.7 4.8 2.6 3.0 1.8 1.4 1.4 1.5 0.0 15.7 5249 
Donmruck 
Dickinson et aI. 32.5 11.9 5.9 7.6 5.9 6.3 5.1 5.0 2.4 2.8 2.5 1.1 0.8 1.7 0.0 8.0 884 
LivelJlOOl 
Ferencz et aI. 26.3 2.6 7.5 7.0 9.2 6.8 3.3 5.0 8.6 5.7 3.2 1.5 1.7 11.6 1494 
Baltimore-Washington 
Bruins et aI. 32.3 5.85 5.6 7.7 6.0 4.3 6.3 4.3 4.4 1.5 1.0 0.9 0.9 1.5 1.1 15.7 2736 
Netherlands 
1 includes pulmonary atresia; 2 eleven with with pulmonary atresia; 3 seven with ASD or VSD; 4 includes ASD I; 5 excluding neonatal cases 
Abbrevations: VSD ventricular septal defect; PDA patent ductus arteriosus; ASD atrial septal defect; PS pulmonary stenosis; ToF tetralogy of Fallot; CoA coarctation of aorta; AS 
aortic stenosis; d-TGA d-transposition of great arteries; A VSD atrioventricular septal defect~ HLH hypoplastic left hean; HRH hypoplastic right heart; T APVC total anomalous 
pulmonary venous connection; SV single ventricle; DORV double outlet right ventricle; Misc. miscellaneous 
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4.3 IMPACT 
4.3.1 Mortality 
One way to estimate the impact of congenital heart disease on the state of health of 
children is looking at mortality rates. A considerable decrease in both perinatal and infant 
mortality has been reported over the last decades. Perinatal mortality amounted to 34.2 
per thousand births in 1950 and has declined to approximately 10 per thousand in 1984 
(12). Infant mortality has shown a similar improvement, dropping from 29.8 to 9.6 per 
thousand live born and from 23.3 to 7.0 per thousand live born for male and female 
infants respectively. The proportion of infant mortality related to congenital malfor-
mations, however, has increased from 26% to 33% for male infants and from 31 % to 
36% for female infants from 1970 to 1990 (13) and may be explained by a declining 
overall mortality and a stable birth prevalence of congenital malformations, which thereby 
gain importance as a cause of morbidity and possibly mortality. The proportional 
contribution of cardiovascular anomalies to infant mortality, however, does not show a 
similar development. In contrast, the proportion of infants that have died due to congenital 
heart disease has remained more or less stable (perhaps slightly decreasing from 12.8 to 
11.6% over the past two decades) (13). Accordingly, the contribution of congenital heart 
disease to infant mortality caused specifically by congenital malformations has declined 
from about 45% in 1970 to 34% in 1990. Paediatric cardiology and surgery with greatly 
improved diagnostic and therapeutic approaches in infancy have contributed to this course. 
Dutch data from Bruins and Temmerman confinn this evolution. Infant mortality as a 
result of structural cardiac malformations appears to have been approximately 9% between 
1980 and 1985 (11). 
Data on prenatal mortality either from spontaneous or induced abortions are still scarce. 
However, as Stein et al. pointed out that children born alive are a selection of the 
conceptions of which a sizable proportion has ended in miscarriage (14). As a result it can 
be anticipated that the incidel!ce of fetal malformations is considerably higher than the 
prevalence at birth. The smdl number of studies on this issue have indeed reported a 
prevalence of cardiovascular malformations among spontaneous abortions and stillborn 
fetuses which exceeds the prevalence encountered at live birth by a factor 2 to 80 (15-17). 
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This extreme range may again be explained by methodological differences between the 
various studies. However, the overall impression of a substantially higher prevalence of 
fetal heart disease as compared to the birth prevalence remains evident. Furthermore, 
Allan et a!. reported on the higher severity of cardiovascular malformations encountered 
prenatally by means of fetal echocardiography (18). She postulated that this could be 
explained by selection of patients referred for fetal evaluation or, alternatively, by 
selective fetal wastage in case of a more serious anomaly. After all, spontaneous abortion 
of severe cases would result in survival to term of comparatively mild cases or cases of 
congenital heart disease lacking major hemodynamic consequences prenatally. 
Nevertheless, although mortality data suggest that the case fatality has decreased it 
remains beyond dispute that congenital heart disease still poses a major health problem in 
infancy. Furthermore, these numbers oniy provide a limited impression of the 
consequences of congenital heart disease. The various diagnoses are quite different with 
specific natural history and prognosis. Accordingly, morbidity, an other major aspect of 
congenital heart disease, should be discussed. 
4.3.2 Clinical features 
A substantial portion of congenital cardiac malformations has oniy a limited clinical 
consequence. For example, a small ventricular septal defect may not have hemodynamic 
consequences and has a tendency to close spontaneously in 30 to 40% of the cases (19). 
Conversely, 60% of the children with congenital heart disease do not require treatment 
and are presumed to have a normal life expectancy and quality of life (11). The remaining 
40%, however, may suffer from a particular malformation on a short or long term basis 
and hence treatment should be provided. Surgical techniques and post operative care, 
including drug treatment, have evolved to such an extent that operative and early post 
operative mortality have reached levels beneath 5 % for the majority of malformations 
even in the neonatal period (20). Furthermore, in recent years interventional paediatric 
cardiology has proven to provide a safe and effective alternative in the management of 
certain cardiovascular malformations (21). 
Clearly, these summary figures do not apply readily to all malformations, some of which 
are very complicated and occasionally treated experimentally. The long term prognosis of 
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many of these problems, especially with respect to the more recently developed 
intervention techniques, has not yet been assessed. However, a proper understanding of 
the impact of congenital heart disease requires an appraisal of the life expectancy and late 
morbidity after treatment, preferably for each diagnosis separately. 
ventricular septal dejects 
Not even ventricular septal defects, the largest single group of malformations, can be 
considered in its entirety because different forms of septal defects may have quite different 
natural histories and require different treatment regimens. Depending upon size and 
morphology of the defect, policies can be adapted. Spontaneous closure within the first 
five years of life in about 60% of the cases is characteristic for a small to medium sized 
muscular defect and hence can be managed medically in the majority of patients (22). In 
the Natural History Study about 70% of all patients with ventricular septal defects were 
initially managed medically of whom 30% subsequently required surgical intervention 
(23). Mortality among those managed medically reached 12.7%. Surgically managed 
patients have excellent short te1m survival of over 98% (22). However, long term survival 
is slightly lower (82.9%) than for those managed medically (23). Evaluation of the causes 
of death of patients with a history of congenital heart disease shows a marked association 
with the anomalies, e.g., in 65% of the patients managed medically to 90% of those 
managed surgically, sudden death (presumably arrhythmia), congestive heart failure, 
bacterial endocarditis or an unspecified cardiac cause is diagnosed. The majority of 
patients with a ventricular septal defect have a good prognosis with a 20 year survival of 
87 % and a New York Heart Association functional status of class 1 to 2, even for those 
who underwent surgery (23,24). Probably, these long term results will improve further 
due to recent developments in diagnostic and surgical techniques 
atria· ventricular septal deject 
A more complicated variant of ventricular septal defect, the atrio-ventricular septal defect, 
which is often found in association with Down syndrome, combines multiple anomalies. 
This malformation is composed of several entities: a low primary atrial septal defect, one 
common atrio-ventricular valve and a ventricular septal defect. The disrupted internal 
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anatomy of the heart then causes several other structures to be displaced. The ostium of 
the aorta shifts ventrally and the atrio-ventricular conduction system moves dorsally. 
Moreover, atrio-ventricular septal defects may occur as a complete variant, where both the 
atrial septal defect and the ventricular septal defect are of importance, or as an incomplete 
variant presenting with an atrial septal defect only. The natural history and hence the 
treatment varies accordingly. The complete variant of atrio-ventricular septal defect may 
cause massive left to right shunting and atrio-ventricular regurgitation of blood, as a result 
of which these patients may develop progressive pulmonary vascular obstructive disease 
and heart failure and as subsequently often succumb before the age of 5 years. The 
extreme variants of atrio-ventricular septal defects have an even worse perspective with 
severe cardiac failure in early infancy resulting in death if surgery can not be performed. 
The partial variant has a far less dramatic course provided that atrio-ventricular 
insufficiency is limited. In view of the poor prognosis, surgical management has a 
relatively favourable outcome in complete atrio-ventricular septal defects. Infant mortality 
reaches 15% and half of the patients develop mitral insufficiency, which may require 
treatment at a later stage. The results of cases with incomplete atrio-ventricular septal 
defects are more favourable with only a 2 % infant mortality. Dutch data from 1980 and 
1985 on 130 patients, complete and incomplete atria-ventricular septal defects combined, 
of whom 56 were operated upon in the first year, confirm the seriousness of this type of 
cardiovascular malformation with an infant mortality of 23% in the surgical group (11) 
patent ductus arteriosus 
The patent ductus arteriosus may close spontaneously as part of normal development in 
neonates born pre-term. Spontaneous closure has also been reported at later age. Defective 
wall constitution, however, precludes spontaneous closure. Bruins & Temmerman reported 
a spontaneous closure rate of about 15% in the post neonatal period and, furthermore, 
reported nil operative mortality in 109 patients (11). Currently, interventional cardiology 
also offers a solution, e.g., trans-catheter umbrella closure with very promising results 
and improved post procedure recovery and morbidity, as compared to surgical treatment 
(25). Patent ductus arteriosus can be treated safely and effectively without major 
complications. 
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atrial septal deject 
Atrial septal defects can be categorised according to the size and morphology of the lesion 
too. Yet, compared to ventricular septal defects spontaneous closure is far less common. 
Bruins & Temmennan reported this to occur in 6% of 152 cases (11). If not treated, 
patients may not have any complaints until adult age despite sizable shunting. However, 
by then irreversible changes of the pulmonary arteries and myocardium as well as 
dysrhythmia may have occurred, resulting in an unfavourable prognosis. Accordingly, 
surgical intervention is imperative at a younger age and has excellent results with a short 
term mortality of less than 1 % (11,23). Of the surgically treated patients some suffer from 
unfavourable consequences of surgery such as dysrhythmia (±5%) or mitral valve 
prolapse (±37%) and may require additional treatment (27-29). Interventional cardiology 
may further reduce these sequelae if umbrella closure can be achieved. Overall, patients 
with atrial septal defects have a very good prognosis. 
pulmonary stenosis 
Pulmonary stenosis is increasingly treated by means of balloon dilatation as an alternative 
for surgical intervention after its introduction by Kan in 1982 (30). Dutch data confirm the 
success of this mode of therapy with outstanding short and longer term prognosis (31). If 
performed on children over six months of age the pressure gradient over the pulmonary 
valve was shown to decrease markedly in aU cases, Long tenn adverse outcomes were 
mainly restricted to mild pulmonary regurgitation which is well tolerated. Severe or 
complicated cases of pulmonary stenosis requiring treatment under six months of age may 
be better off when managed surgically (32). Recently Constance reported on the Natural 
History Study II results of surgically treated patients (23). These patients also appear to do 
very well with a 25 year survival rate of 95 %, comparable to the general population. Of 
the survivors 97 % were in New York Heart association class I condition. Bruins and 
Temmennan also reported excellent results observing no mortality in 210 patients of 
which 24 were managed surgically within the first year of life (11). Morbid events appear 
to be rare irrespective of treatment when properly chosen. Patients with pulmonary 
stenosis may expect a normal life expectancy, excluding procedure related mortality (23). 
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tetralogy of Fallot 
Classical description of Fallot's tetralogy , 'Ia maladie bleue', mentiol15 a ventricular 
septal defect, a to the right deviated aorta, infundibular stenosis of the pulmonary artelY 
and consequently right ventricular hypertrophy. Currently, tlllS complex anomaly is 
regarded as secondary to a mal-alignment, ventrally and to the right, of the outlet or 
infundibular part of the ventricular septum. Subsequently, a ventricular septal defect 
subsists, the aorta is deviated to the right, over-riding the ventricular septal defect, and the 
right ventricular outflow tract is narrowed. Tetralogy of Fallot has many variants 
determining the clinical features of this syndrome of cardiovascular malformations. 
Treatment is invariably surgical but the timing of operation is determined by the 
obstruction of the right ventricular outflow tract, the type of pulmonary stenosis, the size 
and development of the pulmonary arteries and finally the clinical status of the patient 
(33). In particular a cyanotic spell which is a life threatening complication of tetralogy of 
Fallot demands acute intervention. Treatment used to consist of two-stage surgery; early 
palliation by means of a shunt and correction at later age. However, early corrective 
surgery has proven at least equally effective and this therapy is now adopted with less than 
5 % early operative mortality and subsequent 8-year survival of 95 % resulting in a good 
clinical condition for a majority of 85% (34). Data from Bruins and Temmerman on 165 
patients of whom 109 were operated before their first birthday and subsequently 
experiencing a 85% first year survival support these figures (11). 
A subgroup of 5 to 10% of the post operative patients have a residual ventricular septal 
defect which is usually well tolerated. However, approximately 1 in 10 may require re-
operation because of hemodynamic consequences or a remaining pressure gradient in the 
right ventricular outflow tract (34). Another problem that is frequently encountered after 
surgical correction is pulmonary valve insufficiency (35). This insufficiency is often well 
tolerated, although some patitnts may require subsequent valve replacement. Despite these 
relatively favourable outcomes the right ventricular function has been shown to be 
impaired especially in children operated on at later age (36). Perhaps the currently adopted 
policy of corrective surgery before the age of two years will avert this problem. A 
commonly encountered problem in patients operated for congenital heart disease is the 
occurrence of rhythm and conduction anomalies. In approximately 80% of the patients 
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operated for tetralogy of Fallot a disorder of conduction is present and, furthermore, up to 
45 % show ventricular extra systole on 24-hour ambulatory ECG monitoring (36). This is 
a serious problem because despite an anatomically adequate surgical result sudden death 
occurs in 3 to 4 % of the cases sometimes decades after operation. Even after corrected 
tetralogy of Fallot a patient will always require regular follow-up. 
coarctation of the aorta 
Coarctation of the aorta is classified according to the location of the constriction relative 
to the arterial duct into three categories; pre-ductal, juxta·ductal or post-ductal. It can be 
present in isolation or in combination with other cardiovascular malformations 
complicating diagnosis and treatment. However, coarctation is usually considered the most 
serious anomaly predominantly determining the prognosis (3). Coarctation of the aorta 
may present either shortly after birth with severe cardiac failure or may be detected at a 
later age on routine physical examination. Eventually all cases require an intervention 
because of complications occurring with sustained hypertension. Optimal timing of 
operation is still a matter of dehate, although, there is a tendency toward correction at 
younger age (37). Interventional cardiology may offer a solution for selected cases and 
reduce morbidity and mortality (38). In spite of this coarctation of the aorta must be 
considered a serious anomaly with high infant mortality rates of up to 50% in the serious 
and complicated cases (3) and an overall infant mortality of at least 13% (3,11). After 
surgery a proportion of the patients may maintain or develop hypertension usually caused 
by residual-stenosis or re-stenosis and require additional treatment or medication (39). In 
addition, an infrequent but grave complication of the surgical procedure is spinal cord 
injury and subsequent paraplegia. Only a minority of patients free of stenosis, 
hypertension or additional cardiac malformations can be expected to live normal lives. 
aortic stenosis 
Aortic stenosis can also be classified according to the location of the lesion; in this 
instance relative to the aortic valves, i.e. supra-valVUlar, valvular or sub-valvular. 
Furthennore, aortic stenosis may occur in combination with other cardiovascular 
anomalies. Each location and combination of malformations calls for a separate approach. 
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Supra-valvular stenosis occurs rarely and again sub-types are distinguished. With this type 
of malformation the coronary arteries, which insert proximal to the stenosis, are exposed 
to a high blood pressure. Early sclerosis may arise and has to be dealt with accordingly. 
Furthermore, genetic counselling is warranted because autosomal dominant inheritance 
may be involved. Final surgical correction is indicated if there is a pressure gradient of 
over 50 to 70 mm Hg (40). 
Valvular aortic stenosis is by far the most frequent variant. Patients often remain free of 
complaints unless a very serious stenosis exists. These cases may already present in the 
neonatal period and have a poor prognosis in particular if the myocardium has been 
affected. Less severe cases are generally discovered at a later age because of the presence 
of a systolic murmur and sometimes complicated by impaired exercise tolerance or even 
angina pectoris and syncope. Treatment is indicated if the patient presents with physical 
symptoms, ECG anomalies, a resting peak systolic pressure gradient of > 50 mm Hg 
over the stenotic valve, an abnormal exercise ECG or an enlarged heart on the chest X-
ray (41). Management used to be surgical with low risk and good results in the first 
decade or intermediate term. However, balloon dilatation has also proven valuable as a 
therapy for valvular aortic stenosis and may postpone surgical intervention (41). 
Valvotomy and balloon dilatation should be deemed palliative procedures requiring regular 
check-up. Valvular aortic stenosis can be considered an evolving process in need of 
continuous re-appraisal because the valves may become sclerotic, stenotic again Of 
regurgitation may develop, demanding valve replacement or repeat valvotomy in 15 to 
40% of the cases (23,40). Recently published figures on the long term results of 
management of patients with aortic stenosis show a 25 year survival of 92.4 % for patients 
with a gradient < 50 mm Hg at entry, whereas those with a pressure gradient of > 50 mm 
Hg have a 81 % survival (23). Both values are considerably below normal life expectancy. 
Worth mentioning is the fact that over half the cardiac related fatalities were sudden and 
unexpected, supposedly related to arrhythmia. A further fact of concern is the clinical 
status of the patient involved. A proportion of 7.7% did not reach NYHA class I. 
Moreover, only about half of the patients were judged to have an excellent to good status 
(23). 
In about 8 to 10% of the cases of aortic stenosis the constriction is located sub-valvular 
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and is considered an acquired progressive disorder relatively often coinciding with other 
anomalies (42,43). Therapy is surgical and appears to have a good prognosis if treated 
timely. However, recently de Vries stressed the frequent post-operative morbidity and 
recurrence (44). Furthermore, it has not been unequivocally demonstrated that early 
surgery is the preferred strategy. Nevertheless, once the final stage of tunnel-stenosis is 
reached operation will be difficult and carry a considerable risk (45-49). Careful and 
frequent evaluation appears to be essential. 
trallspositioll of the great arteries 
Transposition of the great arteries usually means that the aorta takes a position to the right 
(dextral) and ventral to the pulmonary artery resulting in a ventriculo-arterial discordance. 
This anomaly may be encountered as a single malfonnation or in combination with other 
cardiovascular anomalies complicating the clinical course. Just over half of the cases occur 
isolated or in combination with minor anomalies. About 30% has a hemodynamically 
relevant ventricular septal defect, a further 10% has left ventricular outflow tract 
obstruction and finally another 10% has a combination of these malfonnations (50). 
Before the introduction of modern medical and surgical procedures the majority of infants 
died before their first birthday because of extreme hypoxia. Currently, however, the use 
of prostaglandin E" prevent;ng closure of the arterial duct and subsequently allowing 
mixture of oxygenated and de-oxygenated blood, balloon septostomy, also pennitting 
shunting and mixture, and corrective surgical procedures are applied which have greatly 
enhanced the prognosis resulting in 20 year survival up to 80% (5\). Fyler presented data 
on dextro-transposition of the great arteries in the 70s and reported an infant mortality of 
39% (3). More recent Dutch data from 1985 data illustrate the advances in treatment and 
show an infant mortality of the operated patients of 15% (11). The prevailing operative 
procedure applied used to be a physiologic solution according to Mustard (52). Early 
results were very encouraging with operative mortality of less than 5%. However, several 
late complications such as: obstruction of cardiac inflow at the orifice of the vena cava 
inferior and superior causing high venous pressures, obstruction at the orifices of the 
pulmonary veins with subsequent pulmonary hypertension and finally leakage and shunting 
through the sutures of the conduit between the caval veins and the mitral valves, may 
58 
Statistics alld health aspects 
occur. Furthennore, right ventricular dysfunction may evolve because in the long run the 
right ventricle may not be able to meet the demands of the systemic circulation. In 
addition, though usually this is well tolerated, the left ventricular out-flow tract may 
become obstructed. Finally, dysrhythmia appears quite often in patients operated on, 
which may end in sudden death in 5 to 10% sometimes years after apparently successful 
surgery (53). Obviously, this group of patients is in need of a thorough follow-up. During 
the last decade an alternative for the physiologic correction has increasingly been applied; 
the anatomical correction or arterial switch procedure. The short and mid-tenn results of 
this approach are good. Long-tenn results are not available at the moment, yet seem quite 
encouraging (54). Some sequelae that have been described are stenosis of the pulmonary 
artery at the site of the anastomosis arising in about 10% and minor aortic insufficiency in 
5 to 15%. A major advantage is that arrhythmia can probably be avoided. Late mortality 
has been estimated to be less than 5 %. A remaining point of concern is the development 
of the coronary arteries which first originated from the functional pulmonary artery, the 
anatomical aorta. During the surgical procedure they are reimplanted in the "neo-aorta". 
Future problems may occur due to this extensive handling. Thus, these patients will still 
require long tenn follow-up. 
hypoplastic left heart (syndrome) 
Hypoplastic left heart syndrome is a disorder consisting of several cardiac anomalies: i.e. 
critical stenosis or atresia of the aortic valve and a rudimentary or absent left ventricle, 
mitral valve and ascending aorta (55,56). Circulation is dependent on a patent arterial duct 
which may explain why newborns with hypoplastic left heart syndrome do reasonably well 
at first but then show progressive deterioration when pulmonary vascular resistance 
decreases and the arterial ductus closes. If not treated shortly after birth this anomaly 
almost invariably follows a fatal course within the first weeks post partum. The use of 
prostaglandin EJ to maintain duct patency and additional medical treatment including 
mechanical ventilation allows time to establish the diagnosis and draw up a treatment 
strategy. Once the diagnosis of a hypoplastic left heart is established, three options are 
available to the parents and physician facing this problem (56). Abstinence in combination 
with supportive care is a justifiable option especially given the uncertain results of the 
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current options. Alternatively, when available, a donor transplant may be offered. 
However, immune response and subsequent graft rejection has not yet been resolved 
completely. Furthermore, long-term prognosis has not yet been established since this 
procedure was only started in the mid 1980s. The mid-term prognosis of those operated 
appears encouraging with a 3 year survival rate of over 80% (55). The third alternative, a 
two-staged palliative reconstruction, was first reported by Norwood in 1981 (57). 
Continuing efforts to improve this technique have lead to a 40 to 60% survival of the first 
stage. Subsequently, these patients are candidates for a stage two modified Fontan 
procedure. This procedure again has an inherant mortality, resulting in a 25 to 30% 
overall survival beyond the age of 2 years. A switch from the Norwood procedure to the 
transplant option may improve these overall results slightly. However, the initial advan-
tage of less aggressive neonatal immune response may be lost. The clinical status of post-
operative patients is relatively good. The exercise tolerance of transplant survivors appears 
to approach normal values, yet, immuno-suppression will always be required. Survivors of 
the second stage of the Norwood procedure may never reach a normal exercise tolerance, 
although, the majority will be able to function according to NYHA class I or II without 
medication (58). 
hypoplastic right heart 
Hypoplastic right heart may be considered a consequence of tricuspid atresia which 
prevents blood flow from the right atrium into the right ventricle. Subsequently, the right 
ventricle remains underdeveloped. A co-existing ventricular septal defect may allow some 
flow through the right ventricle and the pulmonary artery which may otherwise also 
remain underdeveloped. Extra-cardiac anatomical variation in particular a transposed 
position of the aorta and pulmonary artery may finally complete this type of malformation. 
The symptoms and prognosis are to a large extent determined by the magnitude of the 
pulmonary blood flow. Progressive central cyanosis, sometimes only appearing after 
several years, as a result of spontaneous closure of a ventricular septal defect, a patent 
arterial duct closing or if pulmonary hypertension evolves, is the major symptom. In 
addition, hypoxic spells may occur as a sign of critically low pulmonary blood flow. 
Without reservation tricuspid atresia, or hypoplastic right heart, can be considered a 
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serious congenital anomaly. It has a 65 to 70 % infant mortality and if not treated only 
10% survives to reach the age of 10 years. Fontan has introduced a physiologic correction 
for this group of anomalies over two decades ago. Subsequent adaptation has resulted in 
improved results and currently operative mortality is <5% under optimal conditions (59). 
Of the survivors > 75 % do well with a NYHA class I functional status and no additional 
medication. However. cautious interpretation is warranted because late complications 
cause a 10 to 15% mortality long after surgery. 
4.4 FETAL CARDIAC STATE 
The anomalies discussed previously constitute the majority of cardiovascular 
malformations encountered in live born, and have all been reviewed from a postnatal 
perspective. However, the fetal circulation is profoundly different from the postnatal 
circulation. Accordingly, the abnormalities described may have different consequences for 
fetal well-being. Therefore, the nature of the fetal circulation may need to be emphasised. 
Applying the sequential approach, oxygenated blood from the placenta, through the venous 
duct, enters the right atrium through the inferior caval vein, mixes with de-oxygenated 
blood from the lower half of the body, then is preferentially passed through the foramen 
ovale into the left atrium. From there flow will be guided into the left ventricle and, 
subsequently, into the ascending aorta. De-oxygenated blood from the superior vena cava 
enters the right atrium, flows into the right ventricle, which pumps into the pulmonary 
artery. Prenatally, pulmonary flow is negligible, thus the blood-flow from the pulmonary 
artery continues through the ductus arteriosus into the descending aorta (60). Specific 
features of the fetal circulation, the foramen ovale and the (patent) ductus arteriosus allow 
preferential shunting of oxygenated blood. As a consequence the left and right heart 
operate in parallel prenatally, hence, at identical after-load and pressure, rather than 
sequentially, that is at different after-loads, postnatally. 
Furthermore, the proportional distribution of cardiac anomalies above is derived from 
postnatal epidemiologic studies on the prevalence of congenital heart disease. Prenatally 
this order may be entirely different because the live-born population can be perceived as a 
selection originating from a much larger 'population' of conceptions many of which ended 
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in miscarriage prematurely, possibly related to congenital (cardiac) anomalies. Yet, to 
indicate what impact the majority of postnatally encountered anomalies may have 
prenatally, and to clarify what current fetal medicine may have to offer, an identical 
hierarchical order will be maintained. 
velllricular septal defect 
As right and left ventricles operate at an equal after-load prenatally, there is no pressure 
gradient between the ventricles. Accordingly, important shunting will not occur and as a 
result a ventricular septal defeot has no hemodynamic importance in fetal life. Possibilities 
for prenatal diagnosis are restricted because a considerable proportion of the 
malformations are too small for the resolution of currently available ultrasound scanners. 
Merely the large defects may be recognised by means of a fetal four chamber view. 
Furthermore, the lack of shunting eliminates recognition by means of Doppler techniques. 
Finally, prenatal detection of this type of anomaly is not likely to alter postnatal 
opportunities and options for treatment because of the usually limited (hemodynamic) 
consequences in the short term. The noted relation with other congenital anomalies and 
chromosomal defects would, however, make prenatal detection desirable. 
atrioventricular septal defect 
The atrio-ventricular septal defect is a more serious defect postnatally, yet again, this 
anomaly does not have a detrimental effect on the fetus. As part of normal development 
blood from the inferior vena cava is shunted through the foramen ovale, which is difficult 
to distinguish from an atrial septal defect. At ventricular level significant shunting does 
not occur as the left and right ventricle operate at equal after-load. Therefore, Doppler 
ultrasound does not offer a solution for the detection of this anomaly. However, the 
anatomy of the fetal heart, in particular the four chamber view, as visualised by 
ultrasound will be affected and renders this malformation detectable prenatally by means 
of 2-D ultrasound. This would be desirable as atrio-ventricular septal defects are often 
related to chromosomal anomalies, in particular Down's syndrome. Prenatal recognition of 
this type of anomaly is an indication for fetal karyotyping and may subsequently determine 
adjustment of obstetrical management if a chromosomal defect is detected. Apart from 
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patients with severe atrio-ventricular valve regurgitation, which may already present with 
heart failure prenatally, postnatal treatment and prognosis will not be affected. Acute 
deterioration of the neonate with atrio-ventricular septal defect is unlikely. 
patent ductus mteriosus 
A patent ductus arteriosus, a normal structure of the fetal circulation, by definition can not 
be considered an anomaly prenatally. This fetal vascular structure can, however, be 
identified prenatally in extended 2-D echocardiography of the right heart connections and 
the outlet of the fetal heart. Flow through the ductus arteriosus should also be 
demonstrable during Doppler ultrasound studies. 
atrial septal defect 
The foramen ovale, if visualised during fetal echocardiography can rarely be distinguished 
from a pathological atrial septal defect. Furthermore, a functional distinction between 
atrial septal defects and the foramen ovale is difficult. Accordingly, anatomical 
deformations and hemodynamic consequences will be limited to accompanying 
malformations which may be present. Still, though not affecting fetal well being, large 
septum primum defects may be detectable because of an altered four chamber view. 
pulmonary stenosis 
Stenosis of the pulmonary valves hampers blood flow through the pulmonary artery. This 
poses a threat to postnatal life since pulmonary circulation is needed for the oxygenation 
of blood. In contrast, prenatal oxygenation occurs via the placenta, hence, fetal life will 
not be in danger. The normal development of the fetal heart, however, may be impeded. 
Hemodynamic complications with markedly increased outflow resistance of the right 
ventricle may bring about changes in the right ventricle such as hypertrophy. The main, 
left and right pulmonary arteries may remain relatively underdeveloped as a result of 
diminished flow. Opportunities for antenatal detection of this type of anomaly depend on 
the above mentioned secondary changes. Therefore, it can be anticipated that only severe 
cases, manifesting with an altered four chamber view and right heart connections, are 
detectable by means of 2-D ultrasound. This also applies to Doppler ultrasound, which 
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may show increased flow velocity in the main pulmonary artery and diminished flow 
through the ductus arteriosus. The prognostic advantage of prenatal detection will depend 
on severity of the stenosis. If the pulmonary circulation is duct dependent prenatal 
diagnosis and subsequent optimal postnatal care may affect the prognosis. 
tetralogy oj Fallot 
Fallot's tetralogy, embryologically emanating from a mal-alignment ventricular septal 
defect, with postnatal persistence of right ventricular hypertrophy as a consequence of 
right ventricular outflow tract obstruction, can be reviewed accordingly. Again, the 
specific characteristics of the fetal circulation with physiological right to left shunting and 
identical after-load, prevent adverse effects on the developing fetus. Prenatal detection is 
dependent on recognition of the three primary defects. As mentioned above, only a large 
ventricular septal defect can be detected during 2-D scanning. The dextro-deviation of the 
aorta may be noticed during 2-D scanning if the left heart connections and outlet are 
imaged. Finally, puhnonary stenosis may only be detected on right heart connections and 
outlet images. Doppler techniques may provide additional information since prenatal flow 
patterns may be disturbed as well. The expected gain, if the anomaly is detected 
prenatally, may be limited to those cases with severe obstruction of the right ventricular 
outflow tract and hypoplasia of the pulmonary arteries. Only this category is subject to 
immediate neonatal problems due to restricted pulmonary circulation and should therefore 
preferably be dealt with promptly after birth. 
coarctation oj the aorta 
Constriction of the aorta may evolve with closing of the ductus arteriosus, and accordingly 
develop postnatally. However, cases that occur prenatally will not have major fetal 
hemodynamic consequences or influence fetal well-being. The delivery of adequate blood 
flow through the upper part of the body is not hampered and flow through the ductus 
arteriosus secures supply to the lower half of the body. As a result prenatal detection of 
coarctation by means of 2-D ultrasound usually depends on ultrasonographic visualisation 
of the outlet, or more specific, the aortic arch with branching arteries and the ductus 
arteriosus. Additional Doppler ultrasound may theoretically reflect increased flow velocity 
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or altered flow patterns at the site of constriction but this has not been demonstrated. The 
impact of prenatal recognition of coarctation of the aorta may be limited to severe cases 
because, due to ductal closure, these may deteriorate soon after birth. 
aortic stellosis 
Aortic stenosis has a limited impact on prenatal life; even severe stenosis appears to be 
well tolerated by the fetus, because a diminished left heart output may be compensated by 
increased right heart output and subsequent increased shunting through the ductus 
arteriosus. In the majority of cases stenosis of the aortic valves will present some time 
after birth with relatively mild symptoms. Very severe outflow obstruction may, however, 
cause problems prenatally if left ventricular myocardial damage occurs. Difficult 2-D 
ultrasonographic detection of this type of anomaly can be anticipated and obviously 
depends on imaging the left heart connections, more specifically the aortic valve. 
Secondary myocardial changes and left ventricular dilatation may lead to the diagnosis in 
severe cases. Altered flow may be observed with Doppler techniques. As mentioned 
above, the natural history is generally mild and as a consequence the potential profit of 
prenatal detection is confined to the severe cases. 
trallspositioll of the great arteries 
The nature of this type of anomaly assures adequate blood flow to all fetal parts and as 
left and right ventricles operate at equal after-load the right ventricular function will not 
be affected prenatally. Accordingly, heart failure will not evolve prenatally. Antenatal 
diagnosis is limited to outlet images of the great arteries. A neonate with transposition 
may benefit from prenatal detection because subsequent to the transition of the fetal 
circulation to the postnatal circulation severe hypoxia may develop. However, the ductus 
arteriosus does not usually close abruptly after delivery and current prostaglandin 
treatment will prevent deterioration of the compromised neonate. 
hypoplastic left heart (SYlldrome) 
Hypoplasia of the left ventricle implies that the left heart is (functionally) absent. 
However, the right ventricle is capable of supplying the fetal circulation with sufficient 
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blood flow shunted through the ductus arteriosus. Hence, only after birth with diminishing 
ductal flow life becomes dependent on both ventricles functioning sequentially and will be 
threatened. It is clear that the anatomy of the fetal heart is very much affected and this can 
be demonstrated by means of 2-D echocardiography. Because of the circulatory evolution 
(the systemic circulation becomes dependent on the left ventricular function with closure 
of the arterial duct) which commences after birth prenatal detection would be important to 
be able to offer optimal care shortly after delivery. Furthermore, taking into account the 
still serious prognosis for these cases of congenital heart disease, the parents may strongly 
favour termination of pregnancy. 
tricuspid atresia/hypoplastic right heart 
From a fetal circulatory point of view, hypoplasia of the right ventricle results in a 
situation comparable to that of hypoplasia of the left ventricle. It has no impact on fetal 
well being. Prenatal detection is feasible by means of 2-D ultrasound since the anatomical 
features of the heart are completely distorted. Whereas, in this condition a normally 
developed pulmonary artery is essential during postnatal life, this is not the case 
prenatally. Antenatal ultrasonographic evaluation of the peripheral pulmonary arteries may 
be difficult because flow is limited prenatally and can only be visualised in the right heart 
connections and outlet images. As progressive deterioration will occur postnatally with 
diminishing shunting through the ductus arteriosus, advantages of prenatal detection are 
particularly related to the assessment of pulmonary arterial connections. In case the 
outlook is grim termination of pregnancy may be an option. 
ulliventricular heart 
A univentricular heart, similar to hypoplastic right and left heart, has a limited impact on 
fetal well being prenatally. During routine ultrasound evaluation the fetal four chamber 
view should disclose the absence or severe hypoplasia of one ventricle. In fact, 
univentricular heart la;gely is a general diagnosis, often occurring in combination with 
other anomalies such as double inlet left ventricle or certain types of double outlet right 
ventricle. Most cases of univentricular heart are part of complex malformations that 
invariably predict a complicated postnatal course. In particular the volume of pulmonary 
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blood flow will detennine the prognosis. Accordingly, assessing the pulmonary vascular 
dimensions is of prime importance after birth. 
4.5 GENERAL COMMENTS 
Papers on the actual occurrence of congenital heart disease are scarce. A cohort study to 
assess the frequency of occurrence of cardiovascular malfonnations should ideally 
prospectively gather follow-up data on each conception, which is a demanding task. 
Currently, only limited retrospective data are available from some attempts that have been 
made to estimate the rate of anomaly related abortions. It appears that even the birth 
prevalence of congenital heart disease has not yet been accurately established, although a 
reasonable estimate is available especially on the relative proportions of the various sub-
types of cardiac malfonnations. With this limitation of the data in mind and the treatment 
options presently available for neonates or infants with congenital heart disease, which 
have resulted in a substantially improved prognosis with less than 10% overall mortality, 
one might conclude that cardiovascular malformations no longer have a major impact on 
children's health(care) in general. This, however, is not justified as the efforts and 
resources these patients take are tremendous. Prenatal detection has been proposed as a 
(partial) solution of the problem of congenital anomalies. Table 2 summarises the 
infonnation on prevalence and mortality presented. Additionally, table 2 gives an 
interpretation of the potential of an ultrasound screening programme for congenital heart 
disease as encountered in a live-born population. 
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Table 2 Summary-table of the prevalence, impact, detectability and expected effect of prenatal detection on 
post-natal prognosis. 
type of anomaly prevalence (%); mortality (%) prenatal delectability prognostic advantage 
of all CHD by means of 4CV of prenatal detection 
ventricular septal 30 < 5 - (±) 
defect 
atrio-venticular 5 ~ 25 + (±) 
septal defect 
patent ductus 10 II 
arteriosus 
atrial septal defect 10 <5 - (±) 
pulmonary stenosis 10 ± 
tetralogy of Fallot 7 < 10 - (±) - (±) 
coarctation of 7 ~ 15 ± 
aorta 
aortic stenosis 5 ~1O 
transposition of 5 ~ 15 
great arteries 
hypoplastic left 2 ~ 70 + ± 
heart 
hypoplastic right 2 ~ 70 + ± 
heart 
CHD = congenital heart disease; estimated birth-prevalence: 8 per thousand live-born. 
4CV = four chamber view; suggested ultrasound technique of prenatal screening for congenital heart 
disesase. 
- = detection not possible or no prognostic effect; ± = delectability and effect depending on size and 
location of (anatomical) defect; + = detection possible or positive prognostic effect; a minority of the cases, 
between brackets, may be detectable or have a prognostic advantage of prenatal detection, again depending 
on size and location of the anomaly. 
Many of the cardiovascular anomalies presenting in a newborn population have a limited 
impact on prenatal survival. This implies that the yield in prognosis for the subgroup of 
fetuses that would have survived to term may not improve significantly in a society that 
can provide immediate high level paediatric care to all critically ill neonates. A 
numerically small proportion may benefit from prenatal detection especially if prenatal 
treatment becomes available. We must keep in mind that indeed the live born are a 
selection of the cases present at 20 weeks gestation, and may well be less severely 
affected. Currently, very little is known about the prenatal natural history of congenital 
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heart disease. It may be that prenatal detection of cardiovascular anomalies in the second 
trimester has a potential yield for the subgroup of affected fetuses that would othenvise 
have aborted spontaneously. Future research on this specific group of cases of congenital 
heart disease should disentangle the natural history and possibilities for treatment. The 
gain could be sizeable as data on incidence and causal mechanisms may be directly 
interrelated. Furthermore, the impact of cardiac anomalies on fetal survival could also be 
established with greater accuracy. 
Despite the fact that prenatal detection may not have the benefit one might intuitively 
expect, the association of cardiovascular anomalies with other congenital malfonnations 
and chromosomal anomalies may indicate the need for prenatal detection indicated. The 
presence of congenital heart disease in the fetus is a risk-factor that should engender to 
more extensive fetal exantination. Furthermore, one should bear in mind that prenatal 
detection of severe congenital malformations may dissuade obstetricians and women in 
labour from interventions like a Caesarian section on account of fetal distress. Thus, 
possible maternal risks of such a procedure may be averted. Finally, it appears that 
exclusion of fetal anomalies by means of an non-invasive screening test is highly 
appreciated by future parents. After all, in Western societies the majority of expectant 
women choose to have a prenatal ultrasound. 
The issue of a screening test touches upon yet another crucial point. Even well-trained 
optimally equipped sonographers can attain limited returns as a substantial proportion of 
the malformations encountered may just not be detectable with the current ultrasound 
machines and techniques. Therefore, we feel that before a screening test for prenatal 
detection of congenital heart disease is implemented, the efficacy of such a strategy should 
be evaluated. 
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CHAPTER 5 
PRENATAL DIAGNOSIS OF CONGENITAL HEART DISEASE; 
PROSPECTS AND PROBLEMS 

INTRODUCTION 
Over the last decades diagnostic ultrasound examination of the human fetus has evolved 
from a research tool into a valuable clinical diagnostic test. With improvement of 
ultrasound equipment its use has gradually shifted from mere evaluation of gestational age, 
position and number of fetuses and placenta location to more formal and systematic 
screening for congenital anomalies. Among those, congenital heart disease, with a 
relatively high prevalence of about 8 per thousand live births (I), has proven to be 
accessible for prenatal detection in many cases (2-11). 
The aetiology of congenital heart disease to a large extent still is unknown. Approximately 
90 % of the cases are of multifactorial origin, e.g., result from an interaction between 
genetic constitution and environmental influences without further aetiologic specification 
(12). Accordingly, the majority of affected infants is born to mothers without previously 
known risk factors for bearing children with congenital heart disease. This implies that 
most of the severe cases will become apparent at or soon after birth unless detected 
prenatally. A systematic prenatal screening procedure for congenital malformations of the 
heart, made available to all pregnant women may accelerate the diagnosis to a point in 
time which allows adjustment of obstetrical management (13,14). Generally, it is assumed 
that this in turn could have beneficial effects for the neonate and the parentis). The 
timing, location and the mode of delivery can be determined to grant the neonate optimal 
chances for survival (10,15,16). The strong association with chromosomal defects and 
non-cardiac malformations implies that karyotyping and extended structural ultrasound 
examination of the fetus should be performed after detection of an anomaly (12,17-19). 
Subsequently, genetic counselling can be offered to the parents to inform them of the risk 
they carry for having affected offspring in the future. In case of fetal tachycardia, possibly 
associated with fetal hydrops, subsequent transplacental drug treatment may be offered to 
try and improve fetal condition (20-22). The recent development of fetal medicine has 
created a new era of possibilities. Furthermore, detecting a non-viable fetus early in 
pregnancy offers the option of termination of pregnancy. Eventually, reassuring the future 
parents after exclusion of (severe) fetal anomalies may be perceived as the greatest value 
of screening. 
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Many reports have appeared on the efficacy of ultrasound screening for congenital heart 
disease in obstetrics (23-32). However, most of the results available are obtained from 
teaching hospitals or tertiary referral institutions with above average expertise and interest 
in the subject. Additionally, and perhaps more important, the patients involved may be a 
selection of high-risk cases. Without due consideration the findings of these experts can 
not be extrapolated to a hypothetical yield that a screening programme may have if applied 
routinely to all pregnant women or low risk pregnancies. The purpose of this paper is to 
review the results of screening programs as presently available and to arrive at some 
conclusions and recOlrunendations for further study. 
APPROACH 
Papers 
Papers and books on ultrasound screening in obstetrics published before 1993 were 
selected using several sources of infonnation. Computer based literature reference systems 
Medline and Current Contents have been applied in order to check for reports published 
from 1980 and onward. A lateral reference search mainly aiming at the period before 
1980 completed the survey. This rendered a considerable list of reports on ultrasound 
employed to detect congenital heart disease prenatally. Ultimately a limited number of 
reports (table 1) appeared to be relevant to this review, comprising infonnation published 
on prenatal "creening progm!us for congenital cardiovascular malformations by means of 
ultrasound. 
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Table 1 Prenatal ultrasound screening programs for congenital heart disease as reponed from 1986 to 1993. 
,,,',,' y~ ",",'" gcstllionaJ di:Ignostic procedures follow up study method of sWdy number of ~"''''''''''' yield sensitivity 
of$ll.ldy 'YP< age rnnge p""",,, 
""""" 
""""', design !lScertainment popul:l1ion ,,"'''' OfClSCS (10~ (10"")' 
Allim 80·85 
"""" 
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-
89 w"'no~ 45' 
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H"", 81-86 
"""'" 
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et al.ZlI 
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""'tiro 86·87 
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23 two dimensional routine exam.ioaIion. 2 - 3 months prospective follow up of low risk 1841 18 9.8 38.9< 
et:ll..1t (average) ecboc:ardiography clinicaJ. and autOpsy po" portwn :ill children 
('O!: 1) ~'" 
V",,", 87·89 
"""'" 
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ctal." 
"'" ""'P'Y p= all children high risk ~,," 
Bromley 87·90 
"""'" 
,18 4CV(fet:ll clinical. :wd not specified retrospective follow up of 1~"'" 
_O~ 
69 
-
60.9 
et a1.~ echoc:udiography) • autopsy records = only high risk (82.6) ... 
(~ I) 
Tcgn:mder 88·90 
"""" 
18 4CV (once) ecbocardiography 1-3y= prospective follow up of non selec- 7182 43' 6 7.0 
et m.l' clinical and cases only 
"" autopsy records 
Achiroo 88·90 teaching 18·24 4CV (fetal routine e:xa:ninatiOIl, ~- pl"O$)Xdive follow up of lownsk 5400' 23 4.3 2S.5 et:ll..:D echoe:u"diogruphy) < echocardiogruphy pori"" oll """= (41.7) <.r 
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"""" 
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et:ll..;10 cases ollly hisn risk 
4CV: Four Chamber View. Plane of the ultrasound examination used in all screening procedures. Number of ultrasound examinations applied in order to achieve a 4CV; 
between brackets if specified. 
a: Unless specified calculated with an assumed prevalence of congenital heart disease of 8 per 1000 live births. 
b: Population-base unknown; calculation according to reported number of cases. 
c: Calculation according to reponed prevalence of 9,8 per 1000 births. 
d: Extended prenatal echocardiography; including shon axis,long axis inflow and outflow tracts. 
e: Calculation according to the reported prevalence of 6 per 1000 live births. 
f: Ignoring the reported lost to follow up of 53 feruses; subsequent calculations accordingly. 
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Analysis 
The birth prevalence of congenital malfonnations is defined as the number of cases 
divided by the number of births and is usually expressed per thousand live births. The 
prevalence figures of congenital heart disease reported have been shown to vary over a 
wide range related to various issues of study design (33,34). Because a similar problem 
may have occurred in the studies reviewed, only the original study size and number of 
cases detected have been summarised. Subsequently, direct calculation of various 
measures of occurrence is possible from the quantitative information in most of the 
reports. For instance, the yield of cases, or proportion of infants affected by congenital 
heart disease, is calculated by dividing the actual number of malformations detected 
prenatally andlor postnatally by the number of fetuses screened. Also, the sensitivity of 
the diagnostic procedure, defined as the proportion of cases detected, calculated as a 
fraction of the total number of cases detected, can be estimated. However, as mentioned 
above, differences in study design across the various studies may have resulted in 
incomparable yields of congenital heart disease which in turn may have biased the 
sensitivities originally reported. Accordingly, an attempt was made to correct for this 
source of bias. It appeared that the yield of cases varied markedly and was not in 
accordance with what may currently be a best estimate of the prevalence of cardiovascular 
malfonnations, namely 8 per thousand live births (I). Dividing the number of 
malfonnations detected prenatally by the number of malformations that may be expected 
in the screened population, assuming a conservative estimate of prevalence of congenital 
heart disease of 8 per thousand live births (1), renders a corrected sensitivity. To help 
illustrate the corrected figures table 2 displays the possible outcomes of a digotomous 
(screening) test and is referred to in the following formulas. 
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Table 2 2 x 2 table of possible outcomes of a (diagnostic) screening test. 
congenital heart disease 
present absent 
screening test positive A B 
negative C D 
A+C B+D 
A review of prellatal diagllosis 
A+B 
C+D 
A+B+C+D~T 
A = number of true positive test results; B = number of false positive test results; C = number of false 
negative test results; D = number of true negative test results; T = total number of fetuses screened, 
The yield of congenital heart disease is calculated by (A + G)IT; A being the number of 
cases detected before birth, G being the number of cases detected only after birth and T 
being the total number of cases screened. Normally one would calculate the sensitivity by 
AI(A + G). However, as mentioned above comparing the different studies regarding this 
test characteristic demands a common denominator. Replacing A + G by a fixed number 
of cases of congenital heart disease that can be expected under the assumption of a 
common prevalence corrects for the apparent variability of the sensitivity due to 
ascertainment methods. The number is calculated by taking the product of the total 
number of fetuses in the study and 0.008 (the above mentioned best estimate of prevalence 
of congenital heart disease). Thus, the sensitivities presented in table I are estimated by 
A/(T*O.008). 
FINDINGS 
Diagnostic ultrasound has been introduced only a few decades ago and the routine use of 
this technique in obstetrics has been proposed even more recently. Reports on the potential 
of fetal echocardiography as a screening test for congenital malformations have been 
appearing since about 10 years (2). In general, these communications originate from 
teaching hospitals or other specialised centres. In the discussion of their work the authors 
frequently speculate on the favourable effects that routine application of ultrasound may 
have on the outcome of pregnancy. Very few papers, however, have been published from 
actual studies designed to quantitatively evaluate the efficacy of ultrasound as a routine 
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screening procedure for congenital heart disease. From an extensive list of articles and 
abstracts on prenatal ultrasonographic detection of congenital malformations, only nine 
reports focus on screening for congenital heart disease. If reported in the publications, 
information on hospital type, gestational age range, prenatal and postnatal diagnostic 
procedures applied, duration of postnatal follow up, study design, method of case 
ascertainment, characteristics of the expectant women or rather the pregnancies 
constituting the study popUlation, the number of fetuses screened and the number of cases 
detected either prenatally andlor postnatally was extracted. These main design properties 
and results are summarised in table 1. Regrettably, definitions of congenital heart disease 
applied are not provided by any of the authors and therefore can not be evaluated. 
Possible consequences of differences in design across studies for the comparability of the 
results can be inferred by partitioning of the studies reviewed according to methodological 
characteristics. 
As is shown in figures 1 and 2 respectively, categorisation according to the type of 
hospital where the prenatal ultrasound examination was carried out indicates that the 
overall yield of cases detected is higher and a larger proportion of malformations is 
detected prenatally (sensitivity) in teaching hospitals. The study by Tegnander et al. (31) 
appears to be an exeption. 
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Figure 1 Yield of congenital heart disease according to type of hospital 
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Figure 2 Sensitivity of fetal echocardiogra~hy according to type of hospital 
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The gestational age at which the ultrasound examinations were performed appears to be 
within a range considered adequate for visualisation of the fetal four chamber view. 
Similar to case definition, the diagnostic procedures applied have not beell described in 
detail. However, with repeated fetal scans and extended examination better detection is 
obtained. 
Also, the completeness of folloN-up should be considered. In fact, several issues influence 
the results in this respect. Duration of follow-up and study design, either retrospective or 
prospective, and case ascertainment are in question. However I as duration of follow-up 
again is not specified sufficiently it is difficult to evaluate the data in this regard. 
Separating data according to either retrospective or prospective demonstrates a relatively 
high sensitivity in retrospective studies. Figure 3 gives the yield of congenital heart 
disease according to the ascertaimnent of follow-up. 
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Figure 3 Yield of congenital heart disease according to ascertainment of follow~up 
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With routine postnatal examination of all infants, irrespective of symptoms of congenital 
heart disease, higher numbers of cases are detected. 
Finally, the populations studied consist of low risk or low and high risk pregnancies. The 
yield of cardiovascular malformations does not appear to vary systematically with either 
population type. However, on average the sensitivity calculated in the low risk 
pregnancies is beneath that attained in the mixed groups. 
DISCUSSION 
Apparent from table 1 is the variability in the proportion of cases of congenital heart 
disease found in the populations studied. The column "yield", with a range of 1.4 to 9.8 
per thousand births, reflects this spread. It is unlikely that this represents a real difference 
in occurrence of congenital heart disease across the various populations studied. For 
instance, case definition, though none of the authors has specified the definition and 
classification of congenital heart disease applied, may have influenced the yield. The 
inclusion or exclusion of several cases of minor defects like small ventricular septal 
defects, especially if the study is of small size, could have had a substantial impact. 
Despite difficulties of interpretation arising from· possible differences in case definition, 
other methodological issues have to be addressed. Several methodological differences have 
84 
A review of prenatal diagnosis 
been shown to be associated with the number of cases of congenital malformations 
detected and therefore the comparability of results. 
Figure 1 clearly shows that studies conducted in teaching hospitals have reported a larger 
proportion of children with congenital cardiovascular malformations. This may represent 
the underlying ability to recognise congenital heart disease in the study population with the 
appropriate diagnostic procedures. Moreover, with the exeption of the study by Tegnander 
et al. (31), it is apparent in figure 2 that the sensitivity achieved, or the ability to detect 
congenital heart disease prenatally by means of ultrasound, is also considerably higher in 
these reference centres. It is quite possible that the limited amount of time and personnel 
available per ultrasound scan and the less specialised skills of the ultrasonographers in 
general hospitals have implications for the feasibility and effectiveness of routine 
ultrasound screening for congenital heart disease. It is unlikely that inclusion or exclusion 
of high risk pregnancies has distorted this observation because both teaching and general 
hospitals have equally included high risk cases. 
The gestational age at which fetal ultrasound evaluation is performed has been shown to 
affect the accuracy of the diagnostic procedure (2,7,11). Currently available ultrasound 
equipment allows trans-abdominal recognition of fetal structures from a gestational age of 
about sixteen weeks onward. This minimal duration of pregnancy for visualisation of 
congenital heart defects appears to have been met by all studies. 
The diagnostic procedures applied prenatally may also influence the results. No uniform 
procedure has been defmed so far, again complicating comparability. Tegnander et al. 
reported on a single four chamber view evaluation in a non-selected population, whereas 
Rustico et al. mention the use of two dimensional echocardiography without further 
specification, offered at least once in a mixed low and high risk population (29,31). Often 
the scanning time, the staff and the resources available for each individual pregnancy limit 
the possibilities for detailed or repeat scans. The situation described by Tegnander (31), 
one single four chamber view incorporated in a structural ultrasound examination in the 
second trimester, seems to best reflect a realistic screening procedure applicable in current 
practice. 
The way which postnatal diagnosis is accomplished is not exactly specified in any of the 
reports, but has also been shown to influence the yield of congenital heart disease (33,34). 
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A standardised protocol including routine examination of all products of conception is 
preferable. 
This has implications for the necessary duration of postnatal follow up. Serious congenital 
malformations will be detected soon after birth. However, less severe defects possibly 
causing fewer and less obvious symptoms may only be detected at a later age unless 
physical examination with history taking is offered routinely to all children. This way, for 
example, an otherwise unnoticed murmur will also be evaluated, establishing a final 
diagnosis. A follow up period of sufficient length, probably (at least) six months post 
partum, seems necessary (35) . By then the majority of the cases of congenital heart 
disease will have been detected. 
The directionality of time in the way data are gathered may bias the results. It is generally 
understood that prospective data collection, as opposed to retrospective data collection, is 
to be preferred. Bromley et al. (25) and Hegge et al. (28) have evaluated the performance 
of prenatal ultrasound using estimates of prevalence based on postnatally recognised 
cardiovascular malformations. The accuracy of this procedure greatly depends on the 
completeness of case ascertainment; incomplete ascertainment may bias the results 
considerably. Cases suspected prenatally will have had a full work up and are not likely to 
be missed postnatally. However, perhaps apart from possible prenatal spontaneous closure 
of a ventricular septal defect, a case of congenital heart disease not detected or present 
postnatally, may well not have been detected prenatally either. Therefore, and not 
surprisingly the calculated seI>sitivities of the two retrospective studies are relatively high, 
e.g., 48.5 % and 60.9 % respectively, and may overestimate the actual situation. 
The same potential flaw in study design exists in prospective studies if not all cases of 
congenital heart disease are recognised and monitored postnatally. A thorough evaluation 
of a screening procedure demands full ascertainment of all cases, Thus, as mentioned 
above, routine follow up of all children, with history taking, physical examination and 
further evaluation if warranted is a prerequisite. 
The fact that the type of population studied did not appear to have affected the yield of 
cases does not mean this is not an important issue. The inclusion of high risk 'pregnaneies 
in the studies presented may' still have subverted the results. High risk pregnancies may 
represent a subgroup with a higher prevalence of congenital malformations, possibly 
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showing a greater number and more severe symptoms. This, in turn, provides an 
explanation for a larger proportion of cases of congenital heart disease being recognised 
prenatally in the mixed population type study. Moreover, the sensitivities reported in this 
review are calculated according to a rather conservative assumption of 8 per thousand live 
births. As the prevalence of congenital heart disease may in reality be higher in the high 
risk group, the sensitivities calculated would decrease proportionally. 
CONCLUSIONS 
Most of the available reports on screening for congenital heart disease by means of 
ultrasound, more specifically the four chamber view, appear to suffer from one or 
multiple flaws in study design which may have contributed to an overestimation of the 
efficacy of routine fetal echocardiography. As mentioned previously, it would seem that 
the study by Tegnander et al. reflects a realistic screening situation (31). The sensitivity 
calculated from their data with an assumed prevalence of 0.008 is very low: 7.0 %, and 
has yet to be confirmed. Other studies, not aiming at evaluation of fetal echocardiography 
in particular, but rather for fetal ultrasound in general have reported similar results 
(16,36-39). These results are in marked contrast with early reports suggesting sensitivities 
as high as 85 to 95 %, which are likely to have produced all too optimistic views (24,26). 
Future research, evaluating the 'efficacy of a screening procedure should evaluate the test 
prospectively in a representative (low risk/non-selected) population and clinical setting. 
Remaining issues to be taken into account are meticulous case definition and case 
ascertainment after a sufficiently long period of follow up. Finally, the study has to be of 
adequate size to allow for statistical variability. 
Evaluating an antenatal screening test for congenital heart disease by means of an 
ultrasonographically obtained fetal four chamber view in a low risk population, as 
performed in a general hospital once at about 20 weeks gestational age, with routine 
(postnatal) follow up of all pregnancies may contribute to the ongoing international 
discussion on the recommendation of fetal anomaly screening. 
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CHAPTER 6 
EVALUATION OF ROUTINE FETAL ULTRASOUND SCREENING FOR 
CONGENITAL HEART DISEASE IN NORMAL PREGNANCY; 
A PROSPECTIVE STUDY IN THE NETHERLANDS 

INTRODUCTION 
Congenital heart disease accounts for a large proportion of congenital malformations. The 
estimated birth prevalence of congenital malformations appears to be within the range of 
20 to 30 per thousand live births (l,2). Cardiovascular anomalies occur in at least 8 per 
thousand live births (3), of which approximately half are of little hemodynamic 
consequence or can relatively easily be corrected (4,5). Yet, cardiovascular malformations 
still constitute a major health problem responsible for over a third of congenital anomaly 
related infant mortality (6). furthermore, as congenital defects may be associated with 
abortions the prevalence is likely to be even higher prenatally. However, limited data are 
available because of difficulties in gathering data on anomalies present prenatally. The 
prenatal prevalence of congenital heart disease appears to range from 12 to 154 per 
thousand, depending on gestational age and study design (7). 
Over the last decade several authors have reported on the potential of a routine fetal four 
chamber view evaluation at approximately 20 weeks gestational age for antenatal detection 
of congenital heart disease (8-17). A normal four chamber view is supposed to exclude the 
majority of serious malformations. The prospect of a safe and simple screening test for 
this important neonatal health problem has led to incorporating the four chamber view into 
fetal ultrasound in the Netherlands (18). The capability of predicting congenital heart 
disease may have obvious benefits for fetus and future parents. If an anomaly is detected, 
obstetric policy, especially regarding time and mode of delivery, could be adapted. 
Subsequently, considering the strong relation of congenital heart disease with 
chromosomal anomalies, fetal karyotyping could be performed combined with genetic 
counselling (19-21). Finally, upon excluding anomalies, reassuring the prospective parents 
may have significant value. 
Currently, the majority of expectant women, to a certain extent routinely, receive fetal 
ultrasound examination for exclusion of congenital anomalies in the Netherlands. In the 
event of suspected fetal or pregnancy pathology extensive structural ultrasound 
examination is requested. The ultrasound unit of the Department of Gynaecology and 
Obstetrics of Dijkzigt University Hospital, Erasmus University Medical School Rotterdam 
serves the Rotterdam metropolitan area as a referral centre. 
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At present, a fonnal evaluation of the fetal four chamber view incorporated into a single 
routine fetal ultrasound scan at about 20 weeks gestational age, as a screening test for 
congenital heart disease, has not yet been perfonned. The relevance of the submitted work 
ensues from this lack of evidence of the efficacy of the proposed screening test. The 
present report conveys the design and conduct of a clinical evaluation of routine 
ultrasound examination as a prenatal screening test for congenital heart disease. 
METHODS 
Population 
To establish the test characteristics of the fetal four chamber view to screen congenital 
heart disease, a prospective cohort study eruoling pregnant women between 16 and 24 
weeks gestation without known risk factors for (re)occurrence of congenital heart disease 
(table 1) was designed. 
Table I Risk factors for the occurrence of congenital heart disease in the offspring currently viewed as 
indication for (non routine) structural ultrasound screening. 
fetal anomalies maternal anomalies 
intra-uterine growth relar- congenital heart disease 
dation 
arrythmia diabetes mellitus 
aneuploid 
polyhydramnion 
oligohydramnion 
non-cardiac anomalies 
(including abnormal 
karyotype) 
collagen diseases 
phenyl ketonuria 
rubella 
teratogens: alcohol 
amphetamines 
anticonvulsants 
lithium 
morphomimetics 
retinoic acid 
familial anomalies 
congenital heart disease 
genetic syndromes 
Cardiac anomalies were defined analogous to the ICD IX, according to the major 
characteristics (22). The time allocated to intake was initially fixed at 18 months. The 
duration of individual postnatal follow-up was set at six months. At that age all significant 
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heart disease is likely to have been identified (23). To estimate the number of participants 
needed for the study, first a conservative estimate of the prevalence of congenital heart 
disease of 6 per thousand live born was assumed. Second, a literature survey of reports on 
fetal four chamber view evaluation suggested a sensitivity of 85 % and a specificity of 
99%. Presupposing a 95% confidence interval of plus or minus 10% for the sensitivity a 
minimal number of 49 cases needed was calculated. The lower margin of the size of the 
population of screened fetuses required to realise 49 cases was subsequently estimated to 
be at approximately 8000. Accordingly, the aim was to recruit 10,000 participants. 
Accomplishment of recruitment of such a number of respondents implied collaboration 
with a number of referring hospitals in the vicinity. Hence, the staff of peripheral 
hospitals were invited to collaborate, providing their personnel was experienced in the 
evaluation of the fetal four chamber view and a sufficient number of fetal ultrasound 
examinations were performed per year. Initially nine centres were invited. According to 
the annual reports of these centres sufficient numbers of pregnancies were scanned to 
establish a cohort of 10,000 pregnant women within 18 months, thus, averaging a weekly 
screening rate of 130 pregnant women. Simultaneously, a procedure to ascertain the 
follow-up of the participating women and their offspring was designed. 
Posfllatal data collection 
In the Netherlands, Child Health Clinics, under the responsibility of the Community 
Health Services, provide health care to all infants at regular intervals. The parents are 
counselled from one month postnatally onward and the infants undergo a standardised 
physical examination routinely. This provides an excellent opportunity to determine 
postnatal cardiac status. Consequently, local Health Services were also invited to 
collaborate. Furthermore, as the investigators represent the regional tertiary care centres, 
complementary medical information would be readily accessible. In cooperation with the 
staff of the participating hospitals and representatives of regional Community Health 
Services a set of forms for completion was conceived, including written explanation for 
the pregnant women and attending physicians of the Child Health Clinics (appendix A to 
E). After consulting the staff of the referring hospitals it appeared that completion of 
extensive forms would hamper clinical practice at the ultrasound units and hence the 
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intake of participants. Therefore, in a pilot phase this particular section of the study was 
evaluated and the forms adapted accordingly. The following procedure was adopted: upon 
identification at a local ultrasound unit as a potential candidate the expectant woman was 
asked to participate. Subsequently, an oral consent for the utilisation of selected medical 
data was obtained. Next, the participant's particulars, the name of the attending general 
practitioner, the date of the examination, the last menstrual period, the gestational age, the 
referring obstetrician, reason for referral and the results of the ultrasound evaluation were 
reported on a numbered form for completion (appendix A), also mentioning whether 
subsequent referral for a tertiary extended structural examination was requested. At the 
end of the ultrasound session the participating woman was handed an envelope containing: 
1) a written explanation for the respondent (appendix B), 2) a second envelope to be 
handed to the physician attending to the infant (at the local Child Health Clinic) during the 
first visit. This second envelope contained: 3) a written explanation for the attending 
physician (appendix C) and 4) a set of forms modelled like business reply-cards (appendix 
D and E) with identification numbers identical to those on the form with ultrasound data. 
The first reply-card notifying continued follow-up, date of examination, birth date, gender 
and initial history and/or physical examination of the neonate (appendix D), was to be 
returned immediately after identification as a participant by the physician examining the 
child. The second reply-card reporting again date of examination, birth date and final 
health status (appendix E), was to be returned at six months of age. The main objective of 
the method described above was that the work load would not markedly obstruct daily 
clinical routine at the ultrasound units nor at the Child Health Clinics, yet would yield the 
necessary information. The Child Health Clinics operate in such a way that when a health 
problem is suspected the infant will be referred for further examination. Therefore, all 
diagnoses could be verified by attending paediatricians, paediatric cardiologists or 
pathologists. 
Validation of recruitment 
As it was realised that selection of pregnancies with regard to the suspicion of pathology 
could jeopardize the validity of this research project a separate validation study was 
planned. At each cooperating ultrasound unit the records of 100 subsequent obstetrical 
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ultrasound evaluations were arbitrarily drawn. These were to be compared to the 
ultrasound records in our possession with respect to gestational age, referring obstetrician, 
reason for referral and finally appearance of anomalies. After matching for gestational age 
and reason for referral, a similar distribution among the validation-sample and the records 
of the research data-base regarding the referring obstetrician and occurrence of anomalies 
would exclude significant selection. Furthermore, Dijkzigt University Hospital is the only 
tertiary referral centre for extended fetal echocardiography in the greater Rotterdam area. 
Therefore, all pregnancies referred with a suspected anomaly of the fetal four chamber 
view could be traced. Subsequently, it could be verified whether the pregnant woman 
would have qualified as a candidate. If referral of potential respondents outside the 
research protocol would appear to be limited this would further assure the validity of the 
study. 
Data handling 
A fmallogistic problem to be solved was the handling and storage of the data. Periodical 
personal visitation of the participating hospitals and the ultrasound units permitted data-
collection and completion if required. Furthermore, accompanied by "news-letters" stating 
the latest results and developments, direct feedback and coaching of the ultrasonographers 
was secured. The anticipated magnitude of the data-set required the development of a 
computer data-base with automated sub-directories to store the particulars of respondents 
and general practitioners, ultrasound data and follow-up data. This was realised using the 
INGRES relational database software (24). Moreover, the completion of follow-up data 
could to a large extent be ascertained automatically. Measures were taken to limit "loss to 
follow-up" to a minimum. In absence of follow-up data six months after the calculated 
term date the general practitioner of the participant was to be approached to try and 
acquire the missing data. 
RESULTS 
Recruitment 
Initially 9 centres for routine fetal ultrasound, including 2 staffed by personnel of 
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University Hospital Rotterdam - Dijkzigt, were invited and agreed to collaborate. 
Depending on local circumstances the scans were performed either by residents in 
gynaecology, gynaecologists, midwives or ultrasound technicians, all trained to evaluate 
the fetal four chamber view. From February 1991 onward the sets of data-forms were 
distributed among the participating ultrasound units and intake started. However, it 
appeared that the influx of screened pregnancies reached just half the required number. 
The initial failure to enrol 130 respondents weekly was evaluated during regular visits to 
the ultrasound units. Overestimation by the physicians in charge of the ultrasound units of 
the number of pregnancies screened at the required gestational age and tight time 
schedules of the consulting hours appeared to be the major causes. Another problem that 
became apparent was that a substantial proportion of the women were of foreign origin. 
The language barrier in these cases may sometimes have prevented participation as it was 
particularly difficult to obtain consent for participation. Consequently, a further 7 centres 
were invited to collaborate, resulting in a total of 15 cooperating ultrasound units 
(appendix F). Due to the protracted follow-up completion of individual data sets lagged 
behind the intake by approximately one year. Moreover, the implementation of the follow-
up procedure did not evolve as intended. Despite the willingness of the Community Health 
Services to cooperate parents often failed to identify themselves as participants. Ordy in 
60% of the cases was follow-up obtained by means of the business reply-cards. Hence, 
consultation of the general practitioner was impelled in a much larger number of cases 
than anticipated. Periodically, the data base was checked for participants of whom follow-
up data was due on the basis of the expected date of delivery plus six months to allow for 
sufficient follow-up time. Next, standardised letters were generated by computer and 
addressed to the attending general practitioner asking for the required follow-up data. If 
after a month no reply had been received a telephone inquiry was attempted. Upon change 
of physician the one currently attending was approached. In case still no follow-up could 
be obtained, firstly, the current address was obtained via the Municipal Registries, and 
secondly, the gynaecologist supervising the participating ultrasound unit was asked to send 
a form, attempting to obtain informed consent along with the address of the attending 
physician. Using this set of measures, follow-up could be obtained in most cases (> 81 %). 
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Validation 
Possible bias due to selection of pregnancies was a point of major concern particularly as 
only a proportion of the eligible women was enrolled. It has, however, been reassuring to 
note that only one patient not participating in the study, yet qualifying according to the 
study protocol, was referred from a participating ultrasound unit because of suspected fetal 
heart disease. Furthermore, the results of the validation study showed that with respect to 
the proportion of pregnancies which were referred with suspected fetal pathology there 
was no difference between the study population and the random validation sub-sample 
(table 2). The proportions of referring obstetricians, though, did differ to a certain extent. 
Table 2 Comparison of characteristics of mothers enroled in the main study and a random sample of 
obstetric ultrasound evaluations. 
study participants % random sample % 
(n ~ 6922) (n ~ 1500) 
gestation (weeks) < 16 1.5 38.7 
16 - 24 96.1 33.8 
> 24 2.3 27.5 
indication of ultrasound routine 70.8 58.6 
pregnancy duration? 18.7 6.7 
miscellaneous 10.3 34.7 
referring obstetrician midwife 58.7 54.2 
general practitioner 6.8 23.9 
consultant 34.3 21.9 
result of ultrasound normal 99.6 92.6 + '7.30 97.4 
abnonnal '0.4 '0.1 2.6 
= other congenital anomalies; 2 = congenital heart disease; 3 = indeterminate ultrasound result; no 
further action, therefore regarded normal 
DISCUSSION 
In a prospective cohort study to evaluate the fetal four chamber view as a screening test 
for congenital cardiac malformations, ascertainment of all cases arising from the study 
population is important. Problems in obtaining follow-up data on all cases of the anomaly 
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or disease of interest in the population or study sample should be minimal. If an 
(experimental) diagnostic test is being evaluated, it is likely that all suspicious findings 
will undergo rigorous follow-up, including additional diagnostic testing. However, those 
cases that have not been detected by the test may remain undetected unless the complete 
study population is routinely submitted to a second ("gold standard") examination. If the 
remainder of the cohort only has incomplete follow-up, selective under-ascertainment of 
false negative experimental tests may result, thus, overestimating the actual test 
performance. This is a problem that pertains to many studies conducted thusfar. A further 
point of concern in the evaluation of a diagnostic test may be the setting in which the 
experiment is conducted. If performed in a teaching/referral centre the expertise present 
and special interest may create an optimal, though perhaps not realistic situation. 
Preferably, a reflection of prevailing clinical practice should be adopted to establish the 
efficacy of the procedure and guidelines of practice. 
Theoretically the design of this study might have enabled straightforward determination of 
the test characteristics, however, several complications arose during the conduct of the 
project. The numbers of eligible pregnant women did faU behind the prognosis and, 
furthermore, the compliance of some of the ultrasound units did not reach the required 
level. To overcome the prospect of too small numbers two solutions were employed. More 
ultrasound units were involved and the intake period was extended. A third concern was 
the rather low compliance of participants with the follow-up scheme. A far higher 
proportion of complete compliance was anticipated assuming that future mothers would 
almost invariably be exceedingly motivated to comply with the protocol of a project 
concerning prenatal detection of congenital anomalies. A great deal of effort had to be put 
into obtaining the follow-up data on the screened fetuses. A pilot study evaluating the 
contrived design completely might have revealed the above issues. These could 
subsequently have been dealt with in the design phase, yet would have added further to 
the complexity and cost of the project. 
Regarding the validity of the data it appears that selection of participants at intake, 
according to anomalies suspected, has not occurred. The over-representation of 
pregnancies under consultant care may well be explained by the fact that referral for 
ultrasound evaluation between 16 and 24 weeks gestational age already had become an 
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established procedure with gynaecologists, whereas midwives and general practitioners 
may still have tended to refer either at earlier stages or later in pregnancy. 
The unique cooperation which was achieved with Community Health Services in the 
Netherlands deserves further attention. From infancy until school age, all children have 
regular medical examinations. Recently, a standardised protocol and medical record has 
been adopted by all local Health Services. Potentially, this provides a valuable source of 
information for future research on a wide variety of issues. 
In conclusion, diagnostic (screening) tests should be evaluated prospectively in a realistic 
clinical setting. However, study design and conduct may need careful consideration and 
pilot evaluation to avoid extensive adjustment of study-procedures and delay. 
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EFFICACY OF ROUTINE FETAL ULTRASOUND SCREENING FOR CONGENITAL 
HEART DISEASE IN NORMAL PREGNANCY 

INTRODUCTION 
Congenital heart disease constitutes an important proportion of all major congenital 
malformations, which are present in 2 to 3 % of neonates (1,2). The estimated birth 
prevalence of cardiac malformations is 8 per 1,000 (3). Approximately half of the cases of 
congenital heart disease have only minor consequences or can relatively easy be corrected 
surgically. Yet, 35 % of infant deaths due to congenital malformations is related to 
cardiovascular anomalies (4,5). Hence, congenital heart disease still is an important issue 
in infant health. In addition cardiovascular anomalies are strongly associated with other 
anomalies or chromosomal aberrations (6,7,8). 
The etiology of congenital malformations of the cardiovascular system is largely unknown 
(7,9,10), and primary prevention is not yet possible. Therefore, prenatal detection and 
subsequent adjustment of the obstetric policy, or termination of pregnancy in case a fatal 
anomaly is detected, are the main options available. Ultrasound visualisation and 
interpretation of the fetal four chamber view at 16 to 24 weeks gestational age has been 
advocated as an efficient and accurate screening test for prenatal detection of the majority 
of severe cardiac malformations (11,12). Accordingly, assessment of the four chamber 
view has been incorporated into routine fetal ultrasound in many countries including the 
Netherlands (13). In spite of its popularity, a formal evaluation of fetal echocardiography 
by means of the fetal four chamber view in a low risk population at a gestational age of 
about 20 weeks has not been performed. 
The efficacy of routine fetal echocardiography has not been proven beyond doubt and this 
encouraged us to establish the performance of the test in normal pregnancies. 
SUBJECTS AND METHODS 
sOllrce poplIlation 
Pregnant women referred for routine fetal ultrasound were invited to participate in the 
study by the sonographers, e.g., ultrasound technicians, midwives or physicians, when 
fulfilling the eligibility criteria. Together 15 referring ultrasound units in the Rotterdam 
metropolitan area participated. All participating women reside in the South-Western part 
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of the Netherlands. From March 1991 until January 1993 6,922 fetuses were scanned and 
included in the study. Mean maternal age was 28.9 years (SD 4.6; range 14 to 47). 
eligibility criteria 
Women were considered eligible if scheduled for routine fetal ultrasound between 16 and 
24 weeks of pregnancy. Determination of gestational age or growth discrepancy, 
reassurance because of a preceding miscarriage, lack of fetal movements, inability to 
detect fetal heartbeats and some miscellaneous reasons were also considered a routine 
examination. All women with known risk factors for congenital heart disease in their 
offspring, e.g. a previous child, their partner or themselves affected with congenital heart 
disease, maternal juvenile diabetes, maternal lupus erythematosus, maternal phenyl 
ketonuria, maternal rubella and maternal drug or teratogen exposure, for example use of 
anti-convulsants, retinoid acid or morphomimetics, were excluded as these characteristics 
currently constitute an acknowledged indication for additional fetal echocardiography. 
personnel and appliances 
In each of the participating ultrasound centres the majority of examinations was performed 
by specific experienced personnel. Accordingly, of 6,922 examinations 3,747 (54%) were 
performed by technicians, 776 (11 %) by midwives, 1,391 (20%) by trainees in obstetrics 
and gynaecology and 1,008 (15%) by consultants. The majority of sonographers involved 
in the study had ample background in fetal ultrasound examination and, in addition, all 
had taken a brief intensive ultrasound training course on the evaluation of the fetal four 
chamber view preceding participation. During the study the ultrasound units were 
frequently visited. Also, the sonographers were counselled by the project supervisor and 
were informed about the study progress without disclosure of the findings. Various brands 
and types of ultrasound equipment, all state of the art 2-dimensional appliances, were used 
in the participating ultrasound units depending on local preference. 
data handling 
All ultrasound examinations of the fetal four chamber view were evaluated and coded as 
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nonnal, abnonnal or impossible to assess, according to standard criteria. The fetal heart 
should be located in the middle of the thorax, occupy approximately 1/3 of the thorax, 
display atria of equal size, ventricles of equal size, an intact ventricular septum, a foramen 
ovale flap demonstrated in the left atrium and have off-set atria-ventricular valves, that is, 
a more apical insertion of the tricuspid valve and possible visualisation of a 'moderator 
band' in the right ventricle (11,12) (fig 1). 
Figure 1 NO':llI!tl. fetal four chamber view 
~-sp 
RA RV 
SP = spine, PV = pulm'Jnary veins, FO = foramen ovale, LA = left atrium, LV = left ventricle, RV == 
right ventricle, RA = right atrium 
In addition, data on gestational age as determined by biometry, a code for the category of 
referring obstetrician (midwife, general practitioner or gynaecologist), the indication for 
an ultrasound scan (routine, detennination of gestational age or other), suspected presence 
of other' congenital malformation(s) and whether or not the pregnant woman was 
subsequently referred for extended fetal ultrasound examination, were registered. 
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Follow-up data on all women and their children were collected until six months 
postnatally. In collaboration with local Child Health Clinics, which offer a physical 
examination of the infants and an interview of the parents routinely, the required data 
(date of birth, sex and presence of congenital anomalies) were obtained for most women. 
If necessary, the woman's general practitioner was consulted. In case an anomaly was 
suspected, hospital records, findings on additional ultrasound examination and autopsy 
records were read over and coded. 
data analysis 
By comparing the prenatal diagnosis (presence or absence of anomalies) to the postnatal 
diagnosis, the latter being taken as a gold standard, all ultrasound examinations were 
categorised as true positive in case a suspected anomaly was confinned, false positive in 
case a suspected anomaly could not be confirmed, false negative in case an anomaly was 
missed by ultrasound examination or true negative in case no anomalies were present. As 
no consequences are attached to an indeterminable four chamber view the cases involved 
were considered to be normal. The data were subdivided according to presence of 
congenital heart disease and non-cardiac congenital anomalies. In addition, all anomalies 
were categorised as major (definitely considered detectable prenatally), minor (possibility 
of prenatal detection is debatable) or undetectable (excluded from analysis). The last 
category consists of anomalies like patent ductus arteriosus, sometimes occurring in 
combination with secundum type atrial septal defect, cryptorchism and syndactyly. As 
there is general consensus that these anomalies may be considered part of normal fetal 
development or can not be recognised on prenatal ultrasound examination these cases were 
subsequently omitted from analysis (14). The sensitivity, the specificity, the predictive 
value positive and the predictive value negative were calculated with corresponding exact 
95 % binomial confidence intervals (15). In addition, the prevalence of congenital 
malformations (the proportion of infants affected) was calculated. 
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RESULTS 
subjects and ultrasound examinations 
Of the total of 6,922 fetuses screened 6,571 (95%) underwent a routine ultrasound 
examination between 16 and 24 weeks gestational age. Figure 2 shows the distribution of 
the duration of pregnancy at which the ultrasound examinations were performed. In 501 
(7.2 %) fetuses an adequate four chamber view could not be obtained. Figure 2 also 
demonstrates how visualisation of the four chamber view related to gestational age. 
Figure 2 Distribution of gestational age at the time of ultasound examination with proportional display of 
adequate four chamber view evaluations 
(ZI 4CV NASS. 
o 4CV ADEQ. 
Legend: 4CV = four chamber view; NASS. = not assessable; ADEQ. = adequate 
Follow-up until six months post partum has been completed for 5,660 fetuses (81.8%). Of 
these, 119 appeared to have oc,n included despite known risk factors for congenital heart 
disease and 222 were screened outside the 16 to 24 weeks gestational age range. 
Consequently, the analysis presented pertains to 5,319 routine fetal ultrasound 
examinations in the gestational age range of 16 to 24 weeks (mean 19 weeks and 5 days; 
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SD 2 weeks and one day), with complete information available on the outcome of 
pregnancy until 6 months post partum. 
outcome of ulrrasound 
Of all women screened prenatally, seven subjects (0.101 %) were subsequently referred for 
extended fetal echocardiography on account of an abnormal appearance of the fetal four 
chamber view. Another 14 (0,202%) subjects were referred because of other suspected 
congenital anomalies. Two cases of intra-uterine referral for suspected congenital heart 
disease could be confirmed on subsequent evaluation. Non-cardiac anomalies were 
detected more accurately; out of the 14 cases referred 12 proved to be affected. 
outcome of pregnancy 
Eventually, congenital anomalies were present in 118 (prevalence 2.22%; 95% C.I.: 1.84 
- 2.65) cases. There were 62 (1.17%; 0.89 - 1.49) cases with congenital heart disease (6 
of which also had other congenital anomalies). Non-cardiac anomalies were detected in 62 
(1.17%; 0.89 - 1.49) cases. Furthermore, 5 cases of congenital heart disease occurred in 
combination with chromosomal anomalies. When evaluated according to categories 
(major, minor or unrecognisable) of anomalies, 80 (1.50%; 1.19 - 1.87) cases (major and 
minor) remained for secondary analysis. These included 44 cases of congenital heart 
disease (4 in combination with other malformations), and 40 cases of non-cardiac 
anomalies. The nature and number of the congenital anomalies encountered in these 80 
cases is listed in table 1. 
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Table 1 Congenital anomalies detected in 80 cases during folow up with numbers detected prenatally in parenthesis 
VSD CoA AVSD ASD PA PS TGA HLH HRH DORV Complex ug gi extr lac..ial ens mise 
total 30 5 4 5 4 2 2 2 11 6 8 8 3 6 
major 4 4 2 (2) 4 (3) 5 (3) 8 4 2 6 (5) 
VSD = ventricular septal defect: CoA = coarct:l.tion of the aorta; AVSD == atrioventricular septal defect: ASD =:: anial septal defect; PA =:: pulmonary atresia; PS == pulmonary stenosis; TGA "" transposition 
of the great aneries; HLH == bypoplastic left hean: HRH == hypoplastic right hean: DORV == double oudet right ventricle: Complex == complex cardiac anomalies; ug == uro-gcnital.: gi "" gastro-intestinaJ.; 
em = extremities: ens ::::: central nervous system; nrisc "" miscellaneous 
A table displaying all cases detected in 5 ,319 fetuses is presented in appendix G. 
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petjoww/lce of ultrasound 
In the categories of cardiac anomalies, non-cardiac anomalies and all anomalies combined 
a distinction has been made between the number of major and minor anomalies together 
and a sub-sample of major anomalies, likely to have generated an abnormal image at 20 
weeks gestational age. This is reflected in separate tables and analyses according to case 
severity. Tables 2a-c show the findings of routine prenatal screening for congenital 
anomalies of the heart, other organs/parts and all anomalies combined, respectively. 
Tables 2a-c Outcome of ultrasound screening for congenital anomalies and findings on follow-up 
a Follow up -
Ultrasound cardiac anomalies' normal major cardiac 
anomalies 
abnormal 4CY 2 5 2 
normal4CY 42 5,270 10 
total 44 (18)' (2)' 5,275 12 
b Follow-up 
Ultrasound non-cardiac normal major non-cardiac 
anomalies! anomalies 
non-cardiac 12 2 12 
screen-positive 
non-cardiac 28 5,277 18 
screen-negative 
total 40 (22)' 5,279 30 
c Follow-up 
Ultrasound congenital normal major 
anomalies! anomalies 
screen positive 13 (I)' 7 13 
screen negative 67 (3)' (2)' 5,232 26 
total 80 (38)' 5,239 39 
1 = major and minor anomalies 
2 = cases not included; non-detectable anomalies 
3 "" non-detectable cardiovascular anomalies yet detectable non-<:ardiac anomalies 
4 = number of cases with both cardiac and non-eardiac anomalies 
5 = major anomalies 
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normal total 
5 7 
5,302 5,312 
5,307 5,319 
normal total 
2 14 
5,287 5,305 
5,289 5,319 
normal total 
7 20 
5,273 5,299 
5,280 5,319 
Efficacy of rouline fetal screening 
The sensitivity for cases of congenital heart disease was low (4.5%; 0.56 - 15.5) even if 
only major anomalies are considered (16.7%; 2.09 - 48.8). Sensitivity was somewhat 
higher for non-cardiac anomalies (30%; 16.6 - 46.5%) and higher still in case of major 
anomalies (40%; 22.7 - 59.4). The sensitivity for all anomalies combined was 
intermediate (overall: 16%; 8.95 - 26.2, major: 33%; 19.1 - 50.2). As expected, the 
specificity is high (>99%) for both categories of anomalies. Also the predictive value 
negative is high (99%). The predictive value positive varies considerably over the 
categories of anomalies and can not be established accurately, as illustrated by the wide 
confidence intervals. All test characteristics and prevalence figures are summarized in 
table 3. 
Table 3 Test characteristics of routine fetal ultrasound 
cardiac anomalies other congenital overall 
anomalies 
sensitivity -major and minor 4.5 (0.6 - 15) 30.0 (16.6 - 46.5) 16.3 (8.9 - 26.2) 
-major 16.7 (2.1 - 48.4) 40.0 (22.7 - 59.4) 33.3 (19.1 - 50.2) 
specificity 99.9 (99.8 - 100) 99.9 (99.9 - 100) 99.9 (99.7 - 100) 
predictive value positive 29 (3.7 -71) 86 (57 - 98) 65 (41 - 85) 
predictive value negative 99.2 (98.9 - 99.4) 99.5 (99.2 - 99.7) 98.7 (98.4 - 99.0) 
prevalence -tr.ljor and nlnor 0.83 (0.60 - 1.11) 0.75 (0.54 - 1.02) 1.50 (1.19 - 1.87) 
-;!,' anomalies 1.1"1 (0.89 - 1.49) 1.17 (0.89 - 1.49) 2.22 (1.84 - 2.65) 
All figures are % with 95% confidence intervals in parenthesis. All anomalies; including non-detectable. 
validation 
As we were concerned about the possibility of selective participation of mothers with 
children that either have no anomalies or represent a population with a relatively high 
number of anomalies, a random sample of 1,500 ultrasound examinations (100 from each 
of the participating ultrasound units) was evaluated with regard to data on gestational age, 
referring obstetrician, indh: .. tion of ultrasound, suspected presence of congenital 
malformations and referral for further evaluatioll. Because this random sample could not 
be selected on gestational age a wider gestational age range is represented. Furthermore, it 
appeared that slightly more examinations in the sample were requested by consultants. 
I 
However, the (small) proportion of women referred on account of suspected fetal 
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anomalies was equal to that in the study population. In addition, we were able to study the 
data-base of the Division of Prenatal Diagnosis of the Department of Obstetrics and 
Gynaecology of Dijkzigt University Hospital, serving the Rotterdam metropolitan area as 
a tertiary referral centre, and check this data-base for cases not included in the study that 
would otherwise have qualified as participants. Only one case of a suspected anomaly of 
the fetal four chamber had been referred during the period of intake of the current study 
that was not known from the common follow-up. 
DISCUSSION 
The objective of the present study was to evaluate the efficacy of the fetal four chamber 
view in routine screening of normal pregnancies to detect congenital heart disease. Our 
findings indicate that the fetal four chamber view, as evaluated during routine fetal 
ultrasound in the second trimester of pregnancy, does not provide an accurate screening-
test. Even major anomalies, likely to create an abnormal fetal four chamber view, were 
not detected to a satisfactory degree prenatally. 
Several factors may explain these results. The size of the fetal structures is related to 
gestational age. Hence, visualisation early in the second trimester, when the fetus is small, 
will be limited by the resolution of the ultrasound equipment. However, as is apparent 
from figure 2, the majority of scans was performed beyond 17 weeks gestational age, a 
time generally deemed appropriate for structural ultrasound examination. In addition, the 
proportion of fetal hearts that could not be assessed remained stable after 17 weeks of 
gestation; the scans appear to have been performed at an appropriate moment. 
Furthermore, all participating ultrasound units had state of the art equipment at their 
disposal. Conversely, other factors may be responsible for the results. The scans were 
performed by specialised technicians in over half of the cases and by sonographers with 
varying degrees of experience in the remainder of the group. We feel that this mix 
adequately reflects the current ultrasound practice of screening and, if anything, quality 
of procedures has been higher than usually encountered. Interestingly, the proportion of 
fetal four chamber views judged as not assessable did not differ among the categories of 
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sonographers. Also, all sonographers had taken similar additional training in the fetal four 
chamber view examination prior to the start of participation in the study. Furthennore, as 
we were aware of the fact that trainees perfonning ultrasound examinations tended to be 
replaced rather frequently, all participating ultrasound units were visited repeatedly. 
During these visits the progress of the study and demand for additional training of junior 
sonographers was assessed. By evaluating the number of inadequate four chamber view 
visualisations during the study the effect of increasing experience of the sonographers can 
be judged. However, the proportion of adequate ultrasound evaluations of the fetal heart 
did not materially fluctuate nor was there any indication of a particular trend during the 
period of participation. Therefore, it appears unlikely that variations in experience and 
skills have had a major impact on the efficacy of the screening procedure. 
For non-cardiac congenital anomalies also a rather poor performance was observed with a 
30 % sensitivity, resulting in a sensitivity of 16 % for all anomalies together. A 
discussion analogous to that on the fetal four chamber view applies to other congenital 
anomalies as well. Again, the results can not be readily explained by any of the variables 
discussed so far. 
The nature of the anomalies encountered in routine screening explains part of the low 
sensitivity of prenatal detection observed in this study. Some malformations, for instance a 
small ventricular septal defect or an atrial septal defect, may not be visible with the 
current ultrasound equipment. The proportional distribution of congenital anomalies 
encountered at birth may clarify this argument. Approximately 30% of the cases have 
ventricular septal defects, 10% have a patent ductus arteriosus, 10% have atrial septal 
defects, 10% are pulmonary stenosis and a further 25% were cases of tetralogy of Fallot, 
coarctation of the aorta, aortic stenosis and transposition of the great arteries (16). It can 
be argued that approximately half may not be detectable (or only with great difficulty) by 
means of a fetal four chamber view. Furthennore, a congenital anomaly may not remain 
in a steady state. A duodenal obstruction, or a urinary tract obstruction for instance, may 
only become visible in late second trimester. The anatomical substrate may be present 
already, but may not yet have functional (recognisable) consequences at 20 weeks 
gestation. This may even apply in some severe cardiac anomalies like hypoplastic left 
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heait (17). Apparently, the sensitivity is partly determined by the (im)possibilities of 
detection by means of prenatal ultrasound and partly by the natural history of the specific 
anomalies. Nevertheless, even if anomalies of which possibilities for prenatal detection are 
debatable were left out of the analysis, low sensitivities were found. The exclusion of 
Hminor U anomalies from evaluation could suggest that one considers these cases irrelevant 
from an obstetric and paediatric point of view. Yet, minor variants of congenital 
malformations may have an identical cause as major defects and may similarly be 
associated with other anomalies. In view of this it would seem irrational to consider such 
cases irrelevant. 
Fetal echocardiography, e.g., the four fetal chamber view, has been advocated as a useful 
tool to detect congenital heart disease prenatally (11,12). Our data are not consistent with 
this view. It should be noted, however, that the authors concerned mostly were experts in 
the field of fetal ultrasound and tended to work in (tertiary) referral centres. Their results 
are likely not to apply to the routine ultrasound clinic, where sonographers may be less 
skilled, face crowded office hours and a non-selected population with a low prevalence of 
anomalies. Furthermore, the present prospective cohort-study has complete follow-up on 
the fetuses, whereas previous reports are limited to cases referred and detected. This may 
have caused a serious bias. Stillborn fetuses or infants affected may not reach (a tertiary) 
hospital or may not be examined routinely. When such false negative cases are not 
considered this will result in overestimated sensitivities. Recent reports on ultrasound in 
second trimester pregnancy, originating from ultrasound units employing regular personnel 
and scanning-time, show an efficacy of routine fetal ultrasound examination for detection 
of congenital anomalies that is compatible with our findings (18-22). The recent Radius 
study actually demonstrated completely similar results (18). 
As discussed, the level of expertise and skills of the sonographers in the present study 
represents the level of quality in ultrasound examination currently observed in routine 
screening practice. Suggestions for additional training of the sonographers as well as 
additional scanning projections have been submitted (23,24). Great endeavour and 
substantial resources may be required to establish a level of ultrasound skills sufficient to 
have a major impact on detection rates. Even if achieved, a sizable proportion of cases 
may remain technically undetectable within the period of gestational age considered 
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optimal for screening. Despite obvious advantages of prenatal detection of individual 
cases, we feel that an overall net benefit of routine ultrasound screening has not been 
established. False negative diagnoses and false positive diagnoses will always occur and 
have to be taken into account. In addition, it may well be that in a major proportion of the 
cases potentially detectable, prognosis will not improve significantly by early detection 
(25,26). 
In conclusion, the findings in this prospective study indicate that in the setting here 
described routine fetal echocardiography at 20 weeks gestational age by means of the fetal 
four chamber view does not suffice as a prenatal screening test for congenital heart 
disease. 
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CHAPTER 8 
EFFICACY AND YIELD OF TERTIARY CENTRE FETAL ECHOCARDIOGRAPHY 
FOR DIFFERENT HIGH RISK GROUPS 

INTRODUCTION 
Technological advances in ultrasound equipment have enabled detailed anatomical and 
functional investigation of fetal structures including the heart (1-4). A prerequisite is that 
the personnel involved has adequate expertise in fetal ultrasound and detailed knowledge 
of fetal anatomy and functional status of the developing organs and structures. In addition, 
sufficient scanning time should be allocated to each patient. These conditions are scarce 
and expensive, restricting full fetal examination to teaching hospitals or other selected 
referral centres. 
A number of risk-factors for congenital heart disease in the history of pregnant women has 
been recognized as indications for an extensive prenatal examination (5,6). The outcome 
of fetal echocardiography may prompt additional diagnostic tests and subsequent 
adjustment of obstetric management. Currently, increased risk for congenital heart disease 
in the offspring is considered on account of a previous infant, one of the parents or an 
other (second degree) relative affected, certain familial or genetic syndromes, maternal 
diseases, e.g., type 1 diabetes mellitus, (autoimmune) collagen diseases, phenyl ketonuria 
and rubella, maternal teratogen exposure. 
As knowledge of the etiology of congenital heart disease is expanding and the technique of 
fetal echocardiography has become well established, the demand for prenatal ultrasound 
diagnosis is increasing rapidly and may exceed current capacity. 
In the present paper the efficacy and yield of tertiary centre fetal echocardiography in 
women at known increased risk for congenital heart disease in their offspring is described 
using data on a 10 year experience. 
METHODS 
subjects and appliances 
A total of 2852 anomaly scans was perfonned on patients with a known risk factor for 
(re-)occurrence of congenital heart disease in their offspring in the Division of Prenatal 
Diagnosis of the University Hospital Rotterdam - Dijkzigt between 01 01 1982 and 01 01 
1992. The examinations were performed on a Diasonics Cardio Vue 100 mechanical 
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sector scanner (carrier frequency: 5.0 MHz) between 1982 and 1989, and on a Toshiba 
SSA-270 A curved linear array scanner (carrier frequency: 3.5 MHz) combined wilb 
colour coded Doppler flow imaging from 1989 onward. 
The majority of scans (83%) was performed between 16 and 25 weeks of gestation « 16 
weeks: 1% and> 24 weeks: 16%) ensuring the best possibilities for visualization of the 
fetal cardiac and non-cardiac structures. The cardiac four chamber view, atrio-ventricular 
and ventriculo~arterial connections, the aortic arch, ductus arteriosus and venous inflow 
were examined in sagittal and short axis views (7). Colour-coded Doppler flow imaging 
may provide additional information on fetal cardiac flow characteristics in the presence of 
structural cardiac anomalies (8). 
dala handling 
The reasons for referral, maternal age (years) and gestational age (weeks) at the time of 
the ultrasound examination, the nature of the anomaly and pregnancy outcome (normal, 
affected, intra-uterine or neonatal death or termination of pregnancy) were recorded. The 
prenatal and postnatal diagnosis of congenital malformations was recorded independently. 
Ascertainment of follow-up on all cases was pursued in various ways on a routine basis. If 
applicable, direct information from the referring midwife, general practitioner or obste-
trician was obtained with regard to the first postnatal evaluation of the newborn. 
Olberwise, the attending general practitioner and/or paediatrician were approached for 
information on the neonatal status. In case an infant had been referred for cardiologic 
evaluation, the paediatric cardiologist was requested to make the diagnosis available. 
Occasionally, the only available information was a birth announcement sent by the parents 
stating that their infant was alive and well. The period of postnatal follow-up ranged from 
less than 1 week to over 9 years. 
validity 
The varying sources for follow up data led us to conduct a separate validation study. The 
available follow-up data of the years 1988 and 1989 (777 cases) were compared with a 
second set of follow-up data regarding potential congenital malformations, obtained by a 
separate request for information which was sent to the general practitioner. In addition, 
122 
Efficacy of fetal echocardiograpJiy 
the data-base of the Division of Paediatric Cardiology, Department of Paediatrics, Sophia 
Children's Hospital, a supra-regional referral institution, was checked for names of those 
pregnant women of whom definitive follow-up was missing. 
data analysis 
Taking the postnatal diagnosis as a gold standard, all prenatal ultrasound examinations 
were categorized as true positive in case a suspected anomaly was confirmed, false 
positive in case a suspected anomaly could not be confirmed, false negative in case an 
anomaly was missed by ultrasound examination or true negative in case no anomalies were 
present. The data were categorized according to the presence of congenital heart disease 
and/or other congenital anomalies. In addition, all anomalies were classified as potentially 
detectable prenatally; or definitely undetectable, such as patent ductus arteriosus or 
cryptorchism. The latter category (n = 13) was excluded from calculation of the test 
characteristics. The sensitivity and specificity, the predictive value positive and predictive 
value negative were calculated with corresponding exact 95 % binomial confidence 
intervals. In addition, the prevalence of congenital malformations (the proportion of 
infants affected) was calculated. 
The relative risk of anomalies detected during fetal echocardiography and postnatally 
confirmed malformations associated with the various indications was estimated by means 
of a multiple logistic regression model (9). Firstly, as an approximation of the relative 
risk, a crude estimate of the odds ratio of an ultrasound diagnosis of a congenital anomaly 
was obtained for the various risk-factors, which was subsequently corrected for gestational 
and maternal age. Next, a similar model was applied to estimate the odds ratio of a 
definitive diagnosis at follow-up for the risk-factors. By mutually comparing the odds 
ratios or relative risks, an estimate of the relative yield of examination according to the 
various risk factors could be obtained. 
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RESULTS 
The mean gestational age at which the 2,852 fetuses were screened was 21 weeks (SD: 4 
weeks). The mean maternal age at the time of examination was 29 years (SD: 4.9 years). 
Referral because of a previous infant with congenital heart disease occurred in 1,062 
cases. This was followed by paternal cardiovascular anomalies: 562 cases, maternal 
cardiovascular anomalies: 326 cases, other relatives with cardiovascular anomalies: 150 
cases, maternal use of anti epileptic drugs: 398 cases, maternal type 1 diabetes mellitus: 
351 cases, maternal morphomimetics/drug abuse: 177 cases, and a miscellaneous group, 
e.g., retinoic acid use, maternal SSa antigen, alcohol abuse: 226 cases. Follow-up was 
obtained from the referring obstetricians, paediatricians, paediatric cardiologists or general 
practitioners in 2,024 cases (71 %). In a further 604 cases only a birth announcement 
stating that the baby was alive and well was available, leaving 224 cases with incomplete 
follow-up. The names and addresses of these 828 women (fetuses) were verified in the 
hospital data-base. In 23 cases there was insufficient information to obtain the full name 
and address (mostly heroin addicted women). The names and addresses of the remaining 
805 cases were matched with the data-base of Sophia Children's Hospital. Apart from a 
case of mild pulmonary stenosis and a case of perimembranous ventricular septal defect 
not yet known at the time of data-matching, no major pathology was revealed. Thus, the 
data of 2,829 fetuses were available for analysis (99%). 
The validation sub-sample of 777 cases, of whom a second set of follow-up data was 
requested (> 88 % completed) revealed no additional anomalies. Follow-up data had to be 
updated in only two cases out of 20 occurring in the sub-sample. 
In total, 80 cases with congenital malformations were detected in the cohort of 2,829 
fetuses (prevalence 2.83%; 95% C.1. 2.25 - 3.51). Subsequently, 13 cases considered 
undetectable were excluded: 3 cases of patent ductus arteriosus, one of which combined 
with a rest foramen ovale; a case of absent right puhnonary artery; a case of aplasia of the 
right earlobe; a case of hypospadias; 4 cases with dysmorphic features; a case of cleft 
palate; a case of oesophageal atresia with fistula; and a case with webbed neck and 
hypoplasia of the lungs (residual prevalence 2.4%; 95% C.1. 1.8 - 3.0). There were 43 
cases (1.5%; 1.1 - 2.0) of congenital heart disease and 31 cases (1.1 %; 0.8 - 1.6) with 
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other anomalies (table 1). There were 8 cases with both cardiac and other anomalies. 
Twenty-five out of 43 cardiac anomalies were not detected; 7 of which on account of the 
documented minute size of the anomaly (a small ventricular septal defect, 3x) or severe 
maternal obesity (coarctation of the aorta, hypoplastic left heart syndrome, truncus 
arteriosus) or associated with unfavourable fetal position (coarctation of the aorta). The 
remaining 18 cases were not detected in spite of the current procedure of fetal 
echocardiography. However, 5 of these cases were ventricular septal defects which were 
only recognised on auscultation and were not verified by means of echocardiography 
postnatally. Another fetus was suspected to have a ventricular septal defect, which could 
not be confirmed postnatally. Though spontaneous intra-uterine closure is a likely 
explanation, this case was included as a false positive diagnosis. Twelve out of the 31 
non-cardiac anomalies were not detected, 5 of which on account of the minute size of the 
anomaly (a dysmorphic hand, a case with multiple minor anomalies (dysmorphic 
features)), or anomalies which may not yet have been functionally obstructive at about 21 
weeks gestational age (multiple bowel atresia, oesophageal atresia) or associated with 
severe maternal obesity (multiple skeletal anomalies). 
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Table 1 Nature of the anomalies observed in 70 cases; detected - undetected 
Diagnosis 
- additional anomalies per case 
VSD 
- ASD (Ix) 
- radial aplasia (Ix) 
ASD 
- aplasia of extremities 
AVSD 
- oesophageal atresia and hypospadias 
TOF 
- hydrocephalus, multi-cystic kydney, skeletal 
malformations 
- cleft lip palate 
COA 
- tricuspid anomaly 
- bicuspid aortic valves 
- ASD, PDA 
PS 
AS 
- peripheral pulmonary hypoplasia 
TGA 
- DILV, DORV, VSD, mitral insufficiency 
- VSD, straddling tricuspid valve 
DORV 
- VSD, right sided aorta 
HLH 
- mitral atresia, APVD, aortic atresia 
HRH 
- DILV, DORV, TGA, PA, straddling 
tricuspid valve 
Univentricular heart 
- truncus arteriosus, ASD, APVD 
Truncus arteriosus 
- multiple skeletal anomalies 
Ectopia Cordis 
- gastroschizis, hygroma colli 
Multiple minor anomalies; cardiac (VSD), 
non-cardiac (dysmorphic features) 
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number of cases 
detected undetected 
3 
1 (non-cardiac) 
1 
1 (non-cardiac) 
1 
5 (1 *) 
1 (non-cardiac) 
1 (non-cardiac) 
1* 
2 
* 
1 
1 
1 
1 
1 
11 (3#) (511) 
1# (non-cardiac) 
2 
5 (2#) 
2 
2 
1# 
1# 
1# (non-cardiac) 
1 (non-cardiac) 
1 
1# (non-cardiac) 
Urogenital anomalies: 
- bilateral hydronephrosis 
- polycystic kidneys, polydactyly 
- hypospadias, cleft lip 
Gastro-intestinal anomalies: 
- multiple bowel atresia 
Skeletal anomalies: 
- multiple 
- agenesis left hand, foot 
- clubfoot 
- dysmorphic hand 
- fibular aplasia 
Facial anomalies: 
- cleft lip and palate 
Central nervous system anomalies: 
- anencephaly 
- hydrocephalus, cleft lip and palate 
- hydrocephalus, spina bifida 
- spina bifida 
Efficacy of fetal ecJlOcardiograplly 
1 
I (cleft lip missed) 
1 
1 
1 
4 
I (cleft missed) 
5 (spina missed Ix) 
1 
1 
1# 
1 
1# 
1 
2 
VSD = ventricular septal defect; ASD = atrial septal defect; A VSD = atrioventricular 
septal defect; TOF = tetralogy of Fallot; COA = coarctation of the aorta; PDA = patent 
ductus arteriosus; PS = pulmonary stenosis; AS = aortic stenosis; TGA = transposition 
of the great arteries; DILV = double inlet left ventricle; DORV = double outlet right 
ventricle; HLH = hypoplastic left heart; HRH = hypoplastic right heart; PA = 
pulmonary atresia; APVD = abnormal pulmonary venous drainage; * = anomaly detected 
but misclassified; II = anomalies verified by means of auscultation only; # = anomaly 
not detected as a result of the minute size of the anomaly, maternal obesity or 
unfavourable fetal position 
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All results, both including and excluding the cases not detected on account of specific 
reasons or conditions, are sununarized in tables 2a-c. Subsequently, sensitivity for 
detectable cases, specificity, predictive value positive, predictive value negative and 
prevalence are presented in table 3. In addition, the sensitivity of fetal echocardiography 
was estimated after excluding the 5 cases of ventricular septal defect detected on 
auscultation only. 
Tables 2a-c Outcome of tertiary ultrasound examination for congenital anomalies and findings on follow-up 
a Congenital heart disease 
Follow-up 
Ultrasound cardiac normal detectable cardiac 
anomalies anomalies' 
suspected 18 1 18 
normal 25 2,785 18 
total 43 (4)' 2,786 36 
b Non-cardiac malformations 
Follow up 
Ultrasound non-cardiac normal detectable non-cardiac 
anomalies anomalies' 
suspected 20 
- 20 
normal 12 2,797 7 
total 32 (9)' 2,797 28 
c All anomalies combined 
Follow up 
-
Ultrasound congenital normal detectable 
anomalies anomalies' 
anomaly suspected 34 (4)' 1 34 
normal 33 (4)' 2,761 24 (1)' 
total 67 (13)' 2,762 58 
1 = excluding cases missed on account of specific reasons or conditions 
2 = non-detectable anomalies (cases not included in calculation of test characteristics) 
3 = cases with both cardiac and non-cardiac anomalies 
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normal total 
1 19 
2,792 2,810 
2,793 2,829 
normal total 
- 20 
2,822 2,809 
2,822 2,829 
normal total 
1 35 
2,770 2,794 
2,771 2,829 
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Table 3 Test characteristics of extensive fetal ultrasound examination. 
All figures are % with 95% confidence intervals in parenthesis 
cardiac anomalies non-cardiac overall 
anomalies 
sensitivity detedable 50 (33 - 67) 74 (54 - 89) 59 (45 - 71) 
confirmed 58 (39 - 75) 64 (50 - 77) 
specificity 99.9 (99.8 - (00) 99.9 (99.9 - (00) 99.9 (99.8 - (00) 
predictive value positive 95 (74 - (00) 100 (87 - (00) 97 (85 - (00) 
predictive value negative 99.1 (98.7 - 99.4) 99.5 (99.2 - 99.7) 98.8 (98.3 - 99.1) 
prevalence 1.52 (1.l0 - 2.04) 1.13 (0.78 - 1.59) 2.37 (1.84 - 3.00) 
total 1.66 (1.22 - 2.20) 1.45 (1.04 - 1.96) 2.83 (2.25 - 3.51) 
detectable = excluding cases missed on account of specific reasons or conditions 
confirmed = excluding the cases of ventricular septal defect verified by means of auscultation only 
total = including undetectable anomalies (excluded in calculation of test characteristics) 
When all postnatally reported cases are considered the sensitivity of fetal 
echocardiography was 42% (95% C.1. 27 to 58). However, if cases known to be difficult 
or impossible to detect are excluded the sensitivity was 50% (95% C.1. 33 to 67). For 
non-cardiac anomalies and overall the sensitivity was 63% (95% C.1. 44 to 79) and 51 % 
(95 % C.1. 38 to 63) respectively. When excluding the non-cardiac cases difficult to detect 
(n = 5) the sensitivity was 74% (95% C.I 54 to 89) and 59% (95% C.1. 45 to 77) 
respectively. Finally, as a number of cases of ventricular septal defect had been verified 
by means of auscultation only, the data were analysed excluding this group. This brought 
the sensitivity of fetal echocardiography and overall to 58% (95% C.1. 39 - 75) and 64% 
(95% C.1. 50 - 77) respectively. Specificity and predictive value negative were high 
(99%) with narrow confidence intervals « 1 %). Predictive value positive was also high 
(> 95%). 
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Figure 1 displays the relative risks of obtaining an ultrasound diagnosis and a definitive 
diagnosis of congenital heart disease given the various risk factors, both crude and 
adjusted for gestational and maternal age. Accordingly, figure 1 displays the attained yield 
of the various risk factors relative to one another. 
Figure 1 Relative risk of a diagnosis of congenital heart disease by indication 
14 -------------------------------------------------
12 
10 
----- +-----------
4 ------
21------- -------
oTT,±rl;, .4d, b 
I maternal CHD other relative CHD maternal epU. m1s«Uaneous 
previous child CHD paternal CHD maternal OM maternal morph. 
indication 
D ultrasound crude (21 ultrasound adjusted 8 defmitive crude &1 definitive adjusted 
Legend: CHD = congenital heart disease; DM = type 1 diabetes mellitus; epil. = anti epileptic drug use; 
morpho = morphomimetic/drug abuse; * = number of cases affected too low for estimation of relative risk 
Parental congenital heart disease and maternal diabetes mellitus are associated with the 
highest yield (relative risk) regarding prenatal diagnosis of fetal congenital heart disease. 
This in contrast to risk factors such as a previous child affected, other relatives affected 
and maternal epilepsy, which seem to (relatively) decrease this yield. Based on the 
postnatal diagnosis of congenital heart disease, the highest yield of congenital heart disease 
is restricted to paternal congenital heart disease and maternal type I diabetes mellitus. 
Maternal morphomimetics abuse and some miscellaneous factors also seem to be 
associated with a relatively low yield of congenital heart disease. 
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DISCUSSION 
The results of ultrasound examinations in our tertiary referral centre for prenatal diagnosis 
over a 10 year period display a high validity. Follow-up was virtually complete or 
validated (99%), resulting in an update of only two cases of minor anomalies. 
The overall prevalence of congenital malformations was 2.5 % and for cardiac anomalies 
1.5 % (2.8% and 1.7%, respectively if undetectable anomalies are included). Though this 
is approximately equal to the prevalence of congenital malformations found in the general 
population the proportion of cardiac anomalies is almost twice as high, confirming the 
increased overall risk of congenital heart disease (10). Nevertheless, some authors have 
reported a prevalence of congenital heart disease in excess of our estimate, detected in 
programs for fetal echocardiography (4,11). These results were, however, obtained from 
different patient popUlations including patients with fetal growth retardation, poly or 
oligohydramnios and anomalies already suspected during a previous routine ultrasound 
examination. We found comparable results in a similar referral group (3). 
The efficacy of tertiary centre known high risk scanning for cardiac anomalies by far 
exceeds that of routine screening in a low risk population (Buskens, submitted). In our 
hands, the overall results of extensive fetal ultrasound examination appear to be reasonable 
with an estimated overall sensitivity of 50%: 42% for congenital heart disease and 60% 
for non-cardiac anomalies. These estimates include cases of gross cardiac pathology, 
which are detectable by means of diagnostic ultrasound, but were not detected as a result 
of unfavourable fetal position or severe maternal obesity. Included are also cases of 
(small) cardiac defects which may be difficult or impossible to detect at the time of 
examination, despite optimal scanning conditions. When excluding these cases, the 
sensitivity improves from 42 to 50% for congenital heart disease and from 63 to 74 % for 
non-cardiac anomalies. In addition, as the diagnosis of 5 cases of cardiac anomalies may 
not been established accurately the sensitivity of fetal echocardiography may have been 
underestimated. Nonetheless, these results imply that even in a more or less optimal 
clinical setting, i.e., expert staff, state of the art ultrasound equipment and sufficient 
scanning time per patient, not all congenital anomalies will be diagnosed. Apparently, the 
sensitivity of a diagnostic test is influenced by several factors, some of which are beyond 
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our control. 
Moreover, the test characteristics are subject to the type, severity and prevalence of the 
anomalies observed. Major structural pathology may be readily recognized especially if 
the prevalence is high. Accordingly, potent teratogenic agents or risk factors which result 
in serious anomalies in a large proportion of exposed fetuses may display a higher 
sensitivity and yield when compared with mild teratogens or the general (non-exposed) 
population. Conversely, as case severity and the proportion of fetuses affected may be 
considered a derivative of the aetiology of congenital malformations, the test 
characteristics and yield are likely to be risk-factor specific. Therefore, the various risk 
factors for the occurrence of congenital malformations should be assessed independently 
when evaluating the yield of a high risk screening procedure. In addition, population 
characteristics such as maternal age and ethnic background can be considered potential 
risk factors and should therefore be included in the evaluation of a diagnostic test. In the 
present study information is restricted to maternal and gestational age. 
Our data were limited to women scanned on account of known risk factors. The findings 
presented in figure 1 are the result of a mutual comparison of the current risk factors or 
reasons for referral. Parental congenital heart disease and maternal diabetes mellitus may 
be considered relatively strong risk factors whereas other risk factors such as a previously 
affected infant, second degree relatives affected, use of anti-epileptic drugs and 
morphomimetic abuse and some miscellaneous risk factors appear to predict a diagnosis of 
cardiovascular anomalies less then average (relative risk < 1). These risk factors may 
subsequently be less relevant regarding the yield of cases affected. Adjustment for 
maternal and gestational age did not essentially alter the results. Similarly, the distinction 
between prenatal diagnosis and postnatally confirmed diagnosis of congenital heart disease 
did not reveal systematic variation of the results. 
Interestingly, within the group of parental congenital heart disease, paternal anomalies 
appeared a stronger risk factor than maternal anomalies (figure 1). Nora and Nora have 
found opposite results (12). However, in view of the wide confidence intervals definite 
inference is not possible. 
In order to establish a proper assessment of the reasons for referral a comparison with the 
(expected) yield of extensive fetal echocardiography in the general population should be 
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available. However, this is not a feasible approach. Alternatively, a theoretical approach 
of such a comparison between the various risk groups and the general population may be 
obtained by comparing the respective proportions of affected fetuses or infants. The best 
estimate of the prevalence of congenital heart disease in the general population is 0.8% 
(10), which is just over half (0.53) of the overall prevalence of congenital heart disease 
(1,5%) established in our high risk group. Assuming that the test characteristics of fetal 
echocardiography would not change, and a similar proportion of detectable and 
undetectable anomalies would occur, the solid line in figure 1 (relative risk = 1) may thus 
at most display a shift to the position of the current figure of 0.53, when comparing the 
high risk group to the general population. Some indication groups would subsequently 
show a yield slightly over the "adjusted" nil effect (modified relative risk = 1) level. 
However, in view of the wide confidence limits more data are needed to be able to infer 
whether the current reasons for referral would result in a significant yield. Furthermore, 
as the psychological impact of performing prenatal diagnosis in these high risk groups has 
not been assessed, defmitive conclusions can not be provided. 
In conclusion, screening for congenital heart disease in a high risk population by means of 
extensive fetal echocardiography shows a moderate effectiveness. Clear differences in 
yield appear to be present across currently accepted risk factors. 
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ROUTINE SCREENING FOR CONGENITAL HEART DISEASE; 
WHAT CAN BE EXPECTED? A DECISION ANALYTIC APPROACH 

INTRODUCTION 
Over the last decade many reports have appeared on the possibilities of ultrasound for 
prenatal detection of congenital heart disease. A limited number of authors, however, has 
tried to assess the actual yield of a (routine) screening program for cardiac anomalies by 
means of fetal echocardiography (1-15). A distinction can be made between two screening 
policies. Either can fetal echocardiography be offered routinely to all expectant women or 
it can be offered to those considered to be at (high) risk for fetal congenital heart disease. 
In the first approach, all pregnant women should undergo a routine ultrasound 
examination, including a fast and simple evaluation of the fetal heart, at a certain optimal 
gestational age. Subsequently, upon suspicion of a congenital anomaly referral to further 
establish a diagnosis and appropriate obstetric policy should follow. The screening 
procedure of choice currently suggested for evaluation of the fetal heart is the four 
chamber view, incorporated in routine fetal ultrasound, between 16 and 24 weeks 
pregnancy (3,6). 
In the high risk approach, extended structural ultrasound examination is offered to a 
selection of women that have a history of increased risk of congenital heart disease in 
their offspring. The type of anomalies encountered in this sub-sample are likely to be 
more severe, more complex and occur more frequently. The ultrasound examination in 
these patients is referred to as extensive structural (or tertiary) fetal echocardiography. In 
addition to the four chamber view, the cardiac connections and cardiac functional status 
are evaluated (16). Obviously, this can only be accomplished by highly skilled experts 
during a lengthy and detailed examination in a referral centre. 
I! would appear that, in order to be able to recommend prenatal screening in low risk 
pregnancies, followed by tertiary ultrasound examination in case of suspected fetal 
pathology, an assessment of the yield and benefit that may be expected is needed. 
However, based on an assumed favourable effect routine fetal ultrasound, comprising a 
four chamber view evaluation, is now offered to the majority of pregnant women in 
several countries including the Netherlands. To our knowledge, this has not been preceded 
by an appropriate evaluation. Accordingly, we suggest that before formal introduction of 
routine fetal ultrasound screening the actual risk of bearing an affected fetus, the efficacy 
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of the proposed screening test, including additional tests required, the natural history of 
the anomaly(ies) concerned and, finally, the valuation or impact of the anomaly(ies), 
related to psychological, social and economic aspects, should be assessed. Medical 
decision analysis offers a possibility to integrate the issues involved and, in addition, 
evaluate the influence of variability of these factors. 
We set out to answer the question whether the benefits of routine fetal ultrasound for the 
detection of cardiac anomalies are sufficiently clear to merit routine examination of all 
expectant women. Finally, an estimate of the impact of routine screening of low risk 
pregnancies is provided. 
METHODS 
Structure of the model 
The present report proceeds from an inventory of currently available literature data. 
Subsequently, these data have been assimilated in a decision analysis model centred on the 
problem to either offer routine fetal echocardiography to all expectant women or omit this 
screening test. Decision Maker software (New England Medical Centre: 1988) was 
applied to structure the model and convey the options and chances future parents and 
clinicians, or policy makers, face at 16 to 24 weeks gestational age (figure 1). The high 
risk approach as a separate option has not been entered into the model as its benefits are 
less debatable (6,8,17-20). In addition, the occurrence of spontaneous abortion or intra-
uterine death prior to any prenatal diagnostic procedure was assumed not to influence the 
choice between the two strategies. The probability of an affected fetus (with either minor 
or major congenital heart disease) was entered into the model at the first chance node. The 
subsequent chance node in the model represents the test of interest; routine fetal 
echocardiography. Given a malformation in the fetus, the chance of a positive test result is 
the true pos;:ive rate or sensitivity. Conversely, a negative test given an anomaly is the 
false negative rate (or I-sen,itivity). Similarly, the chance node given the absence of 
malformations applies to the true negative rate or specificity and in case of a false positive 
test result the false positive rate (or I-specificity). 
The subsequent branch of the model represents referral upon suspicion of a malformation 
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or pregnancy pathology during screening. Thus, extended fetal echocardiography is 
offered to those screened and suspected of a fetal anomaly, to those screened and not 
suspected despite being affected and in addition presenting (pregnancy) pathology, and to 
those not screened yet presenting (pregnancy) pathology. In this respect specific signs of 
possible fetal anomalies, e.g., growth discrepancy, lack of fetal movements or an 
abnormal fetal heart rate, are taken as pregnancy pathology. 
With respect to initial false positive screening results we assumed that subsequent 
extensive fetal echocardiography would always reveal previous diagnostic errors (100% 
specificity), thus excluding false positive diagnosis. This appears to be a reasonable 
simplification of the model since further diagnostic steps or policy adaptation are presently 
not offered unless justified by suspicion of a significant anomaly. Non-adoption of 
screening implies that extended ultrasound is available only in the event of clinically 
suspected fetal or pregnancy pathology. 
Similar to the probabilities at the level of screening, the test characteristics of extended 
fetal echocardiography pertain to the probabilities of the corresponding chance nodes in 
the model. 
Furthermore, in case an anomaly is confirmed during extensive structural fetal ultrasound 
examination, fetal karyotyping is offered; e.g., chorion villus sampling, amniocentesis or 
cordocentesis. These techniques have a (low) risk of inducing abortion which is 
represented by the corresponding chance node in the model. The next step is the decision 
parents face after having obtained all relevant information concerning the diagnosis and 
prognosis of their (affected) fetus. They may either choose to terminate pregnancy or 
carry to term. Obviously, an unaffected or slightly affected fetus is likely to be carried to 
term. In case the gestation of a fetus with a congenital heart disease is continued two 
outcomes are possible. Either, intra uterine death may occur, or an infant with a cardiac 
anomaly is born, which may as a result of the anomaly die. This risk of a fatal outcome 
again represented by a chance node. The situation is essentially similar if parents, 
informed about the presence of a (severe) fetal anomaly, decide not to terminate 
pregnancy, or in case an anomaly is not detected, or if screening does not take place. 
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Figure 1 Diagrams of the decision model 
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* This chance node could also be represented by a dicision node as it is an (parental) option to 
terminate pregnancy after detection of a severe anomaly. 
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Assignment of probabilities 
All variables implemented in the model are summarised in table I. A number of problems 
in the assigmuent of probabilities need to be discussed. An estimate of the chance of 
bearing a fetus with congenital heart disease is preferably provided by the prevalence of 
cardiac anomalies at 16 to 24 weeks gestation. However, whereas a large number of 
reports is available on the prevalence of congenital heart disease at birth, a reliable 
estimate of the prevalence at about 20 weeks gestational age is difficult to obtain. We 
assumed that newborns with a birth prevalence of cardiac anomalies of approximately 
0.008 (21) originated from a larger cohort of fetuses of which a proportion has aborted 
spontaneously or ended in premature death. Thus, the fraction affected required to reach 8 
per thousand neonates with congenital heart disease was calculated backward, given a non-
screening situation. In addition, the notion that only about half the cardiac anomalies 
found in neonates are major or echocardiographically detectable is taken into account (22). 
The probabilities reflecting the test characteristics of routine and extended ultrasound 
evaluations are based on a literature survey. Reports that apply exactly to the situation 
described above are scarce. To account for problems of interpretation arising from 
differences in study design we adopted a case-severity based approach. The sensitivity of 
the fetal four chamber view for detecting severe cases of congenital cardiac anomalies is 
estimated to be 50%. This is in accordance with the upper range of the figures reported in 
the literature (1-15). The lower range of the sensitivity reported, below 10%, is taken to 
apply to minor anomalies. The specificity of the screening test is reported to be very high 
(99%) and has a narrow range, hence, does not need further comment. The test 
characteristics of extended ultrasound evaluation appear to be superior and have been 
reported with a much more narrow range (6,8,17-20). More detailed data on extended 
fetal echocardiography provided the possibility to calculate the test characteristics with the 
specific indication of suspected fetal (cardiac) pathology (8,19,20). A high sensitivity 
(95%) and specificity (99%) is generally reported. The chance of induced abortion after 
fetal karyotyping is low (less then 1 %) (23). Reports on the chance of pregnancy 
pathology in relation to congenital heart disease were not found. Hence, we submitted this 
issue to a panel of obstetricians at the University Hospital Rotterdam and obtained an 
estimated probability of less than 1 %. 
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In case a malfonnation is detected, parents informed about the nature of the anomaly face 
a decision. Specific literature on this subject is scarce. Pryde et al. evaluated several 
factors influencing Ule parental decisions regarding pregnancy outcomes of congenitally 
malformed offspring (24). The prognosis given appeared to be of major influence; two out 
of three parental couples opted to tenninate pregnancy if the outlook was grim. 
Tennination was never decided in case of minor anomalies. Subsequently, we compared 
the results by Pryde et al. to the proportion of pregnancies that were reported to have 
been tenninated on account of the prognosis given after extended fetal echocardiography 
(8,19,20,24). An identical proportion emerged and, hence, is taken to represent the 
chance of tennination of pregnancy in case of a severe fetal anomaly. Apparently, the 
cases detected during routine fetal ultrasound examination and subsequently referred are a 
selection of the total number of fetal anomalies present at 20 weeks gestational age, that 
is, a sample of severe cases. The probabilities of intra uterine death of an affected fetus 
(37%) and infant death after live birth (59%) were again obtained from the reports on 
fetal echocardiography (19,20). 
As we consider the probabilities derived above to apply to cases of major anomalies, we 
submit data on live-born children (mortality less then 10%) as a substitute for the effect on 
survival of minor cardiac malfonnations; the majority of minor cases have no 
hemodynamic consequences prenatally and, accordingly, survive to tenn. 
Finally, a sensitivity analysis was conducted over plausible ranges of the estimated 
probabilities (as presented in the right-hand side of table 1), to obtain an impression of the 
impact of variation in the estimates on the outcome of the model. 
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Table 1 Probabilities entered in the decision model. 
In the sensitivity analysis a distinction is made between major and minor anomalies. The plausible range is given in parenthesis, if possible based on 95% confidence 
intervals. 
point lower value upper value major minor 
estimate 
prevalencP-- 0.008 0.003 0.012 0.004 0.004 
prenatal prevalence * 0.013 0.0063 (0.01 - 0.005) 0.004 
level 1 sensitivity1.15 0.D7 0.07 0.50 0.50 (0.20 - 0.80) 0.D7 (0.01 - 0.20) 
levell specificity1.1!1 0.99 0.99 1.0 
level Z sensitivity"'··17.19 0.95 0.927 0.974 
level 2 specificitf.!·17.1. 0.99 0.987 0.993 1.00 1.00 
p(abnorma! pregnancy! CHD),.c.JWW 0.01 om (0 - 0.03) 0.01 (0 - 0.03) 
p(karyotyping abortion)l' 0.01 
p(induced abortion! CHD)"·19.20 0.678 0.571 0.773 0.68 (0 - 1.0) 0.0 
p(intra uterine death I CHD)19.20 0.370 0.194 0.576 0.37 (0.20 - 0.60) 0.0 
p(neonatal deathl CHD)!9.20 0.588 0.329 0.816 0.59 0.1 
major - minor = category of congenital malformation 
p( ) = chance of event between brackets 
eHD = congenital heart disease 
* = expected prevalence at 20 weeks gestation calculated backward; varies according to p(intra uterine death I eHD). 
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RESULTS 
A fIrst estimate of the impact of routine fetal ultrasound screening in low risk pregnancies 
is obtained by comparing the numbers of corresponding outcomes of the two strategies. 
Table 2 reflects the results from a model based on the estimates in table 1. The estimates 
pertain to one million 2"" trimester pregnancies. In the Netherlands, which has an annual 
birth rate of approximately 190.000, these events would accordingly take about fIve years 
to occur. 
Table 2 Estimated pregnancy outcomes of a million 2M trimester pregnancies (fetuses of 16 to 24 weeks 
gestational age). No screening versus screening and subtraction. 
Outcome no scr ser .t:.. scr 
CHD major 1629 1104 -525 
CHD minor 3600 3597 -3 
neonatal death 2745 1988 -757 
induced abortion 41 2046 2005 
karyotyping abortion 33 32 
intra uterine death 2334 1582 -753 
no CHD (false positive) 0 9897 9897 
noCHD 989651 979754 -9897 
no scr = no screening 
t.. scr = subtraction: scr - no scr 
CHD = congenital heart disease 
With a relatively low sensitivity for major anomalies of 50% it is estimated that the 
number of children born with severe congenital heart disease decreases by a third in case 
routine screening is offered to all pregnant women. The number of intra uterine deaths 
shows a similar trend. The impact of routine screening on minor congenital heart disease 
is numerically negligible. However, the number of terminations of pregnancy would 
increase 50-fold and a substantial number of ahnost 9,900 false positive screening tests 
would result. A further point of interest may be the fact that screening would also imply a 
loss of 32 fetuses, 28 cases of major anomalies and 4 cases with only minor anomalies, 
because of the risk of invasive procedures for karyotyping. (As we consider the specifIcity 
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of extended fetal echocardiogrphy to be 100%, no unaffected fatalities will occur.) 
Table 3 provides the results of sensitivity analysis, demonstrating the effects for different 
estimates of the sensitivity of routine fetal ultrasound, the proportion of parents opting for 
termination of pregnancy in case of a severely affected fetus, the likelihood of pregnancy 
pathology and the likelihood of intra-uterine death due to congenital heart disease. An 
increase in sensitivity (to 80% and 20% for major and minor anomalies respectively) 
reduces the number of cases with an unfavourable outcome of pregnancy. However, 
increased numbers of tennination of pregnancy are a consequence. In addition, as 
increased numbers of anomalies are detected with high sensitivity subsequent fetal 
karyotyping is performed more often causing an additional loss of 23 (affected) fetuses. 
Parental inclination toward termination of pregnancy in case of severe malformations 
appears to have a very much similar effect as increased sensitivity of routine ultrasound 
on the outcome of pregnancy. In case all pregnancies are continued very little effect 
remains. 
Also, an abnormal development of pregnancy does not seem to have a significant impact. 
The likelihood of intra-uterine death resulting from congenital anomalies does not affect 
the number of affected infants born. However, with increasing probability of premature 
death, a larger number of pregnancies is tenninated that would otherwise have resulted in 
spontaneous abortion or intra-uterine death. 
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Table 3 Estimated pregnancy outcome per million 211C1 trimester pregnancies (fetuses of 16 to 24 weeks gestational age); results of the sensitivity analysis. Subtraction of 
the results of screening - no screening. 
Outcome sensitivity routine ultrasound 
high (80%: 20$)* 
CHD major 
eHD minor 
neonatal death 
induced abortion 
kat'yotypinz abortion 
intra uterine death 
false positive 
""CHD 
A scr = subtraction: scr - no scr 
eHD = congenital heart disease 
A scr 
-841 
-7 
-1211 
3208 
55 
-1205 
9897 
-9897 
low (20%: 1%)* 
A ,cr 
-210 
0 
-303 
802 
12 
-301 
9897 
-9897 
p(induced abortion) 
high (100%) low (0%) 
Ascr A'cr 
-772 -8 
-3 -3 
-1111 -11 
2957 0 
32 32 
-1105 -11 
9897 9897 
-9897 -9897 
* = sensitivity of routine fetal echocardiography for major and minor anomalies respectively 
p(abnormal pregnancy) p(intra uterine death) 
high (3%) low (0%) high ,,,,.>11 low (20%)# 
A ,cr A ,cr A scr A ,cr 
-516 -531 -525 -525 
-3 -3 -3 -3 
-742 -764 -757 -757 
1967 2024 3158 1579 
32 33 50 26 
-738 -760 -1923 -321 
9897 9897 9897 9897 
-9897 -9897 -9897 -9897 
# = with regard to cases of major CHD, a high chance (60%) of intra uterine death implies a high (1 %) prenatal prevalence of CHD. whereas, a low chance of intra 
uterine death (20%) implies a low prenatal prevalence (0.5%) 
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DISCUSSION 
In the model it was presumed that approximately half of the severe anomalies would be 
detected. The future parents and fetus may benefit from these results. Obstetric policy 
may be adapted, timing, mode and location of delivery can be optimised, or, in case of 
severe or fatal anomalies, tenoination of pregnancy can be offered (19,20,25-27). The fact 
that fewer children are born with severe congenital heart disease may be considered a 
benefit of routine fetal ultrasound. However, a routine fetal ultrasound programme 
according to current specifications has disadvantages as well. Several remarks can be 
made with regard to the "side-effects" of screening and are illustrated using data from an 
imaginary cohort of one million pregnancies. Apparently, preventing the birth of 1,285 
cases of congenital heart disease, 525 major cases, 3 minor cases and 757 cases of infant 
death, means that over 2,000 induced abortions are needed, 753 of which would have 
ended in spontaneous abortion in absence of intervention, and 32 losses of pregnancy due 
to complications of karyotyping. The model also indicates that almost 9,900 false positive 
screening-tests would result. The women involved may subsequently have to face the 
anxiety caused by the alarming result of routine fetal ultrasound and require subsequent 
referral for extended fetal echocardiography to be reassured that no anomaly is present. 
As some of the literature estimates of the probabilities applied in the model may be liable 
to dispute, the impact of variability of the respective probabilities is important to assess. 
We did not vary the prevalence of congenital heart disease in the model. Clearly, with 
increasing prevalence the numbers of cases detected will increase proportionally and vice 
versa. However, given a constant specificity, the number of false positive cases would 
remain the same. A higher sensitivity of routine fetal ultrasound, as for instance may be 
achieved in a specialised centre, would increase the yield in numbers of births of infants 
with congenital heart disease prevented, and also increase the number of tenoinations of 
pregnancy required. In case the sensitivity does not reach the levels reported in the 
literature the yield would decrease proportionally. 
The effect of parental preference regarding tenoination of pregnancy in case of severe 
anomalies detected in their fetus has been approached by varying the proportion of 
tenoinations. If parents invariably were to accept induced abortion the yield appears to 
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equal that of a high sensitivity of routine fetal ultrasound. However, with decreasing 
proportions of termination of pregnancy, despite severe anomalies, the yield would also 
decrease. Hence, especially, in a community or society that has constraints concerning 
interference with intra-uterine life possible advantages would be limited to adapted 
obstetric policies. 
A change in the likelihood of an abnormal course of pregnancy does not importantly affect 
the impact of screening. As an abnormal pregnancy is an indication for referral in any 
event, an anomaly would likely have been detected during subsequent extensive ultrasound 
examination. 
The impact of the natural history of fetal congenital heart disease requires additional 
discussion. We accepted that the birth prevalence of congenital heart disease remains 
unchanged irrespective of the natural history prenatally. However, with an increased 
probability of intra-uterine death a larger number of affected fetuses would have to be 
present to result in the same number of affected neonates. Note that the number of 
terminations of pregnancy increases by 1,153, i.e., 3,158 induced abortions in case of a 
high proportion of intra uterine death (60%) versus 2,005 in case of the original literature 
estimate (37%), (almost) equal to the decrease in spontaneous intra-uterine deaths, i.e., 
-1,923 versus -753 (tables 2 and 3). Thus, severe anomalies causing fetal loss in a large 
proportion can be viewed a natural screening process. The yield of screening, expressed 
as births of affected neonates prevented remains stable. Consequently, the relative yield of 
screening decreases because the fetuses with severe anomalies would not have been live 
born anyhow. With a less severely affected fetus, e.g., not resulting in fetal loss, yet, 
facing a severe prognosis postnatally, future parents may be inclined to have pregnancy 
terminated. Accordingly, for such cases screening does have additional (and increased 
relative) yield. 
Finally, an additional remark may be made regarding the specificity of extensive structural 
fetal ultrasound examination. The specificity applied in the model was presumed to be 
100%. Therefore, in the model no far-reaching consequences were attached to false 
positive screening tests. However, it may be that this is not correct. Recently, cases of 
apparently severe fetal congenital heart disease have been described that were not 
terminated. Postnatally !hey proved to have only mild to moderate anomalies (28). 
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According to the hest available estimates of the test characteristics of prenatal screening 
for congenital heart disease by means of the fetal four chamber view, the yield, expressed 
as the prevention of the birth of a critically ill neonate, appears to be numerically modest. 
In addition, a sizable number of pregnant women require referral for additional diagnostic 
testing on account of a false positive screening test. In case the sensitivity of prenatal 
screening would in practice be substantially lower, Le., within the lower range currently 
reported, or the majority of parents faced with a severely affected fetus would opt for 
continued pregnancy, the yield would decrease to marginal. 
When factors that may (significantly) influence on the yield of a routine fetal ultrasound 
screening program are considered, only a few appear accessible for improvement. The test 
characteristics of extensive structural ultrasound can already be considered more or less 
optimal. Also, fetal karyotyping is not likely to achieve still lower rates of complications. 
At present, little is known about the natural history of congenital malformations in utero, 
Le., the chance of pregnancy pathology and intra-uterine death. Moreover, even less 
information is available on factors affecting natural history in utero. Next, the final 
decision parents take once a serious fetal anomaly is detected is culturally, socially and 
economically determined. Evidently, a strategy for termination of pregnancy generally 
applicable is inconceivable. Remaining factors are the prevalence of congenital anomalies 
and the sensitivity of routine fetal echocardiography. The actual prevalence of congenital 
malformations is a given hardly accessible to intervention, and, moreover, if accessible 
would imply possibilities for primary prevention. However, it may be possible to select 
patients on account of increased risk, thus creating a subgroup with increased prevalence. 
Pivotal in such a policy of increased risk screening is the quality of the diagnostic test, 
that is, fetal echocardiography. Currently attained results in screening programs for 
routine antenatal detection 'of congenital heart disease seem insufficient to merit such a 
strategy (14). Furthermore, this would also imply that in low risk pregnancies formal 
screening is abolished. 
Alternatively, the currently proposed screening test, the fetal four chamber view 
examination, could be optimised. An adequate screening test can, however, only be 
obtained if sufficient numbers of experienced staff with extensive scanning expertise and 
150 
Routine screening assessed by means of decision allalysis 
high quality ultrasound equipment would be available, requiring a large investment. In 
spite of the results of the present (decision) analysis, that has shown that the yield in 
births of affected infants prevented would be limited numerically and, in addition, only 
apply to a sub-sample of the severe cases detectable. Furthermore, it is important to 
realise the consequences of such a strategy of limited (only severe cases) anomaly 
screening; it implies that the appreciation of a prenatal screening program comes to 
depend on the significance and valuation of the detectable sub-sample of cardiovascular 
anomalies. Also, following a negative screening test, future parents should be told that 
only a minority of severe cardiac anomalies could be excluded. 
The significance and valuation of the cases detected, the cases not detected, the false 
positive test results and their subsequent outcomes have not been assessed in the present 
analysis. This can be attempted by estimating the psychological relief or burden that can 
be attained or by means of estimating the financial consequences. Pauker et a!. and 
Heckerling et a!. have described such a method (23,29,30). They have, after parental 
assessment, assigned specific values or utilities to the various outcomes of pregnancy in a 
prenatal Down syndrome screening programme, and subsequently tried to establish the 
utility of screening. Ekwo et a!. have, similarly, reported on the outcome of pregnancy 
with regard to congenital anomalies and their perceived consequences or burden (31). 
Again it appeared that parents have a specific opinion on the outcomes of pregnancy 
which can be expressed on a preference scale. However, at present, reliable data on 
parental attitudes towards congenital heart disease are lacking. Yet, as parental assessment 
of the various outcomes may, ultimately, have a considerable impact on the appreciation 
and efficacy of a prenatal screening program for congenital anomalies, further research 
seems necessary. 
In conclusion, the results of our analysis suggest only a limited overall advantage of 
routine prenatal ultrasound screening for congenital heart disease. However, data on the 
efficacy of routine screening are scarce and hardly allow definite inference. Moreover, an 
assessment of utilities of various outcomes and parental attitudes and valuation does 
clearly call for additional research. 
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GENERAL DISCUSSION 
Congenital malformations, in particular cardiovascular anomalies, have a prominent 
position throughout the current dissertation. Through lack of substantial evolution in 
knowledge on (preventable) causes and still limited possibilities for curative treatment of 
severe cardiovascular anomalies, prenatal detection has attracted a great deal of attention. 
Promising early results prompted initiatives to adopt routine fetal ultrasound screening 
programmes. However, as the utility of such a screening test has not been established 
confidently an effort to clarify the efficacy was initiated. The assessment of the efficacy of 
routine prenatal screening for congenital heart disease is the main theme of this thesis. 
Additional information on various aspects of congenital heart disease, e.g., causes, 
frequency of occurrence, treatment (options) and possibilities for early detection, is 
provided to comprehend screening adequately. In this chapter the main conclusions and 
implications for screening and future research will be given. 
The prospective study on routine ultrasound examination for congenital heart disease in a 
inherently low risk population has shown that screening does not lead to a sufficient level 
of detection. Several explanations for these results may be considered. 
Firstly, the prevalence of congenital (cardiovascular) anomalies is low in a routinely 
screened popUlation. Furthermore, the scanning-time allocated to each examination is 
limited and the technicians or sonographers may not have sufficient experience and 
expertise in a routine setting. Finally, it is important to realise the technical restrictions of 
the procedure with regard to visualisation of certain anomalies. Conversely, ultrasound 
examination of a high risk population performed in referral centres by specialised 
personnel has shown to be far more effectice. 
In view of the above, there appears to be little basis to propose large scale routine 
ultrasound screening in low risk popUlations. Yet, screening in high risk populations may 
be recommended and could be expanded to include certain additional risk groups. In 
addition, it is as yet unclear to what extent all pregnancies belonging to currently 
recognized high risk groups are identified to take maximal advantage of screening. 
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Defining and identifying high risk pregnancies that justify extensive ultrasound 
examanition will require additional research. In particular, the expansion of the indications 
for high risk screening while maintaining adequate screening performance may necessitate 
further study. 
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As congenital heart disease occurs relatively often, and improvement of prognosis has not 
kept pace with that achieved in infectious diseases, it has become rather an important 
infant health problem (chapter 1). 
Currently, the occurrence of only a minority (10 to 20%) of the cases of congenital heart 
disease can be accounted for by specific factors (chapter 2). Likely, this proportion will 
increase in the next decades as a result of research in epidemiology, embryology, genetics 
and molecular biology. Knowledge of factors that induce malformations could make these 
determinants accessible to treatment or primary prevention. Meanwhile, secondary 
prevention, that aims to avert pre and postnatal morbidity once a fetal anomaly has 
occurred remains the main treatment option. 
Several attempts have been made to estimate the magnitude of the problem of congenital 
heart disease with varying results (chapter 3). Apparently, the methodology applied to 
establish the proportion of fetuses or infants affected is not unequivocal. A number of 
characteristics of study design may influence the estimated (birth) prevalence of congenital 
heart disease. Duration of follow-up and case ascertainment, including diagnostic work-up 
and case definition appear to be important determinants of the estimated prevalence 
reported, in particular for minor anomalies. A satisfactory overall estimate of the birth 
prevalence of congenital heart disease appears to be difficult to attain. An estimate of the 
proportion of affected fetuses, at a certain gestational age, is even more difficult to obtain. 
Reliable information on these cases (preferably autopsy) would allow estimating the 
impact of congenital anomalies on fetal survival. Moreover, incidence figures, that is the 
proportion of embryos or fetuses that actually develop an anomaly, are not available at 
present and may be obtained. As this kind of information is essential in etiologic research, 
further study is warranted. 
Besides numerical information, on the occurrence of congenital heart disease, data on the 
impact of anomalies on longevity and morbidity are also important in estimating the 
consequences and magnitude of the problem. Therefore, a brief overview of current 
knowledge and experience of paediatric cardiology for the majority of cardiovascular 
anomalies found in neonates is provided (chapter 4). Furthermore, the impact of these 
anomalies on fetal survival is assessed. It seems likely that the infants that are (live) born 
with a cardiovascular anomaly are a selection of cases that exist earlier in pregnancy. 
Those cases that end in (early) intra-uterine death are not, or only infrequently accounted 
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for at present. As mentioned above, valuable information is lost with the dead fetus if a 
diagnosis is not provided. 
In addition to describing the consequences of cardiovascular anomalies for the fetus and 
neonate, the possibility and significance of prenatal detection by means of ultrasound have 
been addressed. It appeared that a large proportion of the cases that present after birth 
may not be detectable by means of the currently available technique. Also, the prognosis 
of affected fetuses appears to be difficult to improve. 
Nevertheless, routine fetal ultrasound screening for congenital heart disease has been 
strongly advocated on account of initial reports. A careful assessment of the original 
studies did reveal some explanations for the contradictory results compared to more recent 
research (chapter 5). For instance a number of the early studies have relied on 
retrospective data for follow-up of screen negative cases, thus introducing possible bias as 
some diagnoses may remain obscure. Furthermore, the skills and interest of the 
sonographers involved may have been superior as compared to that observed in regular 
ultrasound clinics. Accordingly, prior to general adoption of a routine prenatal screening 
program a thorough evaluation in a realistic clinical setting should be available. 
The core of this thesis is an account of the design, conduct and findings of a prospective 
cohort study in 6,922 fetuses scanned routinely (chapter 6 & 7). After successful follow-
up on the majority (>81%) of fetuses only 4.5% of the cardiovascular anomalies 
appeared to have been detected prenatally. Non-cardiac anomalies, checked for during the 
same ultrasound session, were detected in 30% of the cases. These results provide little 
support for the introduction of routine fetal ultrasound screening as a mandatory part of 
obstetric care. 
Tertiary referral centres, in contrast, have reported far better results. Especially, the 
proportion of cases detected prenatally is high (60 to 85%). Yet, it is hnportant to realise 
that the sonographers in these centres are far more experienced and that scanning time 
allocated to each examination is not lhnited to a maxhnum of 10 to 15 minutes. In 
addition, the patients involved are a selection, considered at increased risk of having 
affected offspring. The accumulated experience of a tertiary referral centre in Rotterdam, 
the Netherlands gives evidence of similar results with 40 to 60% of the cases detected 
prenatally in women at a known increased risk for congenital heart disease in their 
offspring (chapter 8). However, the actual yield, that is the proportion of affected fetuses 
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fetuses in the cohort screened, appeared to vary considerably within this high risk group. 
Therefore, the risk factors for fetal cardiovascular malfonnations, currently applied as an 
indication for tertiary ultrasound examination may need reappraisal. Selection of cases 
referred may further improve the yield of a high risk screening program. 
Finally, the attainable yield of routine fetal echocardiography has been assessed in 
decision analysis model, reflecting the choices and chances that (future) parents, the fetus 
and obstetrician face (chapter 9). It could be demonstrated that even with more or less 
optimal results of population screening still a limited impact can be anticipated. The more 
so, as such optimal results can only be achieved if all pregnant women are screened 
routinely at about 20 weeks gestation, the prognosis would improve upon detection of a 
severe anomaly and, well trained well equipped sonographers would be available at 
sufficient time and locations. 
In conclusion, routine fetal ultrasound screening for detection of congenital anomalies 
appears to achieve an insufficient level of detection in the setting of the present study to 
merit general introduction. Improved training of the sonographers is required to realise a 
better detection rate. Moreover, it may be difficult to achieve a sufficient yield in a low 
risk population. On the other hand, ultrasound examination perfonned in referral centres 
for prenatal diagnosis on account of a known increased risk of fetal anomalies appears to 
be far more efficient. Merely, identifying the reasons for referral that justify extensive 
ultrasound examination may need additional research. 
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Aangeboren hartafwijkingen komen relatief vaak voor. Voorts is de ontwikkeling, en 
derhalve de verbetering van de prognose, minder snel gegaan dan bij infectieziekten, zodat 
aangeboren hartafwijkingen bij zuigelingen een niet te verwaarlozen gezondheidsprobleem 
vormen (hoofdstuk 1). 
Op dit moment kan slechts bij een minderheid (10 tot 20%) een mogelijke oorzaak worden 
aangewezen voor het optreden van een aangeboren hartafwijking (hoofdstuk 2). Binnen 
enkele tientallen jaren zal, naarmate het samenwerkingsverband tussen epidemiologie, 
embryologie, genetica en moleculaire biologie vruchten gaat afwerpen, dit verklaarbare 
deel toenemen. Bekend zijn met risico- of oorzakelijke factoren zou deze determinanten 
wellicht toegankelijk maken voor behandeling of prima ire preventie. Ondertussen blijft 
secundaire preventie gericht op het voorkomen van verdere gezondheidsproblematiek, 
nadat eemoaal een afwijking is opgetreden, het beste aIternatief. 
Meerdere pogingen om de omvang van het probleem van aangeboren hartafwijkingen te 
beschrijven hebben geresulteerd in uiteenlopende schattingen (hoofdstuk 3). Klaarblijkelijk 
verschilden de gebruikte methoden om de proportie aangedane foetussen of zuigelingen 
(prevalentie) te schatten. Een aantal kemoerken van studie-opzet bleken in dit verband 
bepalend. Met name voor geringe afwijkingen waren duur van vervolging binnen het 
onderzoek en de vaststelling van afwijkingen, waaronder diagnostische techniek en de 
gebruikte definities, van belang. Het blijkt moeilijk te zijn om een bevredigende schatting 
van de prevalentie van aangeboren hartafwijkingen bij levendgeborenen te verkrijgen. 
Voor een schatting van het deel van de foetussen (bij bepaalde zwangerschapsduur) dat is 
aangedaan geldt dit in nog grotere mate. Indien betrouwbare informatie (liefst autopsie 
verslagen) aanwezig zou zijn behoorde het wellicht tot de mogelijkbeden om een 
inschatting te verkrijgen van de invloed van aangeboren afwijkingen op de foetale 
overJeving. Bovendien zou een schatting van de incidentie, de proportie foetussen waarbij 
zich een afwijking voordoet, verkregen kunnen worden. Dergelijke gegevens zijn, 
alhoewel momenteel niet beschikbaar, essentieel voor het wetenschappelijk onderzoek naar 
oorzakelijke factoren, zodat aanvullend onderzoek vereist is. 
Voorts is het, om de consequenties en omvang van het probleem van aangeboren 
hartafwijkingen te kunnen inschatten, van belang om over informatie omtrent overJeving 
en veroorzaakte UziekteU te beschikken. Derhalve werd een beknopt overzicht van de stand 
van zaken binnen de kindercardiologie opgenomen (hoofdstuk 4). Tevens werd een 
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oordeel gegeven over het belang van hartafwijk:ingen voor de foetale overleving. Het ligt 
voor de hand dat levendgeborenen met een aangeboren hartafwijking !runnen worden 
beschouwd als een selectie van de aangedane embryo's of foetussen die reeds in een 
vroeger stadium van de zwangerschap aanwezig waren. GevaHen van (vroege) intra-
uteriene sterfte worden slechts zelden in ogenschouw genomen. Zoals reeds opgemerkt 
gaat met het abortus materiaal waardevoHe informatie verloren indien geen diagnose wordt 
gesteld. 
Naast een beschrijving van de mogelijke gevolgen van aangeboren hartafwijkingen voor de 
foetus en pasgeborene werd ook de mogelijkheid tot, en het belang van, prenatale detectie 
door middel van ultrageluidsonderzoek toegelicht. Het bleek dat een groot deel van de 
afwijkingen dat zieh na de geboorte openbaart met de huidige techniek prenataal 
waarschijnlijk niet is vast te steHen. Voorts bleek dat het moeilijk zou zijn om de 
prognose van aangedane foetussen te verbeteren. 
Desalniettemin is routinematig prenataal ultrageluidsonderzoek ter opsporing van 
aangeboren hartafwijkingen op grote schaal aanbevolen op grond van initiole publikaties. 
Een grondige evaluatie van deze vroege studies gaf enige verklaringen voor de 
tegenstrijdige resultaten in vergelijk:ing met meer recent werk (hoofdstuk 5). 20 bleek dat 
bij een aantal vroege studies, voor foetussen met een negatieve test-uitslag, gebruik was 
gemaakt van reeds eerder verzamelde gegevens omtrent de uitkomst. Hiermee werd een 
potentiole vertekening van de resultaten ge[ntroduceerd omdat men niet kan uitsluiten dat 
een aantal pasgeborenen met een afwijking buiten beschouwing zijn gebleven. Bovendien 
betrof het experts op het gebied van ultrageluidsonderzoek zodat de verkregen resultaten 
minder representatief zijn voor reguliere klinieken voor ultrageluidsonderzoek. Een 
grondige evaluatie van routinematig uitgevoerd ultrageluidsonderzoek, in een realistische 
klinische omgeving, lijkt op zijn plaats alvorens over te gaan tot algemene toepassing. 
Het hoofd-onderwerp van dit proefschrift betreft een verslag van het ontwerp, de 
uitvoering en de resultaten van een prospectief vervolg-onderzoek bij een groep van 6.922 
foetussen, aHen routinematig onderzocht met behulp van ultrageluidsonderzoek (hoofdstuk 
6 & 7). Nadat van de meerderheid van de foetussen (> 81 %) uitkomst gegevens waren 
verkregen bleek dat slecht 4,5% van de hartafwijk:ingen voor de geboorte was ontdekt. 
Overige aangeboren (niet hart-) afwijkingen werden in 30% van de gevaHen voor de 
geboorte ontdekt. Dergelijke resultaten lijken geen aanleiding te geven om routinematig 
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uitgevoerd ultrageluidsonderzoek als een vereist onderdeel van de verloskundige zorg in te 
voeren. 
Vanuit gespecialiseerde verwijs centra, echter, zijn veel betere resultaten gerapporteerd. 
Met name de proportie aangeboren afwijkingen die reeds voor de geboorte ontdekt wordt 
is hoog (60 tot 85%). Hierbij is het van belang dat men zich realiseert dat het om zeer 
ervaren personeel gaat en dat de duur van het ultrageluidsonderzoek niet gelimiteerd is tot 
maximaal 10 tot 15 minuten. Bovendien betreft het een selecte groep patienten waarvan 
verondersteld wordt dat zij een verhoogd risico hebben voor het optreden van aangeboren 
hartafwijkingen. Bij vrouwen met tevoren bekend verhoogd risico voor het optreden van 
hartafwijkingen in het nageslacht werden vergelijkbare resultaten geboekt; in 40 tot 60% 
van de foetussen met een aangeboren hartafwijking werd deze reeds voor de geboorte 
ontdekt (hoofdstuk 8). Behter, binnen deze hoog-risico groep bleek de proportie van 
gevallen met afwijking(en) een behoorlijke spreiding te vertonen. Derhalve verdient het 
aanbeveling om de momenteel gebruikte indica ties of risicofactoren voor gedetailleerd 
ultrageluidsonderzoek nader te evalueren. Aanpassing van selectiecriteria voor verwijzing 
zou de opbrengst van hoog-risieo ultrageluidsonderzoek kunnen vergroten. 
Tenslotte werd met behulp van een beslis analyse model, waarin de keuzen en kansen van 
(toekomstige) ouders, de foetus en de verloskundige weergegeven worden, getraeht de 
bereikbare opbrengst van routinematig uitgevoerd ultrageluidsonderzoek naar aangeboren 
hartafwijkingen te schatten (hoofdstuk 9). Het bleek mogelijk om aan te tonen dat, zelfs 
met min of meer optimale resultaten van routinematig ultrageluidsonderzoek, de invloed 
hiervan gering zou zijn. Te meer, daar dergeJijke optima Ie resultaten slechts kunnen 
worden bereikt indien aile zwangere vrouwen na omstreeks 20 weken zwangerschap 
routinematig zouden worden onderzoeht, er daadwerkelijk verbetering van de prognose 
van voor de geboorte ontdekte ernstige gevallen zou optreden, en goed gesehoold 
personeel met adequate apparatuur besehikbaar zou zijn. 
Samenvattend kan gesteld worden dat routinematig uitgevoerd ultrageluidsonderzoek om 
reeds voor de geboorte aangeboren afwijkingen te kunnen opsporen, in het kader van het 
huidige project, van onvoldoende kwaliteit blijkt om een aanvaardbaar resultaat te 
bereiken. Een verbeterde opleiding in de verloskundige echoseopie is noodzakelijk om tot 
een meer effeetieve opsporing van aangeboren afwijkingen te komen. Bovendien lijkt het 
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hoe dan ook moeilijk om een acceptabel effect te behalen binnen een laag risico groep (de 
algemene bevolking). Ultrageluidsondcrzoek uitgevoerd in gespecialiseerde centra voor 
prenatale diagnostiek. op grond van tevoren bekend verhoogd risico voor aangeboren 
afwijkingen. is daarentegen duidelijk veel efficienter. Slechts het onderkennen van 
indicaties voor uitgebreid ultrageluidsonderzoek verdient nader onderzoek. 
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N~ 04316 
datum onderzoek 
laatste menstruatie 
zwangerschapsduur 
aanvrager echo-onderzoek 
reden echo-onderzoek 
vierkamerverdeling 
andere afwijkingen 
Heeft u verwezen naar het 
Academisch Ziekenhuis Rotterdam 
Dijkzigt? 
Appendix A 
199 __ 
199 .. 
o onbekend 
weken ( ca. 16 - 24 weken ) 
o verloskundige 
o huisarts 
o gynaecoloog ( eigen polikliniek ) 
o routine inspectie 
o termijndiscussie 
o overige ........................................ . 
o normaal 
o abnormaal: 0 anatomie 
o ritme 
o niet te beoordelen / niet gezien 
o nee 
o ja .................................................. .. 
o nee 
o ja 
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Appendix B 
dfedhit~it routine 
intra - utell(ne 
e(OOcardiografie 
lruUtuul 
Epidemiologie 
en BJostatlstlek 
N2 04316 
Uw brief Ons kenmer\( Datum 
15 januari 1991 
Fa.~nummer Doorldesnum=r 
010·408 7494 010·408 7475 
Zeer geachte mevrouw, 
In samenwerking rnet de Nederlandse Hartstichting gaan de Erasmus 
Universiteit, het ziekenhuls waar u wordt onderzocht en het consultatie-buro 
voar zuigelingen, oa hoe effectief het echo·onderzoek is dat u zojuist heeft 
ondergaan. Met andere woorden; wij willen te weten kamen of er misschien 
afwijkingen zijn die Diet gezien kunnen worden met dit onderzoek. Het gaat 
hierbij vocral am afwijkingen van het hart. 
Wij willen hiervoor graag uw medewerking vrageo en verzoeken u de 
bijgevoegde formulieren bestemd vocr het consultatie-buro (of eventueel een 
andere arts die uw kind zal onderzoeken) blj het eerste bezoek af te geven. 
Verder hoeft u niets te doen. 
Uiteraard worden aUe verzamelde gegevens strikt vertrouwelijk verwerkt en 
bJijven medisch beroeps geheim. 
Mocht u vragen hebben dan kunt u rnij op werkdagen van 09.00 - 17.00 uur 
bereiken op telefoonnummer 010 - 4087475. 
Wij danken u bij voorbaat hartelijk voor uw medewerking. 
E. BuskensJ arts. 
Dr. D.E. Grobbee Prof. Dr. J.W. Wladimirof( 
afdding G)l1a~o!ogi(/ Vedoskunde 
Acadcmlsch Ziekenhu~ DijUigt 
Prof. Dr. J Hess 
~n::~~~ :Jni~,~~:~~~g~ollerd~[Q 
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afde!ing Kinduc.ardiologlc 
Sophia Kinderzjek~nhui,~ 
Appendix C 
effectil"itelt rQuline 
intra - uteriene 
ecbocardiografie 
aan de consultatie-buro arts c.q. 
arts jeugd gezondheidszorg 0 - 4 
jarigen. 
Insthuut 
Epldemlologle 
en Biostatistle}: 
Uw brief 
Onderwcrp 
OM "enmen Datum 
15 januari 1990 
f.unummcr Doorkiesnummcr 
010·408 7494 010·408 7475 
Geachte collega, 
Van de huidige methode van intra-uteriene echocardiografie, als onderdeel van 
het routine prenatale screenings-onderzoek, is de effectiviteit onbekend. Derha"ve 
wordt met subsidie van de Nederlandse Harlstichting, een grootschalig onderzoek 
uitgevoerd door de afdelingen Epidemiologie, GynaecologieNerioskunde en 
Kindercardioiogie van de Erasmus Universileit, naar de waarde van deze 
diagnostiek bij het vastslellen van aangeboren hartafwijkingen. Tevens is de 
Stichting Samenwerkende Rotterdamse Kruisverenigingen, bij monde van dhr. 
RE. Juttmann, dlstrictsarts jeugdgezondheidszorg Rotterdam, frequent 
geconsulteerd in verband met de praktische uitvoering van dit project. Wij 
vragen voor dit onderzoek graag oak uw medewerking. 
Van de baby, waarop deze brief betrekking heen, zijo de gegevens van 
routinematig vervaardigde intra-uteriene echocardiografie bij ons reeds bekend. 
Indien u bij het consultatie-buro onderzoek aanwijzingen heeft gevonden voor de 
aanwezigheid van een hartafwijking, vernemen wij dat graag van u, Bij verwijzing 
naar een kindercardioloog van het Sophia Kinderziekenhuis Rotterdam of het 
Academisch Ziekenhuis Leiden. zullen wij de gegevens verkregen bij intra-
uteriene echocardiografie kunnen vergelijken met die verkregen bij nadere 
klinische diagnostiek. Wilt u daarom aangeven of u de huisarts heeft voorgesteld 
het kind te verwijzen .. 
Het is voor het onderzoek van groot belang dat u de bijgesloten briefkaarten 
invult en vervolgens opstuurt. Ben na het eerste onderzoek en de tweede, na 
contrOle, een half jaar later of eerder iodien u verwijzing naar een 
kindercardioJoog geTndiceerd acht. 
Prof. Dr. J.W. WLadimiroff Prof. Dr. J Hess Dr. D.E.. Grobbee 
IM!i!uut EpiMm!o!ogit 
ErasmU$ Univeniteit Rouerdarn 
afdeling Gynllerologie/ Verloskunde 
Ao:ademiKh Ziekeohuis Dijktigt 
afdeling Kindercardiolo&ie 
Sophia Kindeniekenhu,! 
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Wij danken u bij voorbaat hartelijk voor uw medewerking. Macht u over het 
onderzoek nadere informatie wensen dan kunt u op werkdagen kontakt 
opnemen mel ondergelekende op lelefoonnummer 010 - 4087475, lussen 09.00 
en 17.00 uur, of mel mevr. I.M.E. Frohn-Mulder, kindereardioloog, Sophia 
Kinderziekenhuis Rotterdam, ( rna., di. & vrij.) op lelefoonnummer 010 -
4656566 1st. 2293. 
Mel collegiale hoogaehling, 
Mede namens Prof. Dr. J. Hess, kindereardioloog, 
Prof. Dr. J.W. Wladimiroff, gynaeeoloog, en 
Dr'bE. Grobbee, epidemioloog A)..l----
E. Buskens, arts 
N~ 04316 
datum onderzoek 
geboortedatum 
geslacht OM 
DV 
199 .. 
199 .. 
Het betrokken kind is voar de eerste rnaal gczien op het c'B.. 
D Geen afwijkingen waargcnomen; verderc contrale zal op 
gebruikclijke wijze plaatsvindcn. 
o Anders; namelijk: ............................................................................ .. 
(bijvoorbceld: direct indicatie verwijzing, ander specialisme, 
andere aangeboren afwijkingcn enzovoorts.) 
Aub. na ecrste bezock \'ersluren. 
N~ 04316 
datum onderzoek : " - .. 199 .. 
geboortedatum :.. - .. 199 .. 
o Bij hercontrole wederom geen afwijkingen waargenomen. 
o Oclet op symptomen passend bij harlafwijkingen, zoals afbuigen 
van de groeicurve, voedingsproblematiek, ademhalingsproblcmatiek, 
cyanose, afwezige liespulsaties of eeo hartgeruis, is vcrwijzing, 
door de huisarts, naar eeo kindercardioloog gci'ndicecrd 
DAnders; namelijk: .......................................................................... . 
(bijvoorbeeld: verwijzing ander speciaJisme, eventuecl symptomcn 
of diagnose) 
Aub. in dossier be-,\'arcn en oa eindbcoordeJing VCr.i!ureo. 
Appendix D 
Appendix E 
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Appendix F 
The following clinics for routine prenatal ultrasound participated in the study: Holy 
Ziekeuhuis, Vlaardingen, Ikazia Ziekeuhuis, Rotterdam, Jacobus Ziekeuhuis, Zwiindreeht, 
't Lange Land Ziekeuhuis, Zoetermeer, Merwede Ziekeuhuis, Dordreeht, Reinier de 
Graaf Gasthuis, Delft, Refaja Diakonesseuhuis, Dordreeht, Schieland Ziekeuhuis, 
Rotterdam, Sint Franciseus Gasthuis l' lijn, Rotterdam, Sint Franeiseus Gasthuis 2' lijn, 
Rotterdam, Stiehting Trombosedienst en Artsenlaboratorium Rotterdam, University 
Hospital Rotterdam - Dijkzigt, Rotterdam, Westeinde Ziekeuhuis, Den Haag, Usselland 
Ziekeuhuis, Rotterdam, Zuider Ziekeuhuis, Rotterdam. 
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Appendix G 
CONGENITAL HEART DISEASES AND OTHER ANOMALIES ASCERTAINED 
R_R<uin< U-IJrde'HmitJod 
GA_ 00stm:aJ ... 
)1_ Misecil=<>Jl 
Diagnosis Remarks Indication Outcome Gestational 
US US age (weeks) 
Valvular pulmonary stenosis. Paediatric cardiologist. Chronic GA 18 
obSiroclive alrway disease. 
VSD small. munnur. Paediatric cardiologist. R 20,117 
PA: complex heart defect; leva isomerism Structural ultrasound: complex CHD: R + 16,311 
syndrome. 2 morpho!ogicalleft-atria, large hypoplastic left-heart, 
VSD. hypoplastic pUlmonary artery. ASD, lsomerismlheterolula. 
etc. 
large VSD + ASO. Corrected surgically. R 23 
Aortic valve Insufficiency; coarctation Corrected surgically. R 20,617 
juxladuclaI. 
Small VSD. dysmature, deformation of Corrected surgically. GA 24 
skull. 
Large VSD, ASDII, sinus coronarius Paediatric cardiologist: corrected R 22 
absent. surgically. 
Routine utrasound: no anomalies. Pollow- Structural ultrasound: ASO, probably R 18,511 
up: under-development of right-ventricle VSD, Hypoplastic right-ventricle, 
with reduced compliance + varying microcephalic, left clubfoot. 
rightlleft shunting through the foramen 
ovale. 
ASDII, VSD. Developing heart failure. Paediatric R U 20 
cardiologist. 
Coarctation. PDA, VSD. Corrected surgically. GA 16.311 
Small apical muscular VSD. Paediatric cardiologist. R 19,111 
VSD, Pulmonary artery atresia, PDA. Paediatric cardiologist; oorrected R 19,111 
surgically: Blalock Gorete:t shunt left. 
VSD closed spontaneously. First Cardiologist. R U 23 
examination: IIINI systolic murmur + 
echocardlography; shunt flow. Follow-up: 
INl no anomalies. 
Pulmonary atresia, VSD, PDA. Paediatric cardiologist; corrected R 18,311 
surgically: aortic/pulmonary Goretex 
shunt. 
AVSD; incomplete atrial component only. Paediatric cardiologist. Corrected GA 18,611 
surgically 
VSD, PDA. Trisomy 21 R 16 
Small VSD. Paediatric cardiologist. R 19,211 
S«ond feNS of triplets. MUltiple CHD, StmcNral ultrasound 24 weeks: right- R U 19 
advanced ascites. ventricular reduction, probable VSD. 
PA: • Children 1 + 3: no anomalies. 
Pulmonary atresia, VSD, PDA. Corrected surgically. R 20 
PDA + muscular apical VSD. Follow·up: no murmur, spontaneous GA 20.311 
closure. 
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loud murmur, small perimembranous Paediatric cardiologist. R 17,417 
VSD. 
Hypoplastic left-heart. small ascending Paediatric cardiologist; deceased 3 days R 18.317 
aorta. postnatally. 
Systolic munnur. small perimembraneus Paediatric cardiologist. R 18,617 
VSD. 
Routine ultrasound: anatomy 4CV Structural ultrasound: no anomalies. GA + 18 
abnormal. Postnatally no anomalies. 
Routine ultrasound: anatomy 4CV Structural ultrasound: no anomalies. R + 21 
abnormal; no/small atrial septum. Postnatally no anomalies. 
Large muscular VSD + coarctation Paediatric cardiologist. R 21 
preductal. 
Routine ultrasound: anatomy + rhythm Structural ultrasound: no obvious R + 18 
abnormal. structural anomalies, nonnal rhythm. 
Transposition great arteries. Paediatric cardiologist. Corrected R 17,317 
surgically; artial switch-operation. 
Routine ultrasound: Cardiac connections: Structural ultrasound: no anomalies. GA + 19 
double outlet. 4CV normal. 
Perimembraneus VSD, ASDII, PDA with Paediatric cardiologist; corrected R 20,517 
left/right shunt. surgically. 
Systolic munnur; perimembranous VSD. Paediatric cardiologist; spontaneous R 20 
closure. 
Neonatal echocardiogaphy: d-Transposition Paediatric cardiologist; corrected R 20 
great arteries. . surgically: arterial switch-operation. 
Deceased 3 days postnata1ly due to post 
operative pulmonary haemorrhage. 
Atrioventricular septal defect. Paediatric cardiologist. Trisomy 21. R 21 
Small innocent VSD. Paediatric cardiologist; spontaneous R 18,317 
closure. 
VSD. Paediatric cardiologist. R 20,317 
Systolic munnur HUN; VSD. Paediatric cardiologist. R 20 
YSD, perimembraneus ·oullet". Paediatric cardiologist. R U 19 
Coarctation of aorta. Corrected surgically. Pylorus stenosus. R 19,317 
VSD, muscular. Paediatrician. Follow-up: 03-03-95. R 17 
Systolic munnur, VSD, pulmonary Paediatric cardiologist. R 17 
stenosis + double outlet right ventricle. 
Atrio-vemricular septal defect, chondro Ellis v. Creveld syndrome. PA: R 23,417 
ectodermal dysplasia, IUD. chondro ectodermal dysplasia. 
Coarctation juxtaductal, patent ductus Paediatric cardiologist. R 21,317 
arteriosus. 
YSD, ASDII, PDA. Corrected surgically. Trisomy 21 R 19 
Systolic murmur JINI, VSD. Paediatric cardiologist. R 21 
Medium size perimemhranous YSD. Paediatric cardiologist. R 22 
Pulmonary atresia + YSD, PDA. Paediatric cardiologist; corrected R 20 
surgically: Blalock Goretex shunt. 
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Routine ultrasound: density in left 
ventricle. bradycardia. 
Omphalocele, exstrophia cloacae. 
Cystic structure in liver: 15d8mm. 
Structural ultrasound: so-called 
'golfbaJl' + occasional bradycardia. 
Paediatrician. Premature, decaesed 3 
days postnatally. PA: + 
Structural ultrasound: no anomalies. 
Oesophagus atresia, PDA. Paediatrician.: Died despite surgical 
correction. 
Oesophagus atresia + tracheo-oesophageal Corrected surgically. 
fistula. 
Gastro-schizis. 
Diaphragmatic hernia (detected 
prenatally). 
Diaphragmatic hernia, Prune Belly. 
polyhydramnios. 
Hydronephrosis, bilateral compensated 
subpelvine stenosis. 
Hydronephrosis. 
Primary obstructive mega-urethra left. 
Hydronephrosis double sided + hydro-
ureters. 
Primary obstructive mega-urethra left. 
hydronephrosis left. 
Extrophia vesicae. 
Double sided hydronephrosis; urethra-
valves. 
Hydronephrosis right. microcephaly. 
multiple dysmorphia, PDA, ASD. 
Cystic kidneys. 
Hydronephrosis left. 
IUGR, Wolrs syndrome, palato-scbizis, 
hypertelorism, additional ears, 
dysmorphia. 
Double-sided Cheilo-gnato-palato schizis. 
Double-sided Cheilo-gnato·paJato schlzis. 
Apert's syndrome. 
Cheilo·gnato-palato schizis. 
PaJato scbizis, micrognatia. 
Palato schizis, glossoptosis. 
Structural ultrasound: omphalocele. 
Paediatrician: BeckwiU-Wiedeman 
syndrome, dysmorfia. 
StructuraJ ultrasound. 
Paediatrician. Hydrocephalus. 
Paediatrician. 
Paediatrician. Double sided reflux m. 
Paediatrician 
Paediatrician. Corrected surgicaJly. 
Paediatrician. 
Paediatrician. Corrected surgically 
Paediatrician. 
PA: + Chromosomes 
46,XY,del(7),(q34), 
Paediatrician. 
Paediatrician: no hydronephrosis. 
Follow-up: post natally more or less 
doubled left kidney. 
Kidney-dysplasia 
Paediatrician: schizis-team. 
Paediatrician; schizis-team. 
Craniosynostosis, mld-facial 
hypoplasia, syndactyly, ocular 
anomalies. 
Paediatrician; schizls-team. 
Paediatrician. 
Paedialrician. Pierre Robin's 
Syndrome. 
GA 
R 
R 
R 
R 
GA 
R 
GA 
R 
R 
GA 
R 
GA 
R 
R 
R 
GA 
R 
GA 
R 
R 
GA 
GA 
R 
GA 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
16,317 
21.317 
19,3n 
20,311 
22 
16,2n 
21 
24,3n 
24,3/7 
19,617 
22 
20,3n 
21,4 
17,3n 
23 
18 
18 
23 
22 
18 
16,6n 
19,1n 
21 
19.217 
22 
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Unilateral enlarged cerebral ventricle. Structural ultrasound: no anomalies R + 19 
(probably ~drop-out·). 
Hydrocephalus caused by osteopetrosis. Corrected surgically; lumbo-peritoneal R 20,417 
drain. 
Occipital encephalocele. Paediatrician. M 16 
Spina Blftda, systolic munnur UVI. Paediatrician. Dysmorpbia. R 19,617 
Essentially absent left foot. Paediatrician R 20 
Clubfoot. Corrected surgically. R 21,517 
Amelia dislalleft ann. Paediatrician R 16,217 
Left clubfoot. Paediatrician R 19 
Syndactyly righlJleft foot, left-hand, Paediatrician; orthopaedic/plastic R 24 
hypoplasia dig. II to V. surgery, clinical genetics. 
Clubfoot. Paediatrician. R 23 
Clubfeet, PDA. Dysmorphla R 19,317 
Scoliosis, body stalk anomaly. Autopsy: Tennination of pregnancy. R + 16 
VSD. 
Osteogenesis imperfecta. Tenninatlon of pregnancy at 20,317 R + 18 
weeks. 
Klippel Trenauny Weber. Tennination of pregnancy at 21 weeks. R + 20,317 
Hydrops fetalis + hygroma colli, IUD ecL Intra-uterine referral. PA: extensive GA + 19 
maceration, hydrops fetalis + hygroma 
colli. 
indication M = mother Askennans syndrome 
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DANKWOORD 
Eigenlijk meer dan woorden kunnen zeggen ben ik dank verschuldigd aan de medewerkers 
van het Instituut Epidemiologie en Biostatistiek van de Erasmus Universiteit Rotterdam, de 
afdeling Kindercardiologie van het Sophia Kinderziekenhuis, en de afdeling Prenatale 
Diagnostiek van het Academisch Ziekenhuis Rotterdam Dijkzigt. Zij vormden de 
afgelopen vier jaar het motiverend gezeischap dat door zijn positieve sfeer heeft 
bijgedragen aan het tot stand komen van mijn proefschrift. Naast dit aigemene woord van 
dank wi! ik !'Chter een aantal mensen in het bijzonder danken voor hun onmisbare inbreng. 
Allereerst de toekomstige ouders die deelnamen aan het onderzoek. De gegevens die zij 
ons ter beschikking stelden vormen de basis voor dit proefschrift. Een volgende onmisbare 
schakel in het geheel was de enthousiaste medewerking van "collega-echografisten" en hun 
medewerkers. Zij hebben zorg gedragen voor het verrichten en de verslaglegging van 
bijna 7.000 echo-onderzoeken. Daamaast was er meestal ook nog tijd voor een kop koffie 
tijdens mijn "ophaalronden" op de motor, en nader overleg ais er van onze kant 
onduidelijkheid bestond over de echo-gegevens. Voorts hebben vele consultatie-bureau 
artsen verslag gedaan van hun bevindingen bij de zuigelingen uit het onderzoek. Ook 
huisartsen, kinderartsen en kindercardiologen vonden wij bereid ons de noodzakelijke 
informatie te verschaffen. 
Aan de wieg van het project stonden naast mijn promotores onder andere Rikard 
!uttmann, Ingrid Frohn-Mulder en Patricia Stewart. Hun inbreng en ideeen waren 
onontbeerlijk om tot een uitvoerbaar onderzoeksvoorstel te komen. Patricia Stewart was 
daamaast gelukkig ook nog bereid om zo nu en dan met een kritisch oog naar mijn Engels 
te kijken. Vervolgens heeft Marcel Eijgermans, samen met Gerrit-Anne van Es, een data-
base ontworpen zodat de verkregen gegevens konden worden opgeslagen en bewerkt. In 
een later stadium kon ik bij Marcel ook altijd terecht ais ik weer eens een specifieke 
selectie van gegevens nodig had. 
Dat het controleren, invoeren, bijhouden en desnoods aanvullende informatie opvragen 
voor een omvangrijke data-base een formidabele inzet vereist kunt u zich wellicht 
voorstellen. Andrina Cleveringa, Sharmila Bhikha, Petra Steenman-Fontein, Agnes van 
der Yoorn en Desire de Kruijff hebben wat dat betreft lief en Ieed met mij gedeeld. In 
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tijden van tegenspoed gaven zij morele steun en in tijden van voorspoed waren zij er am 
de vreugde te delen. Of de meerderheid van hen zich door het onderzoek heef! Iaten 
inspireren weet ik niet. Ben feit is weI dat Andrina, Petra en Agnes vervolgens oak zelf 
voor prenatale echodiagnostiek in aamnerking kwamen. 
Voor mijn promotores, drie in getaI, was het vaak moeilijk am op een bepaald tijdstip 
bijeen te komen. Het innemen van eon bepaald standpunt Iukte ook niet altijd. Maar juist 
deze verschillen hebben mij geleerd om zorgvuldig de mogelijkbeden na te gaan om tot 
weloverwogen beslissingen te komen. Professor J. Hess, nestor en hoofdaanvrager van het 
project, u gaf mij altijd het vertrouwen, ruime vrijheid en het vooruitzicht op een carriere 
als kinderarts. Dank voor de prima samenwerking, en bewondering omdat u altijd op 
relevante momenten en punten de aandacht wist te vestigen. Professor D.E. Grobbee, 
Rick, jij fungeerde als het ware als dagelijks bestuur en hield "de Yinger aan de pols". 
Met je creativiteit en enthousiasme voar wetenschappelijk onderzoek, rapportage en 
allerhande wist je mij zodanig te inspireren dat ook ik gezwicht ben voor het dynamische 
vakgebied van de epidemiologie. Professor J. W. Wladimiroff, dank want toonde mij de 
visie van een clinicus en waakte ervoor dat de patienten niet vervaagden tot getallen in een 
tabel. 
Dat aan de overstap op epidemiologie een moeilijke afweging vooraf ging zullen enkele 
van mijn junioren-collega's (-kamergenoten) !runnen beamen. Door met hen de gedachten 
en twijfels te delen kwam mijn keuze tot stand. Cuno ViterwaaI, met wie ik gedurende 
een groot deel van de tijd op eon kamer heb gezeten, wiI ik hier met name noemen en 
danken. Cuno ik ben blij dat jij paranimf bent. Jan Luyendijk, vriend en ook paranimf, jij 
nam mij mee uit jagen en vissen. Deze totaal andere bezigheden, gepaard met de nodige 
gezellige uurtjes (met name achteraf), vormden een zeer welkome afwisseling en punten 
van rust. Ik hoop dat wij hier samen nog lang mee door !runnen gaan. Andere vrienden en 
familieleden die ik met name het Iaatste jaar te weinig heb gesproken dank ik voor hun 
geduld. Als ik straks de race tegen de kIok heb voltooid is er weer tijd am de draad op te 
pikken. 
Tenslotte zijn daar nog mijn ouders en Sylvia. Het feit dat ik hen als Iaatste noem staat in 
geen enkel verband tot het belang van hun rol. Mijn ouders dank ik voor de liefde, 
vrijheid en steun waar ik altijd op heb !runnen rekenen. Sylvia, mijn maatje in alles, door 
dik en dun, dank jel 
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